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Emerging literature has reported reduced treatment toxicity in head-and-neck radiotherapy (HNRT) 
with 3 instead of 5 mm planning target volume (PTV) margins. However, the loco-regional (LR) control 
rate was not preserved in all studies. As it was considered whether it was possible to implement reduced 
treatment margins at the Wellington Blood & Cancer Centre (WBCC) with the aim to improve patients’ 
treatment-related toxicity, it was recognised that many department-specific aspects of HNRT can 
influence treatment outcomes and should all be considered when the treatment margins are amended. 
PTV margins are applied to target volumes during treatment planning to account for uncertainties such 
as patient positioning, geometrical accuracy of the treatment machine and geometrical accuracy of 
target volume definition. However, these margins do not standardly account for non-rigid anatomy 
changes (e.g., changes in patient pose, weight loss, tumour response) which are commonly observed 
during HNRT and can undermine the planned dose objectives. Under the assumption that a loss in target 
coverage during treatment may occur more often and may become more relevant with reduced mm PTV 
margins, it was proposed that a safe PTV margin reduction could be achieved by accounting for 
systematic changes in patient anatomy using timely and appropriate treatment adaption. This approach 
required quantification and separation of the different modes of anatomical change during treatment, 
and subsequent investigation of their dosimetric impact. Therefore, the retrospective studies included 
in this dissertation first investigated the application of deformable image registration (DIR) in 
combination with Exponentially Weighted Moving Average (EWMA) Statistical Process Control 
(SPC) charts, and DIR-facilitated dose accumulation. In the first study, DIR between the computed 
tomography for treatment planning (pCT) images of twelve patients and their daily on-treatment cone 
beam computed tomography (CBCT) images quantified anatomical changes during treatment to 
investigate corresponding trends using EWMA charts. The application of EWMA SPC charts showed 
that trends in patient positioning of bony anatomy with respect to the first five treatment fractions could 
only be confirmed at a 90% confidence level in a small number of cases when EWMA process limits 
were used, whereas absolute patient position deviations could be confirmed in the vast majority of cases 
when an a priori 2 mm clinical limit was used. EWMA process limits were however effective when 
detecting trends of soft tissue structures. Structure-specific action thresholds for trend detection using 
SPC charts enabled detection of systematic anatomical changes. The second study defined the intended 
clinical workflow based on DIR-facilitated dose accumulation to assess the actually delivered dose and 
the uncertainty in the delivered dose was determined using in silico deformations based on clinically 
observed anatomical changes as ground truth. The uncertainty in DIR-facilitated dose accumulation 
was accurately quantified and the methodology how to incorporate these prospectively in dose-volume 
histograms (DVHs) was described. These results demonstrated that the intended clinical workflow is 
sufficiently accurate to assess the adequacy of target coverage during HNRT. In the third study, the 
estimated uncertainty derived in the second study was included in the dose reconstruction and 
accumulation over all fractions for the twelve patients to investigate the robustness of volumetric 
modulated arc therapy (VMAT) plans that were optimised using either 3 or 5 mm PTV and planning 
risk volume (PRV) margins. It was shown that loss in target coverage was independent of margin 
expansion and very patient specific. In addition, it was found that the tightness of target volume 
coverage at planning was a common factor leading to underdosage. The developed clinical workflow 
to reconstruct the delivered dose using DIR-facilitated dose accumulation found that PTV/PRV margin 
reduction did not significantly reduce the robustness of treatment plans to attain adequate target 
coverage during treatment. This indicates that a safe PTV margin reduction from 5 to 3 mm in HNRT 
can be achieved. Patient specific verification of the delivered dose using the developed methodology is 
recommended irrespective of the applied margin expansions considering the patient specific nature of 
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Emerging literature has reported reduced treatment-related toxicity after reducing treatment margins in 
head-and-neck radiotherapy (HNRT) [1–4]. Treatment margins are applied volumetrically around the 
tumour to ensure adequate coverage by accounting for various treatment related uncertainties. As it was 
considered whether it was possible to implement reduced treatment margins at the Wellington Blood & 
Cancer Centre (WBCC) with the aim to improve patients’ treatment-related toxicity, it was recognised 
that many department-specific aspects of HNRT can influence treatment outcomes [5] and should all 
be considered when the treatment margins are amended.  
 
The goal of the research detailed in this dissertation was to facilitate a safe treatment margin reduction 
in HNRT at the WBCC by developing a quality management “safety net” for patients who may be at 
risk of unacceptable loss in target coverage and/or overdosage to normal tissues with reduced treatment 
margins. The quality management “safety net” developed in this research was underpinned by 
deformable image registration (DIR). Background information regarding HNRT, DIR and current 
practices at the WBCC is provided in this Introduction chapter to aid comprehension of the three linked 
studies which constitute this dissertation. 
 
1.2 Head-and-neck cancer 
Head-and-neck (HN) cancers are a group of malignancies that include tumours of the nose and sinuses, 
orbits, salivary glands, thyroid and parathyroid glands, skin, lymph nodes and mucous membranes. 
Mucous membranes line structures in the HN region such as the nasopharynx, oropharynx, oral cavity, 
hypopharynx and larynx (Figure 1.1). Squamous cell carcinoma (SCC) of the mucous membranes 
 
  






comprise approximately 95% of HN cancers [6–8]. The most important risk factors are tobacco, alcohol 
and more recently, the human papillomavirus (HPV) infection [7,9–11]. At presentation, about two-
thirds of patients with HN SCC demonstrate advanced stage disease although incidence of metastasis 
is infrequent [12]. Patients that survive loco-regional (LR) advanced disease face an increased risk of 
mortality from cardiac and respiratory illnesses [6,13–15]. In addition, these patients also face an 
increased risk of second primary tumours which are often related to tobacco [6,13–15]. In 2016, New 
Zealand recorded 520 new HN cancers of the lip, oral cavity and pharynx with incidences in men 
constituting over 65% of these cases [16]. Despite HN cancers accounting for only about 2% of newly 
registered cancer cases [16], a five-year relative survival rate of approximately 63% [17] indicates a 
significant health issue which is complex to treat. In comparison, the five-year relative survival rate of 
prostate cancer and female breast cancer is approximately 91% and 87%, respectively [17]. For brain 
and pancreatic cancer, this rate drops to approximately 19% and 5%, respectively [17]. Radiotherapy 
as either the sole treatment modality, concurrent with chemotherapy or adjuvant following surgery is 
an extremely effectual treatment for HN cancers [18].  
 
Figure 1.1: Structures of the head-and-neck (HN) region. Reused under a Creative Commons licence, 










1.3 Radiotherapy for head-and-neck cancers 
Radiotherapy utilises a linear accelerator (Figure 1.2) to deliver radiation dose to a patient. Radiotherapy 
aims to deliver high radiation doses to tumour volumes and/or areas of suspected microscopic malignant 
disease whilst attempting to spare adjacent healthy tissues. Radiation is delivered to target volumes 
through surrounding normal tissues and as a result, the normal tissues cannot be completely spared. 
 
 
Figure 1.2: A linear accelerator. Radiation is emitted through the head of the linear accelerator and 
deposited in the patient. Revised and reproduced with permission: for the National Cancer Institute © 
(2016) Terese Winslow LLC, U.S. Govt. has certain rights. 
 
Tumour control probability (TCP) and normal tissue complication probability (NTCP) models are often 
used to describe the probability of achieving local control and corresponding normal tissue toxicity for 
a given radiation dose [19]. Maximising the TCP while minimising the NTCP is the optimal radiation 
delivery regime. The therapeutic ratio generally refers to the ratio of TCP to NTCP at an arbitrary level 
of response (typically 0.05) for normal tissue (Figure 1.3). Typically, an appropriate radiotherapy 
treatment has a TCP ≥ 0.5 and an NTCP ≤ 0.05 [19]. A higher therapeutic ratio is present when the 
NTCP curve is further to the right of the TCP (Figure 1.3). A higher therapeutic ratio [20] makes it 
easier to achieve the radiotherapeutic goal and reduce the likelihood of treatment complications. 
Radiotherapy dose distributions that can conform tightly to target volumes to spare healthy tissues as 
much as possible will maximise the therapeutic ratio.  
 
  







Figure 1.3: The principle of the therapeutic ratio. The therapeutic ratio is the ratio of tumour control 
probability (TCP) to normal tissue complication probability (NTCP) at an arbitrary probability level 
for normal tissue (typically 0.05). 
 
The introduction of intensity modulated radiation therapy (IMRT) and volumetric modulated arc 
therapy (VMAT) in the last decade has enabled dose deliveries that conform more tightly to tumour 
volumes compared to the previously applied treatments using three-dimensional conformal 
radiotherapy (3DCRT) [21–23]. The principle of 3DCRT involves shaping a dose distribution to the 
target as prescribed while avoiding normal tissues as much as can be achieved. For 3DCRT, this is most 
commonly accomplished through the application of a limited number of radiation beams (typically 3 – 
9 [24,25]) at static gantry angles, the use of lead inserts or multi-leaf collimators (MLC), and through 
treatment planning dose calculations. The treatment planning dose calculations are based on radiation 
transport models [26] which are applied to 3D anatomical patient data from computed tomography (CT) 
imaging. The treatment planning dose calculations are performed using a treatment planning system 









shapes and dose distributions with intent to maximise tumour control and minimise normal tissue 
complications [19]. MLCs are beam shaping devices made up of individual “leaves” that move 
independently from one another to shield normal tissues. The leaves are constructed from a high atomic 
number material, typically tungsten. IMRT is an approach more advanced than 3DCRT and is able to 
provide improved dose distribution conformity to irregularly shaped target volumes compared to 
3DCRT, and has the ability to produce concave dose distributions [18]. Figure 1.4 illustrates the 
difference in dose distribution conformity between 3DCRT and IMRT. The increased conformity of 
IMRT is achieved by varying the photon fluence [27] across the beam aperture through using a large 
number of beam segments with a distinct shape for each static gantry angle. The progress in 
technological development of MLCs and inverse planning algorithms to optimise individual patient 
treatment plans was instrumental for the development of IMRT. VMAT also produces photon fluence 
variation across the beam aperture. However instead of delivering multiple beams at static gantry 
angles, VMAT delivers subsequent segments in a dynamic fashion by rotating the linear accelerator 
gantry while the gantry rotation speed, dose rate and MLC leaf movement speed are varied. The 
advantages of VMAT in head-and-neck radiotherapy (HNRT) are shorter delivery times, superior target 
dose homogeneity (double arc VMAT) and lower number of total monitor units (MUs), in comparison 
to IMRT [28,29]. Shorter delivery times imply a reduction in the risk of patient movement during 
treatment, and possibly a reduction in psychosocial factors attributed to being in the treatment room 
[30]. A reduced number of MUs (a measure of dose output from a clinical accelerator) indicates that 
equivalent treatment goals can be achieved with the overall production of less dose. 
 
During the treatment preparation phase, the planning computed tomography (pCT) scan is acquired and 
used to delineate the following tumour target volumes as defined by the 1993 International Commission 
on Radiation Units and Measurements (ICRU) Report 50 - Prescribing, Recording, and Reporting 
Photon Beam Therapy [31]:  
 The Gross Tumour Volume (GTV), the gross palpable or visible/demonstrable extent and 











Figure 1.4: Colourwash representation of dose distributions’ conformity to the target volumes (solid 
red contours). A three-dimensional conformal radiotherapy (3DCRT) plan (left) and a Volumetric 
Modulated Arc Therapy (VMAT) plan (right). The colourwash represents 95% of the prescribed dose. 
The 95% isodose conforms highly but not perfectly to the target volume for the VMAT plan in 
comparison to the conformity of the 3DCRT plan. Two different patients are shown. 
 
 The Clinical Target Volume (CTV), a tissue volume that contains a demonstrable GTV and/or 
subclinical microscopic malignant disease, which has to be sterilised. This volume has to be 
irradiated to an adequate dose to achieve a successful treatment [31]. For HN cancers, two 
different approaches to delineating the primary tumour CTV exist, one based on geometric 
expansion of the GTV and the other one based on anatomical expansion of the GTV using 
compartmentalisation of HN anatomy [32–34] 
 A Planning Target Volume (PTV), which consists of the CTV plus an expanded margin. The 
PTV margin ensures CTV coverage by accounting for various uncertainties including patient 
positioning, geometrical accuracy of the treatment machine and geometrical uncertainties of 
target volume definition. Most of these uncertainties can be quantified and applied in a so-
called PTV margin recipe to estimate the appropriate PTV margin [35,36]. However, for HNRT 
it is difficult to quantify the uncertainty in target volume definition because a gold standard is 
seldom available. Studies directly comparing histopathological analysis with delineation of the 
GTV using pre-treatment imaging indicated that target delineation was the main source of 









addition, it was noted that the inter- and intra-observer variation in clinician target delineation 
was considerable [37,38]. An example of inter-observer delineation variation at the WBCC is 
shown in Figure 1.5. 
 
 
Figure 1.5: Blue and orange contours illustrating an example of inter-observer gross tumour volume 
(GTV) delineation variation of two clinicians at the Wellington Blood & Cancer Centre (WBCC). 
 
A number of CTVs and PTVs may be delineated on a patient’s pCT scan and these are irradiated to 
different dose levels depending on their risk [39–41]. Figure 1.6 shows the GTV relative to the high-
dose CTV, the high-dose PTV, the low-dose CTV and the low-dose PTV. In addition to the target 
volumes, a number of patient- and treatment-specific organs at risk (OARs) are delineated. An OAR is 
defined as a normal tissue organ whose sensitivity and tolerance for radiation may result in unacceptable 
radiation treatment toxicities [19]. Typical OARs in HNRT include the brainstem (BS), spinal cord 
(SC), parotid glands (PGs), submandibular glands (SMGs), oral cavity, optic chiasm, optic nerves, 
pharyngeal constrictor muscles, laryngeal cavity and eyes. Similar to the PTV, a planning risk volume 
(PRV) takes the net effect of geometrical variations, uncertainties in OAR delineation and patient 
positioning into consideration [42,43]. The PRV is a geometrical concept, and is frequently used in the 
treatment plan optimisation for the critical serial OARs (i.e., the BS and SC) as opposed to the BS and 
 
  






SC contours themselves. A treatment plan (beam arrangement, monitor units, fluence maps) is 
generated on the pCT and optimised according to target coverage [44], critical OAR avoidance and 
non-critical OAR sparing requirements [45]. 
 
 
Figure 1.6: Target volumes shown relative to each other in the axial (left), sagittal (top right) and 
coronal (bottom right) planes. The gross tumour volume (GTV) is indicated by the bright green contour. 
The high-dose clinical target volume (CTV) in blue. The high-dose planning target volume (PTV) in 
red. The low-dose CTV and PTV are shown in purple and orange, respectively. 
 
1.3.1 Dose-volume histograms 
Dose-volume histograms (DVHs) [46] are an effective tool often used in radiotherapy to quantify the 
treatment plan’s target coverage, critical OAR avoidance and non-critical OAR sparing [19]. A 
cumulative DVH is a frequency plot showing the volume receiving a dose greater than or equal to a 
given dose, plotted against dose. DVHs are typically displayed in the form of percentage of total volume 
[46]. Example DVHs are shown in Figure 1.7. Structure-specific DVH quality metrics are used to ensure 
that the treatment plan provides appropriate target coverage, critical OAR avoidance and non-critical 
OAR sparing. For PTVs, the D98% achieving at least 95% of the prescribed dose is commonly used as 









PTV should receive at least 95% of the prescribed dose. This requirement is one of the many requisites 
of an acceptable treatment plan. The orange filled circle in Figure 1.7 shows the high-dose PTV’s 
planned D98% which is equal to 63.8 Gy. Considering that the prescribed dose was 66 Gy, the planned 
D98% for the high-dose PTV must exceed 62.7 Gy. The DVH quality metric typically used for critical 
OARs (i.e., SC and BS PRVs) is the max dose Dmax (Figure 1.7) or the minimum dose to 0.1 cm3 of the 
volume that receives the highest dose, D0.1cc [45]. For non-critical OARs, the DVH quality metric is 
typically the mean dose received by the structure, Dmean [45]. 
 
 
1.3.2 Radiotherapy toxicity  
In general, radiation toxicity can be separated into two groups: stochastic and deterministic. With 
increasing dose, stochastic effects increase in occurrence probability but do not increase in severity 
Figure 1.7: Selected dose-volume histograms (DVHs) for an example patient’s planned dose. The red filled circle is the high-
dose (HD) clinical target volume (CTV) D99%. The orange filled circle is the HD planning target volume (PTV) D98%. The teal 
filled circle is the brainstem planning risk volume (PRV) Dmax. D99% = dose to 99% of the volume. D98% = dose to 98% of the 
volume. Dmax = max dose. 
 
  






[19]. An example of a stochastic effect is the induction of a secondary cancer [48]. Even at low doses 
there is a probability of a stochastic effect occurrence and as such, stochastic effects do not have a 
threshold dose below which they do not occur [19]. Deterministic effects increase in severity with 
increasing dose, often above a threshold dose. The remainder of Sub-section 1.3.2 details deterministic 
toxicities. 
 
One of the main challenges in HNRT is reducing toxicity for the patient while maintaining tumour 
control due to the intimately located target volumes and normal tissues. Radiation-induced toxicity for 
HN cancer patients has a deleterious and well-documented impact on a patient’s quality of life following 
treatment [49–51]. Despite significant improvements in a patient’s quality of life after the introduction 
of modulated radiotherapy techniques compared to 3DCRT [52,53], continued efforts should be made 
to further improve quality of life for all patients during and after HNRT. Toxicities as a result of HNRT 
are separated into early and late adverse effects. Early effects are characterised as occurring during or 
immediately after HNRT and mostly decrease in severity over time. Conversely, late effects are 
generally considered irreversible and persist for months or years after completion of HNRT [49]. It 
should be realised that the recent introduction of IMRT and VMAT implies that studies reporting on 
the late effect toxicities associated with these techniques are limited.  
 
Dryness of mouth, oral pain and difficulties with speech are characteristic symptoms of the most 
common HNRT late toxicity, xerostomia. Xerostomia is induced as a result of salivary gland (PG, SMG, 
sublingual and minor) irradiation during HNRT [54–56]. Figure 1.8 visualises the major salivary glands 
in the HN region. It is well-documented and well-known that a reduction in xerostomia can be achieved 
through PG sparing [25,55,57–62]. In contrast to the PGs, studies reporting on xerostomia endpoints 
and dose reduction strategies pertaining to the SMGs, sublingual and minor salivary glands are scarce.  
 
Dysphagia is defined as difficulty in swallowing and commonly presents in the oral cavity, oropharynx 
and oesophagus [63,64]. Dysphagia can present as an early adverse effect through soft tissue 









Figure 1.8: Major salivary glands of the head and neck. Modified under a Creative 
Commons licence, from the University of Dundee. 
function even after healing of the early adverse effects can occur due to soft tissue fibrosis, scar tissue 
formation and neurological impairment [65]. A reduction in dose to the swallowing structures 
(pharyngeal constrictor muscles, glottis, supraglottis, and oesophagus) has been directly linked to a 
reduction in patient-experienced dysphagia [66–68].  
 
Osteoradionecrosis [69], particularly of the mandible, is another documented adverse effect of HNRT 
and can lead to pain, loss of bone mineral and skin fistulas [70,71]. Hearing loss as a result of treatment 
is less-documented, however a small number of studies seeking to determine the underlying 
mechanisms of radiation-induced otological toxicity recommended consideration of dose to the inner 
ear [72,73]. Finally, a reduced opening of the jaw, known as trismus, is another recognised adverse 

































1.4 Anatomical changes 
For HNRT, the length of treatment typically consists of daily treatment fractions from Monday to Friday 
for 4-7 weeks. The fractionation regime is based on radiobiological models of cancer and normal tissues. 
Fractionation takes advantage of the increased survival ability of normal tissues compared to cancer 
cells considering that normal cells are able to more effectively repair radiation damage if the total dose 
is split into smaller doses [75–77]. Normal tissue cells proliferate at a slower rate than cancer cells 
consequently having more time to repair damage before replication [75–77]. During each treatment 
fraction, the position of the patient must be carefully reproduced and patient-specific anatomy must be 
carefully monitored due to the intimately located target volumes and normal tissues. The dynamic 
nature of changes within the human body during the treatment period implies that the pCT acquired 
during the treatment preparation phase may not accurately represent the patient’s anatomy during 
treatment [78]. Rigid setup errors and non-rigid deformations (which include non-rigid setup errors) of 
a patient’s anatomy relative to the pCT anatomy have the potential to adversely affect the planned dose 
distribution [79,80].  
 
1.4.1 Setup errors 
The most common method of reducing patient positioning setup errors [81–85] in HNRT is to 
immobilise the patient using a head support and a thermoplastic fixation mask, and apply treatment 
couch corrections to correct any rigid patient setup deviations. Generally, treatment couch corrections 
are carried out immediately prior to delivery of each treatment fraction, based on the registration of an 
in-room imaging modality scan to the pCT. This technique of imaging a patient immediately prior to 
delivery of their treatment fraction and correcting for rigid patient setup errors is known as image guided 
radiotherapy (IGRT) [86]. Typically, the in-room imaging modality is a cone beam CT (CBCT). CBCT 
integrates CT imaging with a linear accelerator and involves acquiring multiple planar images from a 
kilovoltage or megavoltage cone beam of photons rotating about the patient on the treatment couch 
[19]. Residual setup errors that cannot be corrected for with rigid couch movements are known as non-










Figure 1.9: Reduction of setup errors in image guided radiotherapy (IGRT): (top left) The patient is 
positioned on the treatment couch with a head support and thermoplastic fixation mask in an attempt 
to reproduce the planning computed tomography (pCT) scan position; (top right) A cone beam CT 
(CBCT) scan is taken (magenta) and digitally overlaid on the pCT (green); (bottom right) The CBCT 
and pCT are digitally matched by treatment staff prioritising a region of interest. In this case, the C1-
C3 vertebral bodies; (bottom left) the digital match is applied to the treatment couch in three 
translational degrees of freedom. Note that an additional three rotational degrees of freedom can be 
used. Residual setup errors (bottom right) seen at the mandible and hyoid are non-rigid deformations. 
Top and bottom left panes revised and reproduced with permission: for the National Cancer Institute 
© (2016) Terese Winslow LLC, U.S. Govt. has certain rights. 
 
1.4.2 Non-rigid deformations 
Non-rigid deformations include non-rigid patient positioning change, weight change, OAR shift and 
OAR shrinkage. Examples of non-rigid deformations that can occur during HNRT are illustrated in 
Figure 1.10 by means of a patient’s pCT overlaid with an on-treatment CBCT.  
 
Table 1 summarises non-rigid patient positioning as reported in the literature and reports the group 
mean, M, in accordance with population statistics described in the Appendix of Remeijer et al. [87]. 
The largest non-rigid patient positioning deformations (i.e., M) were typically observed for the 
 
  






mandible. Non-rigid patient positioning deformations were calculated relative to C1-C3 or a similar 
structure. The selection of this reference structure provided a clinically relevant measure of deformation 
considering its common prioritisation in HNRT (Figure 1.9). A comparison of the literature reported 
dispersion of the systematic deformation ∑ and random deformation σ can be found in a previous study 
conducted at the WBCC [88]. 
 
Weight change is commonly recorded during HNRT treatment to monitor the overall health status of 
the patient [89–92]. However, a patient’s overall weight change is not necessarily an indicator of volume 
change in the HNRT treatment region considering that weight loss may not be evenly distributed over 
the entire body. A number of investigations have reported on the change in volume and neck diameter 
of various HN sub-regions [78,93–95]. These studies then correlated the HN sub-regions’ contour 
change with total weight change. For example, Barker et al. [78] found a significant correlation (ρ = 
0.92; p < 0.01) between patient weight and external volume (one CT slice) at the level of C2 in their 
fourteen patient study. However, these investigations [78,93–95] do not account for changes in patient 
positioning between planning and during-treatment images. Patient tissue could enter/exit the measured 
zone due to patient positioning inconsistencies and not represent true treatment region contour change. 
To further clarify, a tilt of the head not present at planning may cause tissue to leave the measured HN 
sub-volume (or neck diameter plane) when no total change of patient weight is observed, a false positive 
for weight loss. There is no true gold standard to quantify anatomical changes in the HN treatment 
region solely due to weight change. 
 
Brouwer et al. [79] have comprehensively summarised 51 studies reporting on anatomic and dosimetric 
changes in HN OARs during radiotherapy. The majority of papers (n = 38) in their review included 
anatomical changes to the PG. The high number of investigations can be attributed to the PG’s well-
known dose relationship with xerostomia and saliva production [56,59]. For the 38 reviewed studies, 










Table 1: Group mean deformation, M, relative to C1-C3 or similar structure* 
 
 
*The regions of interest (ROIs) used in WBCC [88] and van Kranen et al. [83] are the same however, other studies used varying sub regions which were compared to the ROIs 
of Table 1’s column header. Polat et al. [82] matched on C4-C6 and the whole skull, which were compared to the results for C3-C5/C5-C7 and the occipital bone, respectively. 
Giske et al. [96] and Graff et al. [81] both used C1-C2 as the reference structure for the calculation of deformation as opposed to C1-C3. Zhang et al. [84] used the marked 
isocentre on the immobilisation mask as the reference structure. The results for Giske et al. [96] presented for C6, T2 and left maxillary sinus were compared to C5-C7, C7-
caudal and maxilla, respectively. Graff et al. [81] included C7-T1, which was also compared to C7-caudal. The results for Zhang et al. [84] presented for C2, C6 and palatine 
process of the maxilla were compared to C3-C5, C5-C7 and maxilla, respectively.
MROI (mm) 
C3-C5 3D dev. C5-C7 3D dev. C7-caudel 3D dev. Mandible 3D dev. Maxilla 3D dev. Occipital 3D dev. Larynx 3D dev. 
vrt lng lat 3D vrt lng lat 3D vrt lng lat 3D vrt lng lat 3D vrt lng lat 3D vrt lng lat 3D vrt lng lat 3D 
WBCC [88] -0.3 -0.1 0.0 1.6 -0.2 -0.1 -0.2 2.3 0.4 0.1 -0.3 2.9 1.0 -0.7 -0.2 2.9 - - - - -0.4 0.3 0.2 2.2 0.0 0.4 0.1 3.2 
Polat et al. [82] - - - 3.0 - - - 3.0 - - - - - - - 3.2 - - - - - - - 2.7 - - - - 
Van Kranen et al. [83] 0.1 0.1 0.1 - 0.2 -0.2 0.4 - 0.8 0.5 0.9 - 0.3 1.3 0.0 - - - - - 0.3 0.6 0.4 - 0.2 -0.3 0.5 - 
Giske et al. [96] - - - - 1.2 0.3 0.1 - 2.0 0.3 0.0 - 0.3 -0.6 0.0 - 0.2 -0.6 0.0 - - - - - 1.7 -0.5 0.2 - 
Graff et al. [81] - - - - - - - - - - - 2.7 - - - 4.0 - - - 3.5 - - - - - - - - 
Zhang et al. [84] -0.5 0.9 -0.7  -0.3 1.1 -1.0 - - - - - - - - - 0.4 1.9 -1.2 - - - - - - - - - 
 
  






Only three studies in the Brouwer et al. [79] review investigated the SMGs which is in line with the 
general scarcity of SMG investigations in the context of HNRT. On average, a SMG volume reduction 
of 22% (range; 15 – 32%) during HNRT was reported.  
 
In general, the volume of the brainstem and spinal cord remained constant during HNRT [97]. Swelling 
of the larynx and/or pharyngeal constrictor muscles was found in two studies after at least five weeks 
of treatment [98,99]. An increase in the width of the pharyngeal constrictors to 111% of their width at 
planning was observed in Popovtzer et al. [100] for those structures receiving more than 50 Gy. 
 
 
Figure 1.10: Examples of non-rigid deformations that can occur during head-and-neck radiotherapy 
(HNRT). The planning computed tomography (pCT) scan (green) overlaid with a during-treatment cone 
beam computed tomography (CBCT) scan (magenta). (Left) Non-rigid patient positioning 
characterised by differential movement of bony regions. (Middle) Weight loss resulting in a volume 
reduction of the treatment region, shown by a shrinkage of the external contour in the posterior region. 
(Right) Parotid gland shrinkage and shift shown by the pCT (orange) and CBCT (blue) contours. 
 
 
1.4.3 Dosimetric consequences 
IMRT has reported improved quality of life, increased sparing of salivary glands and no change in two- 
and three-year local-regional control rates for HNRT, compared to 3DCRT [52,53,61,62,101,102]. 
However considering the highly conformal dose distributions (Figure 1.4) of modulated radiotherapy 
(i.e., IMRT and VMAT), a small change in patient anatomy can lead to target volume underdosage 
and/or unacceptably high dose to normal tissues [58,93,103–110]. In the Brouwer et al. [79] review, 24 
papers reported on the dosimetric consequences to the PGs as a results of anatomical changes during 








these studies. The largest average PG Dmean increase for a single study was 10.4 Gy from the study of 
Chen et al. [111]. Only one paper reported changes to the delivered SMG Dmean relative to the planned 
Dmean. An approximated actually delivered SMG Dmean increase of 0.9 Gy relative to the planned SMG 
Dmean (i.e., 52.8 vs. 51.9 Gy) was reported. Not included in the Brouwer et al. [79] review, Dijekma et 
al. [55] found a significant correlation between grade 4 or 5 night-time xerostomia and a reduction in 
SMG saliva production, caused by SMG irradiation. Changes to Dmax, D1% or D2% of the spinal cord 
and/or brainstem was reported by 15 studies in Brouwer et al. [79] which observed an average increase 
of less than 1.5 Gy. It must be stated that the chronological end-points in these studies were largely 
determined by availability of re-CT images and were not always at the end of treatment. Zhao et al. 
[112] observed the largest increase in D1% over treatment which was 5.6 and 2.5 Gy for the SC and the 
BS, respectively. The relatively large number of papers reviewed by Brouwer et al. [79] has started a 
consensus on the expected dosimetric impact to OARs in the presence of anatomical changes during 
HNRT. However, the notable inter-study heterogeneity restricted completely unambiguous 
conclusions. In addition, it must be realised that patient-specific local dose gradients, patient-specific 
OAR geometry relative to target volumes and additional department-specific treatment factors [5] will 
ultimately cause non-uniform deviations in dose between patients. This could further explain the 
variation in results reported by Brouwer et al. [79]. 
 
1.5 Adaptive radiotherapy 
The planned dose distribution is frequently undermined in HNRT due to anatomical changes (Sub-
section 1.4.2) occurring during treatment. Adaptive radiotherapy (ART) is the process of administering 
accurate and precise treatment in the presence of these anatomical changes [113–117]. As described by 
Yan et al. [116], a comprehensive ART implementation should include four key steps: (1) Treatment 
dose assessment, the use of on-board imaging in combination with the therapy machine output to 
provide feedback of the accumulated dose in structures of interest at a given time point during treatment; 
(2) Treatment variation identification/evaluation, the multiple-role step that characterises random 
variation in treatment processes, estimates the total treatment dose, estimates the biological equivalent 
 
  






dose (BED) [118] in structures of interest and the corresponding potential dose response, and provides 
feedback information in parametric form for treatment modification decisions; (3) Treatment 
modification decisions, a set of premeditated control rules. The control rules are triggered by the outputs 
of step (2) and used to determine whether the treatment needs modification and what form of 
modification is required. Typical modifications may be a patient positioning correction, a beam aperture 
correction, a new PTV or a treatment plan modification; (4) Adaptive treatment modification, 
application of the treatment modification which may be performed online or offline [116].  
 
Typically, ART in HNRT is based on an ad-hoc re-plan (not necessarily generated on a re-scan CT) 
when a patient experiences considerable anatomical change [93,119–121]. This form of ART is known 
as triggered adaption and can be considered the most common form of offline adaptation in radiotherapy 
[114]. In general, triggered adaption is often based on subjective criteria [93,119–121] such as 
inadequate fixation equipment or anatomical changes which are deemed clinically relevant on visual 
examination [114]. A number of alternative offline and online strategies have been proposed for ART 
such as an average anatomy model [122,123], a library of plans [124–126], a scheduled adaption [127] 
or online re-planning [128]. All of the ART methods mentioned so far have finite accuracy and as a 
result, residual uncertainties will still be present [114]. It is likely that the conceptually simple but 
technologically complex real-time ART [113] will assist the mitigation of these residual uncertainties 
in the future. 
 
1.6 Deformable image registration 
Effective and precise HNRT relies on the ability to incorporate patient information from multiple time-
points during treatment [129]. Image registration is the procedure of aligning different intra- or even 
inter-patient datasets to a single frame of reference and is abundant in radiotherapy [130].  
 








 The transform, applied to the source image to align it to the target image. Typically, the source 
image represents the original anatomy (e.g., the pCT) and the target image represents anatomy 
during treatment (e.g., a CBCT). The transform can be simple, representing a rigid body with 
six transform parameters (i.e., translation along the 3 cardinal axes – sagittal, coronal and axial 
– and rotation about these axes: pitch, yaw and roll, respectively) or complex, representing a 
higher dimensional registration method where the number of transform parameters can equal 
up to three times the number of voxels in the source image (i.e., a unique 3D transform for each 
voxel) [130] 
 A registration metric, the quantification of the degree to which two imaging datasets are 
aligned. A registration metric is typically classified as either geometry-based or intensity-based. 
Geometry-based metrics make use of anatomical features from the image data such as bony 
landmarks or organ boundaries while intensity-based metrics use the voxel intensity data 
directly [130]. The registration metric is minimised or maximised where the minimisation or 
maximisation corresponds to the best alignment of the source and target image  
 An optimiser, which seeks the optimal set of transformation parameters to obtain the best image 
alignment as quantified by the registration metric. Considering the large number of voxels in 
medical images, an efficient optimiser must intelligently search subsets of the parameter space 
while also searching the whole parameter space to find the most accurate solution [130] 
 
When a patient has non-rigid deformation during treatment (Sub-section 1.4.2) and two image sets 
cannot be sufficiently registered with rigid translations and rotations only, there may be a need to utilise 
DIR (a higher dimension registration method). Approaches to DIR can broadly be characterised as 
geometric, such as the B-spline registration (Sub-section 1.6.1) or physical, such as the demons 
registration (Sub-section 1.6.2) [130]. The unique 3D transforms for each voxel are often smoothed and 
regularised to generate an overall transform which is considered to be biologically realistic. The overall 
transform in DIR which models the direction and magnitude of tissue progression is referred to as the 
deformation vector field (DVF) [131]. The deformation described by the DVF can be used to propagate 
 
  






contours from the source image to the target image (Sub-section 1.6.3), and in dose accumulation (Sub-
section 1.6.4).  
 
1.6.1 B-spline registration 
A B-spline DIR transformation generates the overall non-rigid deformation (i.e., the DVF) from a set 
of weighted basis functions [132]. Functions in a set are named basis functions if every continuous 
function in the function space can be represented as a linear combination of those functions in the set. 
A corresponding set of control points are marked on the source and target images to generate the basis 
functions. The deformation at a given point in the image space is calculated as the weighted sum of the 
basis functions. Manipulating the weighting of each basis function affects only a local segment of the 
overall non-rigid deformation considering that each basis function is defined for a discrete sub-volume 
of the imaging space only [132]. Figure 1.11 visualises the B-spline deformation concept for a one-
dimensional case. Increasing the number of control points allows more complex local non-rigid 
deformations to be modelled (Figure 1.11). 
 
1.6.2 Demons registration 
A demons DIR transformation generates the DVF from displacements of the individual voxels, or a 
combined set of these [132–134]. The original demons algorithm (below) and extensions of the original 
algorithm use voxel intensities to derive the estimated displacement ?⃗? between the source and target 
images, and are based on the optical flow equation [133]. For an individual voxel, let the intensity in 
the source image be s and the intensity in the target image t. 
 




+ (𝑠 − 𝑡)2
        
 
Where ?⃗? = (𝑣𝑥 , 𝑣𝑦, 𝑣𝑧) and describes the voxel-to-voxel displacement in the three anatomical planes, 








points. The demons equation is typically solved iteratively by incremental changes in the position of 
voxels in the target image so that the source image can be morphed voxel-by-voxel into a spatial 
alignment with the target image [134,135]. In each iteration, the calculations of ?⃗? are followed by a 




Figure 1.11: One-dimensional B-spline deformation concept in the superior-inferior (z direction). (Top 
plots) The overall non-rigid deformation (black dashed line) as a function of z is a weighted sum of the 
basis functions (blue lines) centred at a series of locations called control points (Cps). Increasing the 
density of Cps (right figures) aids modelling of complex local non-rigid deformations. Note the 
difference in overall non-rigid deformations between the top left and right plot. For the left and right 
plots, the weighting factor of the basis function (red vertical lines) affects the overall non-rigid 










1.6.3 Contour propagation 
As described in Section 1.6, one rationale for aligning imaging data sets is to facilitate matching of 
information from one time point to another. Considering that the DVF models the direction and 
magnitude of tissue progression from the source to target image, contours of the source image can be 
deformed according to the DVF and copied to the target image. The process of deforming contours 
according to the DVF with subsequent copying to the target image is known as contour propagation 
[132,136–138]. Figure 1.12 illustrates the contour propagation procedure of pCT contours to a CBCT 
taken during treatment. 
 
 
Figure 1.12: The contour propagation procedure. A planning computed tomography (pCT) scan (a) is 
matched with deformable image registration (DIR) to a cone beam CT (CBCT) scan (b) which generates 
a deformation vector field (DVF) (c). The original contours of the pCT (d) are deformed according to 
the DVF (e) and copied to the CBCT (f). 
 
1.6.4 Dose accumulation  
DIR can facilitate dose reconstruction and subsequent accumulation of the reconstructed doses to assess 
the actually delivered dose to target volumes and OARs in the presence of anatomical changes [139]. 








using DIR which results in a deformed pCT. This match is described by a ‘forward’ DVF. The plan 
(beam arrangement, monitor units, fluence maps) is then recalculated on the deformed pCT. As 
deformed pCTs still encompass the correct Hounsfield unit (HU) calibration, they can be used to 
reconstruct the delivered dose. The resulting dose distribution is mapped back to the pCT space using 
the inverse or ‘backward’ DVF. Reconstructed doses may then be accumulated in the pCT space. This 
method of dose accumulation is named all-to-one, where the ‘one’ implies a common reference frame. 
Figure 1.13 illustrates the all-to-one dose accumulation procedure for a pCT reference frame. 
Alternatively, a chronological accumulation of dose is possible where the reconstructed dose of a given 
fraction is mapped to the subsequent fraction’s anatomy and summed with the current fraction’s 
reconstructed dose. The resultant dose is then mapped to the following fraction’s anatomy and the 
process is repeated. In the context of HNRT, a number of studies have utilised DIR-facilitated dose 
accumulation to evaluate the advantages of re-planning during the course of treatment [140,141], or to 
assess the impact of anatomical changes on delivered dose as a function of PTV margins [110,142]. 
However, comprehensive uncertainty analyses regarding accumulated dose are frequently lacking and 
when present, often do not sufficiently validate the accumulated dose [143]. Some studies have 
suggested direct calculation of the daily delivered dose in CBCTs (instead of dCTs) [144] by 
manipulating the CBCT HUs. However, intrinsic uncertainties in these adjustment techniques may 
confound the quantification. 
 
1.6.5 Inverse consistency and symmetry  
As introduced in Section 1.6, DIR is used to model the direction and magnitude of non-rigid tissue 
progression from different time-points during treatment. Accordingly, physically plausible DVFs that 
realistically represent the anatomical changes are desirable. To achieve these physically plausible 
DVFs, the DIR algorithm should be both symmetric and inverse consistent [139,145,146]. A symmetric 
algorithm that deforms the source image to the target image will produce a DVF that has the same 
transformation parameters but in opposite directions to the DVF produced when the source and target 
images are swapped. An inverse consistent algorithm derives a source to target DVF that is equal to 
 
  






the mathematical inverse of the target to source DVF. Intuitively, the difference between symmetry and 
inverse consistency can be difficult to recognise as the two concepts are rarely separated in radiotherapy 
DIR literature. Furthermore, many contemporary DIR algorithms are bidirectional that guarantee 
inverse consistency by simultaneously optimising the ‘forward’ and ‘backward’ registrations [147–
149]. Consequently, these contemporary DIR algorithms are also symmetric. The difference between 
symmetry and inverse consistency is shown in Figure 1.14 and becomes clearer when considering 
unidirectional DIR algorithms that only optimise the ‘forward’ registration. Figure 1.14a illustrates the 
concept of symmetry. The ‘forward’ source image to target image registration shown by the red solid 
arrow (Figure 1.14 left) is identical to the ‘forward’ target image to source image registration shown 
by the blue solid arrow (Figure 1.14a right) except acting on opposite directions. Figure 1.14b illustrates 
inverse consistency. The target image to source image registration shown by the red dashed arrow 
(Figure 1.14b right) is the mathematical inverse of the source image to target image registration shown 
by the red solid arrow (Figure 1.14b left). Figure 1.14a shows symmetry and not inverse consistency. 










Figure 1.13: The all-to-one dose accumulation procedure. A planning computed tomography (pCT) 
scan (a) is matched to a cone beam CT (CBCT) scan (b) to generate a deformation vector field (DVF) 
and a deformed pCT (dCT) (c). The plan (beam arrangement, monitor units, fluence maps) is then 
recalculated (d) on the dCT. The inverse DVF (e) is applied to the recalculated dose and the resultant 
dose distribution is reconstructed in the pCT space (f). Reconstructed doses of successive fractions can 
be accumulated (g) in the pCT space (h). 
 
  







Figure 1.14: Two-dimensional schematic of the difference between symmetry and inverse consistency 
in deformable image registration (DIR) algorithms. (a, left) The source image (S) to target image (T) 
deformation vector field (DVF) is simplified and represented by the solid red arrow and results in a 
deformed source image (dS). (a, right) The T to S DVF is simplified and represented by the solid blue 
arrow and results in a deformed T (dT). (b, right) The T to S DVF is represented by the dashed red line 
and is the mathematical inverse of the solid red line. (a) symmetric but not inverse consistent 
considering that the solid lines are equal, opposite and not inverse consistent. (b) inverse consistent but 
not symmetric considering that the solid lines are equal, not opposite and inverse consistent. 
 
1.6.6 DIR validation 
It is imperative to validate any DIR software that is used in a clinical decision making process. However 
it must be stated that validation of DIR software is challenging because a comprehensive ground truth 
when dealing with patient data does not yet exist [130]. This is particularly problematic in regions 
without distinct tissue boundaries. Nevertheless, numerous studies have evaluated the accuracy and 








contours [105,136–138,150–154]. Here, landmarks and contours delineated by the physician are 
typically compared to those deformed according to the DVF with a distance to agreement and/or overlap 
metric (or similar geometric analysis) [130]. Two commonly used approaches are the mean distance to 
agreement [155] and Dice similarity coefficient [156]. However considering the well documented intra- 
and inter-observer contour delineation variation [157,158] which confounds the physician established 
ground truth, many studies have instead opted to focus on the physical plausibility of the DVFs 
[131,159] by utilising metrics such as the Jacobian determinant of the DVF [130]. A number of studies 
have generated a ground truth deformation through use of a mechanical [160] or in silico phantoms 
[134,161] to validate their DIR software.  
 
The methods described here so far (Sub-section 1.6.6) to validate DIR focus primarily on the forward 
DVF and associated applications, such as contour propagation. These validation methods are in 
agreement with guidelines published in the 2017 ‘Use of image registration and fusion algorithms and 
techniques in radiotherapy: Report of the American Association of Physicists in Medicine (AAPM) 
Radiation Therapy Committee Task Group No. 132’ report by Brock et al. [130].  
 
The validation of DIR for dose accumulation was however outside the scope of the Brock et al. report 
[130] and in general, literature tackling this area is scarce. Compared to DIR-facilitated contour 
propagation where the accuracy is most important at the tissue boundaries, every voxel receiving 
clinically relevant dose is required to be accurately aligned for dose accumulation. Furthermore, the 
dose accumulation procedure described in Sub-section 1.6.4 is predicated on inverse consistent and 
symmetric ‘forward’ and ‘backward’ DVFs, as opposed to only an accurate ‘forward’ DVF required in 
contour propagation. The potential for a displacement field error (DFE) in the ‘forward’ registration 
caused by intrinsic limitations of DIR algorithms [134,153] as well as possible inverse consistency 
errors (ICEs) of the ‘backward’ transformation [159] results in uncertainties in the accumulated dose 
[145,162–165]. A perfect ‘forward’ and ‘backward’ registration is shown for a simplified 2-
dimensional case for a single voxel in Figure 1.15a. An incorrect ‘forward’ registration caused by a 
DFE is illustrated in Figure 1.15b and an incorrect ‘backward’ registration caused by an ICE is 
 
  






illustrated in Figure 1.15c. As a consequence of DFEs and ICEs (which are themselves caused by a 
multitude of factors which are discussed in Section 3.4), the suitability of DIR for accurate and precise 
dose accumulation is debated in the literature [143,166–169]. To the best of the author’s knowledge, 
only two studies have evaluated the uncertainty in dose accumulation for HNRT [145,162]. However, 
a comprehensive validation in these studies is hampered by not investigating the dose reconstruction 
uncertainties of structure sub-volumes or by not considering registration errors in the pseudo-ground 
truth registration.  
 
 
1.7 The PTV margin in HNRT 
As prefaced in Section 1.3, the PTV margin ensures adequate CTV coverage and accounts for various 
uncertainties including patient positioning, geometrical accuracy of the treatment machine and 
geometrical uncertainties of target volume definition. PTV margins and IGRT do not standardly account 
for the non-rigid deformations which are commonly observed in HNRT (Sub-section 1.4.2). Classical 
PTV margin recipe calculations [35,36] yield CTV to PTV margin expansions of 6-9 mm, even when 
non-rigid deformations are ignored and low estimates for the uncertainty in target delineation are used. 
Despite this, PTV margins of 5 mm are commonly applied to establish target coverage [170,171] and 
Figure 1.15: A simplified 2-dimensional case of a single voxel’s ‘forward’ and ‘backward’ registration. (a) A perfect 
‘forward’ and ‘backward’ registration shown by the voxel returning to its start position. (b) A displacement field error 
(DFE) is exemplified by the voxel’s incorrect position after the ‘forward’ registration. An inverse consistency error 








high local tumour control rates up to 78-88% are commonly reported [1,2,53,62]. Most treatment 
failures occur well within the high-dose region, while recurrences within or near the PTV-margin 
boundary are exceptional [172–174]. 
 
1.7.1 PTV margin reduction 
Three groups have reported on the clinical outcomes for patients treated with either 3 or 5 mm PTV 
margin plans [1–4]. Chen et al. [1,2] reported a 78% two-year LR control rate for both 3 and 5 mm PTV 
margin expansion patient groups (p = 0.96). Of the 46 (225 total) patients that had a loco-regional 
recurrence (LRR) in that study [2], eight were found to be marginal. A marginal LRR was observed in 
the dermal/subcutaneous surface, contralateral neck in the vicinity of spared PG and retropharyngeal 
area in three, three and two instances, respectively. Five and three of the eight marginal LRRs arose for 
patients treated with 5 and 3 mm PTV margin plans, respectively. It should be noted that these results 
may have been confounded by the application of adaptive radiotherapy (ART) for selected patients 
[119]. At three-year follow up [1], a significant reduction in oesophageal stricture (p = 0.01) and 
gastrostomy-tube dependence at one year (p < 0.01) was associated with a 3 mm PTV margin expansion. 
No significant differences in xerostomia or dysphagia were found for the different margins expansions. 
Similarly, Navran et al. [3] did not observe a significant difference in the two-year LR control rates (p 
= 1.0) which were 79.9% and 79.2% for patients treated with 3 and 5 mm PTV margins, respectively. 
The geography of LRRs was not reported in that study. Navran et al. [3] applied an IGRT protocol that 
accounted for non-rigid patient positioning deviations as well as ART for selected patients. The median 
follow up time was 17.2 and 34.9 months (p < 0.01) for the 3 and 5 mm PTV margin groups, 
respectively. A significant reduction in acute grade three toxicity (p = 0.03), acute grade three mucositis 
(p < 0.01) and acute grade three dysphagia (feeding tube-dependence) (p = 0.03) was associated with 
the 3 mm PTV margin expansion patient group [3]. A significant reduction in the incidence of ongoing 
feeding tube-dependence after three months of radiotherapy was also observed for the 3 mm PTV 
margin patient group [3]. No significant differences in late grade ≥ two xerostomia were found. 
 
  






In contrast to the previous two groups, Franzese et al. [4] found a significant difference (p = 0.045) in 
the two-year LR control rates which were 87.8% and 72.6% for patients treated with 5 and 3 mm PTV 
margins, respectively. Again, the location of LRRs was not reported. Daily IGRT was utilized for both 
margin expansion groups however it is unclear if an ART procedure was employed [4]. The median 
follow up time was 26 months. A significant reduction was not observed for any of the acute or late 
toxicity end points except for grade three acute dysphagia (p < 0.01) which, surprisingly, was lower for 
the 5 mm PTV margin patient group [4].  
 
The difference between 3 and 5 mm PTV margins in visualised in Figure 1.16. It is important to optimise 
the PTV margin so appropriate target coverage is achieved while simultaneously ensuring the margins 













Figure 1.16: Visualisation of the difference between 3 (inner red contour) and 5 mm (outer red contour) 
planning target volume (PTV) margins. The colourwash represents the low-dose 95% isodose line. The 
parotid glands (orange and yellow contours) are located laterally. The spinal cord 3 mm planning risk 








1.8 Wellington Blood & Cancer Centre  
Section 1.8 describes and compares WBCC practices with external departments in areas of HNRT that 
are pertinent to this dissertation’s goal of developing a quality management “safety net” tool for patients 
who may be at risk of unacceptable loss in target coverage and/or overdosage to normal tissues with 
reduced PTV margins. 
 
1.8.1 Contouring  
Target delineation at the WBCC is carried out using pre-treatment CT imaging but is also based on 
clinical information and physical examination. Although magnetic resonance imaging (MRI) 
information is known to reduce inter/intra-observer variation [170,175], it is not always available for 
contouring at the WBCC. Furthermore, the potential added value of MRI imaging has not been exploited 
considering that patient positioning on MRI and CT is markedly different and DIR has not been 
implemented for MRI-pCT matching.  
 
A reasonably common approach exists for target delineation although contouring is ultimately done at 
the discretion of the treating radiation oncologist and a strict contouring protocol does not yet exist for 
HNRT. A procedure for peer review of contours is currently being developed. Details of the WBCC 
target delineation approach for HNRT are: 
- High-dose CTV (i.e., CTV66Gy) = GTV + 5 mm margin + structures at risk. Bony anatomy is 
considered to be an anatomical barrier and is removed from the CTV (unless there is invasion). 
Air cavities are not consistently removed from the CTV 
- Intermediate-dose CTV (i.e., CTV60Gy) = intermediate risk structures; these are anatomical 
structures with a high probability of infiltration based on positron-emission tomography (PET) 
imaging and experience of the radiation oncologist 
- Low-dose CTV (i.e., CTV54Gy) = low risk structures as per The Danish Head and Neck Cancer 
Group (DAHANCA) consensus guidelines [176] 
 
  






- High-, intermediate- and low-dose PTVs = high-, intermediate- and low-dose CTVs + 5 mm 
margin 
 
The precision and reproducibility of target delineation at the WBCC has not been formally assessed. 
However, in a study by Ramadaan et al. [150] investigating the suitability of DIR for efficient 
contouring of structures upon treatment adaptation, it was found that DIR did offer a time saving in re-
contouring [150]. The study also highlighted differences between independently redrawn contours and 
contours adapted after DIR, which was partially caused by intra-observer variability. These finding 
were consistent with those reported by other groups [152,177–179]. 
 
1.8.2 Accuracy of patient positioning 
The introduction of CBCT for patient position verification at the WBCC in 2011 highlighted that the 
reproducibility of patient positioning, in particular the variation in the posture of the patient over the 
treatment course was larger than anticipated. This required a highly individualised patient positioning 
approach and posed a high workload for treatment staff to maintain adequate dose coverage, in 
particular when anatomical changes occurred during the treatment course. For these reasons, a multi-
disciplinary group focussing on patient positioning was instigated in 2012. This group implemented 
various process changes based on the findings of weekly image review meetings. The weekly image 
review meetings were also started in 2012. A review of the patient positioning results using statistical 
process control (SPC) showed that the reproducibility of patient positioning significantly improved at 
the end of 2013 [85]. Furthermore, it was shown that the variation in positioning results from that point 
in time onwards could almost completely be attributed to sub-optimal positioning reproducibility for a 
limited number of cases (7.5%). CBCT guidance was initially carried out weekly in addition to daily 
IGRT using planar kilovolt (kV) imaging for HNRT. Daily CBCT guidance has been implemented 
since November 2015. At the WBCC, treatment couch corrections with three degrees of freedom 
(lateral, vertical, longitudinal shifts) are carried out before each treatment fraction, based on registration 








It is difficult to directly compare the accuracy of patient positioning at the WBCC with other studies 
due to differences in measurement and analysis methods. However, the magnitude of patient 
deformation at WBCC [85] is considerably smaller than reported by Graff et al. [81], Polat et al. [82], 
van Kranen et al. [83] and Zhang et al. [84] (Sub-section 1.4.2). In a later study, van Kranen et al. [180] 
reported on strategies for patient position correction taking the difference in deviation of multiple 
regions of interest (ROIs) into account [180]. With these strategies, they succeeded in reducing the 
average residual deviation for the different ROIs and the overall impact of patient positioning errors. 
The residual deviations [180] were similar to those observed for most ROIs at the WBCC during patient 
positioning, assuming all patient position corrections at the WBCC are carried out based on the location 
of the reference ROI C1-C3. For the tilt of the patient’s head, the results of van Kranen et al. [180] were 
significantly worse compared to the results of the WBCC. It is preferable to physically reduce a patient’s 
non-rigid setup errors at pre-treatment setup, considering that treatment couch corrections only cannot 
reduce non-rigid patient positioning deformations for all ROIs to the same degree. 
 
For the groups reporting on clinical outcomes after reducing PTV margins from 5 to 3 mm, the patient 
positioning accuracy achieved by the study of Navran et al [3] is that reported by the previously 
mentioned van Kranen et al papers [83,180]. The accuracy of patient positioning achieved by the group 
of Purdy et al. [1,2,52,119,181,182] has to the best of the author’s knowledge not been documented in 
literature. In the previously described papers by the group of Purdy discussing the results of PTV margin 
reduction [1,2], it was stated that daily IGRT was applied including CBCT and image registration 
focussing on the high-dose PTV. This is similar to the current practice at the WBCC. However, this 
series of papers [1,2,52,119,181,182] also stated that standard head rests (TIMO, Med-Tec) for patient 
immobilisation were used in contrast to the individual head rests used at the WBCC. The individual 
head rests were fundamental for achieving a high accuracy in patient positioning. It is therefore likely 
that the group of Purdy et al. [1,2,52,119,181,182] did not achieve the same level of patient positioning 
accuracy as the WBCC while treating patients using reduced PTV margins. The accuracy of patient 
positioning achieved by the study of Franzese et al. [4,183] has also to the best of the author’s 
knowledge not been documented in literature. In the work of Franzese et al. [4] it was stated that daily 
 
  






CBCT-guided couch corrections were applied to correct patient positioning setup errors for patients 
treated with both 5 and 3 mm PTV margins.  
 
1.8.3 Review of clinical results 
A recent review of the WBCC clinical results of oropharyngeal cancer treatments found a non-
significant difference between the three-year actuarial rates for LR control before and after the 
introduction of VMAT which were 87% and 89%, respectively [184]. These control rates are well in 
line with international literature reporting on LR control rates before and after the introduction of IMRT 
[53,62]. At follow-up, a significantly lower proportion of VMAT patients experienced grade two or 
higher acute dermatitis: 89% 3DCRT versus 55% VMAT (p < 0.01). At most time points, the proportion 
of VMAT patients experiencing grade 2 or higher late xerostomia was lower for VMAT than for 3D-
CRT patients, although this difference was only statistically significant at 24 months after treatment (p 
= 0.04). The favourable toxicity profile could be related to a significantly lower dose to skin and parotid 
glands in VMAT patients. A PG Dmean less than 26 Gy is commonly used as the main objective to aim 
for to reduce xerostomia [25,59]. The study reviewing the WBCC clinical results [184] indicated that 
an additional future reduction of the PG Dmean by 5 to 10 Gy would result in a PG Dmean of less than 26 
Gy for a considerably larger proportion of patients. Specifically, a Dmean less than 26 Gy for at least one 
of the PGs is estimated to be obtained for 47%, 63%, or 79% of the patients if either the current 
approach, a PG Dmean reduction of 5 Gy, or 10 Gy is pursued, respectively. These levels of PG Dmean 
reduction may be achieved by applying a PTV margin reduction from 5 to 3 mm.  
 
1.8.4 Adaptive radiotherapy 
Patients’ non-rigid deformations are reviewed on an individual patient basis during weekly 
multidisciplinary team (MDT) image review sessions at the WBCC or by dedicated radiation therapists 
who review all patient treatment images. When these non-rigid changes are small and deemed to be 
clinically irrelevant, they are generally ignored. If these non-rigid changes are deemed to be of potential 








changes, the physics department simulates the actually delivered dose using an HU override of the pCT. 
The non-rigid changes are then further discussed in an MDT setting and the necessity of a re-plan is 
debated considering multiple patient specific factors including whether a new CT would be 
representative for the remainder of treatment. If unaccounted for, these changes could cause geometrical 
miss and potentially result in under-dosage of tumour targets or over-dosage to OARs [103]. Changes 
that occur at the end of the treatment are often difficult to counteract, and re-planning is usually not 
possible due to time constraints. In these cases, avoiding an overdose to critical normal tissues is 
standardly prioritised over target coverage. 
 
1.8.5 DIR  
The clinical implementation of DIR at the WBCC is SmartAdapt (SA) [135] which is based on the 
demons algorithm [133,134] and is part of the commercial ARIA-radiotherapy management package 
(v13 Varian Medical Systems, Palo Alto, CA, USA). The following information is made available in 
Varian’s SA user manual [135]: 
 
The DIR algorithm used in SA is based on the original optical flow algorithm [133] with two primary 
modifications [134]. First, SA incorporated a coarse-to-fine multi-resolution approach to allow for 
relatively large deformation recovery without large errors. The original demons implementation 
assumed small deformations between image datasets and could not accurately recover large 
deformations. The coarse-to-fine multi-resolution approach begins by utilising low resolution images 
derived from the original datasets and as such, large deformations become relatively small which 
promotes convergence when solving the demons equation (Sub-section 1.6.2). After convergence, the 
3D vectors of the displaced voxels (Section 1.6) are passed to the next higher resolution. The multi-
resolution approach improves SA’s efficiency relative to the original demons implementation [135]. 
Second, a symmetric force is built into SA. The symmetric force produces a transformation to map the 
source image to the target image consistent with the inverse transformation that maps the target image 
to the source image (Figure 1.14). Realistic patient non-rigid deformations are considered inverse 
 
  






consistent and symmetric [130,131,146]. SA is limited in cases where multiple potential solutions exist. 
For example, a point inside an area of homogeneous image contrast on the source image could be linked 
to any other point in the homogeneous image contrast region on the target image. As such, sufficient 
information to describe the deformation may not be available in the image datasets. Another limitation 
of SA is if a voxel exists in the source image but not the target image. For example, a voxel of normal 
tissue may be present in the pCT but due to patient weight loss ‘dissolves’ from the CBCT. The SA 
DIR will not be able to find the one-to-one correspondence for this voxel. Therefore, the registration 
may not be accurate [135]. 
 
A small number of studies have evaluated the accuracy of SA propagated structures in the head-and-
neck region utilising CT scans [104,138,150,185,186]. Investigations regarding the accuracy of 
structures deformed to CBCTs are even more limited [104,185,186].  
 
1.9 Dissertation structure 
This Introduction chapter presented a brief introduction to HNRT, DIR and current practices at the 
WBCC to provide context to this dissertation. As prefaced in Section 1.1 and detailed in Sub-section 
1.7.1 , recent literature has reported reduced treatment-related toxicity after reducing PTV margins from 
5 to 3 mm for HNRT [1–4]. However, equivalent LR control rates were not always maintained [4]. As 
it was considered whether it was possible to implement reduced PTV margins from 5 to 3 mm at the 
WBCC with the aim to improve patients’ treatment-related toxicity, it was recognised that many 
department-specific aspects of HNRT including, but not limited to, plan design, constraint adoption, 
prioritisation of OARs and target coverage, technical aspects of treatment accuracy, robustness of the 
planning solution for anatomical changes and method of immobilisation can influence treatment 
outcomes [5] and should all be considered when the PTV margins are amended. Considering these 
sources of possible treatment variability, it is important to have adequate quality management tools in 









The overall goal of the research described in dissertation was to enable a safe PTV margin reduction in 
HNRT from 5 to 3 mm at the WBCC. One approach to safely implement a PTV margin reduction is to 
account for systematic changes in patient positioning and/or anatomy using timely and appropriate ART 
[115]. However, this approach requires quantification and separation of the different modes of non-
rigid deformation as they can be corrected for with different adaptive methods. Furthermore, it requires 
investigating the dosimetric impact of non-rigid deformations. Chapters Two, Three and Four detail the 
development of the tools to (a) quantify and separate the different modes of non-rigid deformation; and 
(b) investigate the dosimetric impact of the non-rigid deformations. These tools aimed to form the 
quality management “safety net” to detect those patients who may be at risk of unacceptable loss in 
target coverage and/or overdosage to OARs with reduced PTV margins. 
 
Chapter Two introduces Exponentially Weighted Moving Average (EWMA) Statistical Process Control 
(SPC) charts [187] in combination with DIR to monitor and quantify individual patient non-rigid 
deformations during treatment. An individual patient’s positioning reproducibility and non-rigid 
deformations must be well controlled and monitored to enable safe PTV margin reduction. SPC is 
widely used in manufacturing as a quality management tool and recently, its use in radiotherapy for 
quality assurance has been discussed [188]. EWMA charts, also known as process-behaviour charts, are 
frequently used as an SPC tool to examine and monitor process time trends [189]. The unambiguous 
instructions surrounding control chart initialisation and interpretation allow time trends to be reviewed 
in a standardised way. To the best of the author’s knowledge, no previous study has reported on trend 
analysis that quantifies and separates different modes of patient-specific anatomical change using SPC 
and DIR. 
 
Chapters Three and Four are closely related to each other considering their predication on dose 
reconstruction and accumulation. Dose reconstruction and accumulation (as introduced in Sub-section 
1.6.4) in the context of the research described in this dissertation refers to the utilisation of DIR-
facilitated reconstruction and accumulation of the delivered dose between different treatment time 
points. Consequently, the actually delivered dose for a HNRT treatment in the presence of anatomical 
 
  






changes can be quantified. The dose accumulation procedure may be particularly applicable to the 
objective assessment of the adequacy of target coverage during HNRT with reduced PTV margins. 
However, registration errors (Sub-section 1.6.6) can introduce an uncertainty in the dose reconstruction 
and accumulation [145,162–164]. Chapter Three utilised an in silico ground truth based on clinically 
observed deformations to investigate the uncertainty of a DIR-facilitated dose accumulation workflow. 
The uncertainty in the accumulated dose was incorporated as a confidence interval in DVHs. Dose 
accumulation is currently not facilitated in Varian’s SA module and requires external software. 
Considering that only limited literature is available on the accuracy of DIR-facilitated dose 
accumulation in general and that no previous study has reported on the accuracy of the intended clinical 
workflow, the retrospective study in Chapter Three was instigated.  
 
Chapter Four investigated the impact of anatomical changes on the robustness of treatment plans 
constructed with 5 and 3 mm PTV and PRV margins. DIR-facilitated dose accumulation was used to 
investigate the robustness of treatment plans’ target coverage, critical OAR avoidance and non-critical 
OAR sparing. The target coverage, critical OAR avoidance and non-critical OAR sparing was first 
quantified with DVH metrics. However, DVH metrics inherently lack spatial information regarding the 
dose distribution within a volume of interest [190] and for large target volumes, a clinically relevant 
loss in local sub-volume coverage may not be detected. Therefore, a more in-depth voxel-specific 
investigation was conducted. In the context of reducing PTV margins from 5 to 3 mm in HNRT, the 
retrospective study in Chapter Four contributed to the scarce body of literature regarding the robustness 
of treatment plans for anatomical changes and presented key recommendations. 
 
Chapters Five and Six contain the Discussion and Conclusion, respectively. The Discussion chapter 
presents further considerations that are relevant to each study which are not provided in the 
corresponding discussion Sections (i.e., 2.4, 3.4 and 4.4) and links the individual studies together to 
present a collective summary showing how they constitute a coherent body of research. Conclusions to 
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I, along with co-author RL developed the strategy of monitoring individual patients’ anatomical 
changes with SPC and DIR. I collected all patient data, performed all tasks within the treatment 
planning system and wrote all the MATLAB scripts for data analysis. I integrated standardised 
uncertainty equations with the mathematics of SPC and performed all the data and statistical 
analyses. Co-authors DH, HK and JE are consultant radiation oncologists at the Wellington 
Blood & Cancer Centre and contributed to this study by providing re-contouring of the PGs on 
CBCTs. I, along with co-authors SM and RL developed the conclusions. I wrote this paper with 
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Background and purpose: Reduced toxicity while maintaining loco-regional control rates have been 
reported after reducing planning target volume (PTV) margins for head-and-neck radiotherapy (HNRT). 
In this context, quantifying anatomical changes to monitor patient treatment is preferred. This 
retrospective feasibility study investigated the application of deformable image registration (DIR) and 
Exponentially Weighted Moving Average (EWMA) Statistical Process Control (SPC) charts for this 
purpose. 
 
Materials and methods: DIR between the computed tomography for treatment planning (pCT) images 
of twelve patients and their daily on-treatment cone beam computed tomography (CBCT) images 
quantified anatomical changes during treatment. EWMA charts investigated corresponding trends. 
Uncertainty analysis provided 90% confidence limits which were used to confirm whether a trend 
previously breached a threshold. 
 
Results:  
Trends in patient positioning reproducibility occurred before the end of treatment week four in 54% of 
cases. Using SPC process limits, only 24% of these were confirmed at a 90% confidence level before 
the end of treatment. Using an a priori clinical limit of 2 mm, absolute changes in patient pose were 
detected in 39% of cases, of which 82% were confirmed. Soft tissue trends outside SPC process limits 
occurring before the end of treatment week four were confirmed in 90% of cases.  
 
Conclusion: Structure specific action thresholds enabled detection of systematic anatomical changes 
during the first four weeks of treatment. Investigation of the dosimetric impact of the observed 
deviations is needed to show the efficacy of SPC to timely indicate required treatment adaptation and 
provide a safety net for PTV margin reduction. 
  







The introduction of intensity modulated radiotherapy has enabled highly conformal dose deliveries 
which allows dose reduction to organs at risk (OAR) and reduced treatment toxicity [21,191,192]. These 
highly conformal treatments require image-guided radiotherapy (IGRT) to warrant accurate patient 
positioning and monitoring of changes in patient anatomy [115]. Planning target volume (PTV) margins 
of 5 mm are commonly applied to establish target coverage [170,171]. PTV margins and IGRT do not 
standardly account for non-rigid anatomy changes which are commonly observed in head-and-neck 
radiotherapy (HNRT) [78]. Nevertheless, two retrospective studies have suggested that 3 mm planning 
target volume (PTV) margins are sufficient if daily IGRT is used to correct for rigid patient position 
variations [193,194]. The study of Chen et al. has also clinically implemented reduced PTV margins 
from 5 mm to 3 mm and reported a reduction in late toxicity side-effects while maintaining equivalent 
two- and three-year loco-regional control rates [1,2,194]. However, these results may have been 
confounded by the application of adaptive radiotherapy (ART) for selected patients [119]. A recent 
study by Navran et al. also reported on favorable toxicity profiles for reduced 3 mm PTV margins while 
maintaining good tumor control rates [3]. The latter study applied an IGRT protocol that accounted for 
non-rigid patient positioning deviations as well as ART for selected patients.  
As we considered whether it was possible to implement reduced 3 mm PTV margins after achieving a 
large improvement in patient positioning in our department [85], it was recognized that many other 
aspects of HNRT including accuracy of target delineation, robustness of the planning solution for 
anatomical changes influence treatment outcomes [5] and should all be considered when the PTV 
margins are reduced. In addition, objective and generally applicable guidelines to select patients who 
will benefit from treatment adaptation are lacking [79,115], and most studies on ART apply subjective 
criteria to select patients for treatment adaptation [93,107,119,121]. In an effort to create a safety net 
for patients who exhibit large non-rigid deformations and objectively select patients who would benefit 
from treatment adaptation in the context of PTV margin reduction, this feasibility study investigated 
the first step to build such a framework. Specifically, the suitability of deformable image registration 









objectively quantify and monitor individual patients’ deformation, i.e., non-rigid changes in both pose 
and anatomy of the patient during treatment were investigated.   
  






2.2 Materials and methods 
2.2.1 Patient group 
This retrospective study included twelve patients with cancers of the head-and-neck (HN) region that 
were treated radically. Comprehensive information regarding the patient cohort can be found in the 
Supplementary Data (A.1: Patient group). The patients included in this retrospective study provided 
written consent to use their data in clinical audits. 
 
2.2.2 Planning CT contouring  
Nine bony anatomy (BA) structures were delineated on each patient’s computed tomography for 
treatment planning (pCT) scan: C1-C3, C3-C5, C5-C7, mandible, maxilla, base of skull, hyoid, occipital 
and larynx. A pre-defined neck volume 𝑉𝑛𝑒𝑐𝑘 was defined as all tissue within the volume bounded by 
axial planes at the base of C3 at the anterior cortical boundary and base of C4 at the anterior cortical 
boundary (Figure 2.1). The original parotid gland (PG) contours were reviewed by a radiation 
oncologist and corrected where necessary to minimize the uncertainty of the DIR results. 
 
2.2.3 Deformable image registration  
The pCT of each patient was deformed to match the anatomy of each daily cone beam computed 
tomography (CBCT) using SmartAdapt v.13 (Varian Medical Systems, Palo Alto CA, USA), resulting 
in 30 deformed CTs (dCT). The deformed structures of the dCT as well as the non-deformed structures 
of the pCT were propagated to the corresponding CBCTs. These data sets were exported in Digital 
Imaging and Communications in Medicine (DICOM) format for subsequent analysis with in-house 











Figure 2.1: Definition of bony anatomy (BA) structures and neck volume 𝑉𝑛𝑒𝑐𝑘 in the central sagittal 
plane. The superior end of the occipital bone contour was defined as to just include the external 
occipital protuberance. 
 
2.2.4 Quantifying non-rigid deformations 
The exported contours were used to quantify the non-rigid deformations: BA positioning 
reproducibility, centroid shifts of the PGs, volume changes of the PGs (𝑉𝑃𝐺) and 𝑉𝑛𝑒𝑐𝑘 changes. The 
BA positioning reproducibility was quantified by first calculating the change T in centroid position C 
of all BA structures with respect to its pCT position for each direction k = x, y, z, and each fraction f: 
 𝑇𝑓,𝑘
𝐵𝐴 =  𝐶𝑓,𝑘,𝑑𝐶𝑇
𝐵𝐴 − 𝐶𝑓,𝑘,𝑝𝐶𝑇
𝐵𝐴      (1) 
  






Subsequently, the 3D-deviations of all BA structures were calculated relative to the reference structure 














    (2) 
 
Similarly, the 3D-shifts of the PGs were calculated relative to C1-C3 according to Eq. 2.  
To assist with readability, the 3D-deviation of BA structure X relative to C1-C3 will be referred to as 
“deviation of X” from here onwards. 
2.2.5 Statistical process control 




𝑃𝐺over time were monitored using EWMA charts 
[195]. The values Ef of the EWMA statistic were calculated using:  
𝐸𝑓 = 𝜆𝑋𝑓 + (1 − 𝜆)𝐸𝑓−1    (3) 
where is a constant defined as 0 < 𝜆 ≤ 1 that determines the depth of memory (smoothing) of the 
EWMA and Xf is the metric of interest for fraction f. As shown in Figure 2.2, E0 is the average metric 
of interest during the EWMA reference period. The first week of treatment (i.e. fractions 1-5) is used 
as the EWMA reference period, assuming that prospective monitoring of EWMA statistics would be 
conducted from fraction six onwards in a clinical scenario, with EWMA statistics for fractions 1-5 
analyzed retrospectively.  
The lower and upper process limits LPL and UPL, which indicate a statistically significant difference 
from the reference period, were calculated using:  
LPL, UPL =  𝜇0 ± 𝐿𝜎√(
𝜆
2−𝜆
) [1 − (1 − 𝜆)2𝑓]   (4) 
The initial deviation 𝜇0 and variation σ were calculated as the mean and SD for the reference period, 









metrics of interest were not always normally distributed,  and L were set to λ = 0.05 and L = 2.492 to 
obtain similar type I and type II error probabilities as for normally distributed data [187]. 
PGs were grouped according to mean dose at planning: low- (< 26 Gy, n = 7) and high-dose (≥ 26 Gy, 
n = 17) consistent with the different impact of radiation dose predicted below or above this cut-off point 
by normal tissue complication probability (NTCP) models [25,59]. In cases where the superior or 
inferior extents of the CBCT did not contain a specific BA structure, that structure was excluded from 
the analysis for that patient. 
The fraction numbers at which the EWMA statistics went outside the corresponding process limits were 
recorded. Where possible, EWMA trends that were obtained using DIR were compared with results 
obtained using an alternative manual method. 𝜕𝑓
𝐵𝐴 results obtained using DIR were compared with 
results obtained using a manual method of registration (MMR) as described by various authors [83,85]. 
The MMR used rigid image registrations (translations only; no rotations) of the individual structures to 
assess the shift of the structure centroids relative to the pCT. DIR results for 𝑉𝑓
𝑛𝑒𝑐𝑘 trends were 
compared with the change of a single axial slice volume at the base of C2 that was manually contoured 
for all CBCTs as well as changes in patient weight. Considering that a change in patient weight may 
occur at any location of the patient’s body, 𝑉𝑓
𝑛𝑒𝑐𝑘 trends were expected to describe volume change of 
the treatment region more appropriately than a simple weight metric.  
  






2.2.6 Detection of trends 
In this study two methods to detect trends were investigated: 
2.2.6.1 SPC limits for trend detection 
A detailed uncertainty analysis was carried out to assess whether DIR and EWMA charts can accurately 
monitor non-rigid deformation trends of individual patients, and detect changes in patient positioning 
or anatomy in a timely manner. In these analyses including both the DIR and manual results, the 
uncertainty was calculated as per the Guide to the Expression of Uncertainty in Measurement (GUM) 
[196] (see Supplementary Data A.2: Uncertainty analysis). The results of the uncertainty analyses were 
used to quantify the accuracy of trends as the average 90% level of confidence interval of the EWMA 
statistics for each metric over all treatment fractions. The sensitivity to detect a trend (i.e., the minimal 
detectable trend magnitude) with 90% confidence with respect to the reference period (i.e., E0 set to 
zero) was defined as the difference between the 90% level of confidence of the upper EWMA process 
limit and the EWMA center line at the last treatment fraction. Differences between the sensitivity and 
accuracy of the two methods over all patients were assessed using paired t-tests at the 0.05 level of 
significance. The robustness of trend detection using SPC limits was quantified as the proportion of 
cases where the accuracy interval of the trend exceeded the 90% level of confidence of the process 
limits before the end of treatment relative to the number of cases where the EWMA statistic itself 
exceeded a process limit before the end of the fourth week of treatment.  
2.2.6.2 Clinical limit for trend detection 
Preliminary SPC trend results highlighted sub-mm process limits for specific structures which would 
likely not provide an efficient threshold for clinically relevant process changes. Also the exact moment 
that a BA deviation trend exceeded the control limits within a certain statistical confidence level was 
not easily defined, in particular for shallow trends in combination with narrow process limits of a 
structure. The EWMA trend analysis was therefore also carried out using an a priori 2 mm clinical limit 
as detection threshold for absolute BA deviations. The robustness of trend detection using a 2 mm 









interval of the EWMA statistic exceeded this limit relative to the number of cases where the EWMA 
statistic itself exceeded this clinical limit before the end of the fourth week of treatment. 
 
 







Figure 2.2: Workflow detailing the exponentially weighted moving average (EWMA) statistics monitoring procedure based on DIR. (a) The planning CT (pCT) is 
deformed to match the anatomical configurations of each cone beam CT (CBCT) of treatment week 1; (b) Deformed pCT contours propagated to the CBCTs are used 
to calculate metrics of interest Xf for fractions 1-5. The average metric of interest is defined as E0 and used to calculate the EWMA statistics E1… E5 as per Eq. (3); (c-









2.3.1 SPC trends 
Overall, 31% of the trends describing BA positioning reproducibility acquired with DIR remained 
within the EWMA process limits during treatment, while 54% and 15% of the trends exceeded a process 
limit before and after the end of the fourth week of treatment (i.e., fraction 20), respectively 
(Supplementary Data A.3: SPC results). Figure 2.3a shows the deviation of the mandible for patient 
three exceeding the upper DIR process limit at fraction 18.  
2.3.1.1 SPC limits for trend detection 
Both the average accuracy and sensitivity calculated over all patients were smaller than 1 mm for BA 
deviations. Table 2 summarizes the average accuracy and sensitivity recorded for the various structures 
and compares the results obtained for DIR and MMR. Except for the deviation of the occipital bone 
calculated with DIR, the average accuracies were smaller than the corresponding average sensitivities 
indicating that the minimal detectable trend with a 90% level of confidence was generally equal to the 
observed sensitivity. Statistically significant differences between DIR and MMR accuracies were 
observed for all BA structures except deviation of the maxilla. Conversely, only the sensitivity to detect 
a C5-C7 deviation was significantly different between the two methods.  
The robustness to detect a statistically significant change relative to the reference period for each trend 
is summarized in Table 3 (individual patient results available in Supplementary Data A.4: Individual 
patient 90% level of confidence SPC results). For BA deviations, the overall robustness of trend 
detection was 24% (95% CI: 11-38%), with none of the potential trends for occipital, base of skull, 
maxilla and larynx deviations confirmed to be an actual trend at a 90% level of confidence. In contrast, 
the robustness of trend detection for soft tissue trends was 90% (95% CI: 80-99%), due to steeper 














Figure 2.3: Example of the exponentially weighted moving average (EWMA) charts used in this study of the mandible 
deviation for patient three. EWMA trends derived from deformable image registration (DIR) or the manual method of 
registration (MMR), are shown in orange and blue, respectively. Trends are plotted either as deviations relative to the 
SPC reference period (panels a and b) or absolute deviations including E0 (panel c). (a) DIR derived EWMA chart 
including uncertainty analysis and corrected for initial deformation E0; (b) comparison of DIR and MMR derived 
EWMA charts; (c) DIR and MMR derived EWMA charts including observed E0 for the purpose of comparing the trends 













2.3.1.2 Clinical limit for trend detection 
The absolute BA deviations exceeded the 2 mm clinical limit in 33/84 (39%) of the available cases 
(Table 4) (individual patient results available in Supplementary Data A.5: Individual patient 90% level 
of confidence clinical limit results). Figure 2.3c provides an example of this analysis where the deviation 
of the mandible for patient 3 acquired using DIR did not exceed the 2 mm clinical limit during the 
treatment period. In the majority of cases (29/33) these deviations were already larger than 2 mm from 
the start of treatment in particular for the hyoid and larynx, indicative of the high mobility of these 
structures (see also Supplementary Data A.6: Differences between E0 values of SPC charts based on 
DIR or MMR). The overall robustness of trend detection for BA deviations larger than 2 mm was 82% 
(95% CI: 67-96%). 
2.3.1.3 Trends returning to control 
EWMA trends for BA deviations did not move back within either the process limits or clinical limits in 
any of the cases after previously exceeding control at the 90% level of confidence. In 2 - 3% of cases a 
prior confirmation of a trend was negated as the lower boundary of the trend’s accuracy interval moved 
back either within the upper process limit’s 90% level of confidence or the clinical limit. 
 
2.3.2 Soft tissue analysis 
For eight patients (73%), the trend describing a volume change of 𝑉𝑓
𝑛𝑒𝑐𝑘 exceeded a process limit before 
the end of the fourth week of treatment, and for one patient (9%), this occurred during the final two 
weeks of treatment. These trends usually represented a decrease of the neck volume, however for two 
of these nine patients, an increase in 𝑉𝑓
𝑛𝑒𝑐𝑘 was observed.  
A strong correlation (r2 = 0.87; p < 0.01) was found between the changes in 𝑉𝑓
𝑛𝑒𝑐𝑘 and patient weight. 
A slightly lower correlation (r2 = 0.76; p < 0.01) was found between the changes in 𝑉𝑓
𝑛𝑒𝑐𝑘 and those of 
the single axial slice volume at the base of C2. The 90% confidence intervals of the EWMA trends of 
the latter two metrics overlapped in 91% of cases. 
  






Ninety-four percent of the 48 trends describing shift or shrinkage of a PG exceeded a process limit 
during HNRT treatment. EWMA trends describing shrinkage of high and low mean dose PG groups 
exceeded a process limit before the end of the fourth week of treatment in 94% and 86% of the cases, 
respectively. A decrease in volume was observed for all parotid glands. EWMA trends describing PG 
shift exceeded a process limit before the end of the fourth week of treatment in 76% and 71% of the 
cases, respectively. The Supplementary Data (A.7: Average parotid shift and volume EWMA) shows 
EWMA trends of average volume and shift for both PG groups. 
The average volume change of the PGs from planning to end of treatment was not significantly different 
(p=0.20) for the high dose PGs (-5.9 cm3; range -3.3 to -10.0 cm3) and the low dose PGs (-4.8 cm3; 
range: -3.5 to -9.4 cm3). Similarly, the average shift during treatment was not significantly different 
(p=0.38) for the high dose PGs (2.1 mm; range 1.1 to 3.1 mm) and the low dose PGs (1.1 mm; range 










Table 2: Average sensitivity S and accuracy A of exponentially weighted moving average (EWMA) 
charts established from deformable image registration (DIR) and manually acquired raw data (MMR). 
 represents the difference between DIR and MMR results. Accuracy A= average 90% level of 
confidence interval over all treatment fractions. Sensitivity S= half the EWMA process limit 90% level 
of confidence at the last treatment fraction. *indicates a statistically significant difference. 
 DIR MMR  
Structure A S A S A S 
Occipital bone [mm] 0.3 0.3 0.2 0.3 0.1* 0.0 
Base of skull [mm] 0.2 0.3 0.2 0.3 0.0* 0.0 
Maxilla [mm] 0.2 0.3 0.2 0.4 0.0 -0.1 
C3-C5 [mm] 0.1 0.3 0.2 0.3 -0.1* 0.0 
C5-C7 [mm] 0.1 0.4 0.2 0.5 -0.1* -0.1* 
Hyoid [mm] 0.2 0.7 0.3 0.7 -0.1* 0.0 
Larynx [mm] 0.2 0.8 0.3 0.8 -0.1* 0.0 
Mandible [mm] 0.2 0.4 0.2 0.4 0.0* 0.0 
High dose PG dev. [mm] 0.1 0.3 - - - - 
Low dose PG dev. [mm] 0.1 0.3 - - - - 
High dose PG vol. [cm3] 0.3 0.5 - - - - 
Low dose PG vol. [cm3] 0.3 0.5 - - - - 
𝑽𝒇
𝐧𝐞𝐜𝐤 [cm3] 2.0 3.9 - - - - 
 






Table 3: Median and range of the fraction number where the exponentially weighted moving average (EWMA) statistic exceeded an SPC process limit before the end 
of treatment week 4, and the proportion of cases where the existence of a trend was confirmed by the accuracy interval of the trend exceeding the process limits 90% 
level of confidence before the end of treatment. This proportion is also expressed as percentage representing the robustness of the trend detection with the corresponding 
95% confidence interval. EWMA parameters were established from deformable image registration (DIR) raw data. (PG = parotid gland; BOS = base of skull; Occ = 




Table 4: Median and range of the fraction number where the exponentially weighted moving average (EWMA) statistic exceeded a 2 mm clinical limit before the end 
of treatment week 4, and the proportion of cases where the existence of a trend was confirmed by the accuracy interval of the trend exceeding the clinical limit before 
the end of treatment. This proportion is also expressed as percentage representing the robustness of the trend detection with the corresponding 95% confidence 













Median 1 1 6 NA 1 1  1 1 
Range 1-1 1 1-11 NA 1-19 1 1 1-10 
Proportion 
confirmed  
3/4 0/1 1/2 0/0 3/3 9/9 8/9 3/5 
Robustness 75% 0% 50% NA 100% 100% 89% 60% 




















Median 13  15 11  14  14  14  19  15  14  9  10  12  13  
Range 12-19 9-20 8-15 10 -18 12-19 11-17 14-20 8-18 9-20 7-18 8-20 9-20 9-18 
Proportion 
confirmed  
0/4 0/6 0/5 3/7 3/5 2/7 0/4 3/7 12/13 4/5 14/16 6/6 7/8 
Robustness 0% 0% 0% 43% 60% 29% 0% 43% 92% 80% 88% 100% 88% 
95% CI 0-13% 0-8% 0-10% 0-87% 7-100% 0 - 69% 0 -13% 0% -87% 74-100% 35-100% 68-100% 92-100% 58-100% 









This study investigated the suitability of DIR and EWMA SPC to quantify and monitor individual 
patients’ changes in pose and anatomy during HNRT. This method facilitates a standardized approach 
to quantify patient deformations with an estimated robustness derived from comprehensive uncertainty 
analyses. It is a first step in developing a safety net for PTV margin reduction in HNRT as well as 
objective guidelines to select patient for treatment adaptation. Considering that loss in target coverage 
during treatment might occur more often and might become more relevant with reduced mm PTV 
margins, EWMA-facilitated detection of non-rigid changes in pose and anatomy during treatment of an 
individual patient could allow for early treatment adaption.  
Previous studies investigated the application of SPC charts to monitor the reproducibility of patient 
positioning based on MMR [85]. However, MMR is very labour and time intensive; hampering clinical 
implementation. The application of DIR and SPC to quantify and monitor individual patient 
deformations during treatment can largely be automated and is therefore attractive from an economic 
and efficiency perspective. Considering that a change in treatment is usually not feasible in the final 
weeks of treatment due to the time required for re-scanning the patient, contouring and re-planning, this 
study assumed that clinically relevant changes in pose and anatomy should be detected before the end 
of treatment week four. 
Over all patients, DIR EWMA trends exceeded a process limit before the end of treatment week 4 in 
54%, 73% and 83% of cases for BA deviations, volume changes of 𝑉𝑓
𝑛𝑒𝑐𝑘 and PG changes, respectively 
(Supplementary Data A.3: SPC results). However, these process limits represent the boundaries of the 
variation expected for a ‘process’ based on the observed variation during the reference period. The SPC 
limits therefore ignore the offset E0 during the reference period relative to the desired patient position 
as defined during CT-planning which can be several mm’s in case of highly mobile structures. 
Therefore, deformation trends exceeding an SPC process limit itself is not indicative for the clinical 
relevance of an observed BA deviation and would require additional interpretation rules. In addition, 
potential trends occurring during the reference period add to the uncertainty of the SPC limits. 
Furthermore, the exact moment that the trend of a BA structure deviation relative to the initial value 
during the reference period exceeded an SPC process limit was not easily defined due to the shallow 
  






trends that were observed, in spite of the sub-mm accuracies of the EWMA statistic and process limits. 
The latter problem is exemplified in Figure 2.3a where the EWMA statistic exceeds the upper process 
limit at fraction 18, but the 90% level of confidence interval of the EWMA statistic does not cross the 
90% level of confidence of the upper process limit during the treatment course. Similar behavior was 
observed for MMR derived EWMA charts (Figure 2.3b). At the 90% level of confidence, BA deviation 
trends where the EWMA statistic exceeded the process limits during the first four weeks of treatment 
were only confirmed in 24% of the cases. For these reasons, it is more efficient to apply a clinical limit 
to detect BA deviations that could potentially have a clinical impact during treatment. This study 
showed that EWMA statistics representing BA deviation trends exceeding a generic a priori 2 mm 
clinical limit before the end of treatment week four were detected in 82% of cases at the 90% level of 
confidence. However, this clinical limit should be individually set for each BA structures’ deviations 
based on expected impact to target coverage and/or OAR sparing, which is subject to future 
investigations. Alternatively, the robustness of SPC limits can possibly be improved by also considering 
the rate of the changes during the treatment to define SPC control limits.  
In contrast to the observations for BA deviations, SPC process limits were useful to detect soft tissue 
trends that exceeded the process limits before the end of treatment week four which could be confirmed 
in 90% of cases.  
DIR precision is important for correct anatomical mapping of the pCT to daily CBCTs. In the absence 
of a golden standard, trends acquired using DIR were compared with results obtained using an 
alternative manual method where possible in combination with an uncertainty analyses were conducted. 
Overall at the 90% level of confidence, BA deviation trends acquired with DIR and MMR overlapped 
in 77% of cases. This was slightly lower than expected (0.92) and may be caused by the assumption that 
various factors in the uncertainty analyses were normally distributed. Differences in E0 between DIR 
and MMR ranged from -1.5 to 1.5 mm (Supplementary Data A.4: Individual patient 90% level of 
confidence SPC results). Further investigation into the differences between the two methods revealed 
two main causes: 1) Large deviations of mobile structures such as mandible could not always be 
recovered by DIR; 2) BA structures appeared to have expanded (‘creep’) after DIR due to structure 









and due to differences in pCT and CBCT Hounsfield Unit (HU) calibration. For the DIR algorithm used 
in this study, application of local rigidity constraints to the delineated BA may reduce the impact of 
‘creep’ [197,198]. 
Precision of PG propagation using DIR was evaluated by comparing these results against independent 
radiation oncologist CBCT re-contours (Supplementary Data A.8: Radiation oncologist PG review) and 
were found to be in excellent agreement with values reported in literature [138,151,178]. Well aligned 
to literature [79], the PGs included in this study demonstrated an average volume decrease of 21% and 
an average medial shift of 2.6 mm during HNRT. 
Considering the high correlation between these metrics, there was no indication that 𝑉𝑓
𝑛𝑒𝑐𝑘 provides a 
more accurate metric to assess changes of the treatment volume than overall changes in patient weight. 
Dosimetric analysis establishing the clinical relevance of the observed non-rigid changes in pose and 
anatomy is required to define objective decision rules and appropriate thresholds that can be applied in 
a safety net for patients who exhibit larger non-rigid deformations in the context of PTV margin 
reduction. We are therefore currently investigating these aspects in concert with the most efficient 
treatment adaptation approach for anatomical changes. 
In conclusion, this study assessed the potential to quantify and monitor an individual patient’s 
deformation, i.e., non-rigid changes in pose and anatomy during HNRT using DIR in combination with 
SPC. BA deviation trends occurring before the end of treatment week four could only be confirmed in 
24% of cases when SPC process limits were used, whereas absolute BA deviations could be confirmed 
in 82% of cases when an a priori 2 mm clinical limit was used. SPC process limits were useful to detect 
soft tissue trends occurring before the end of treatment week four which could be confirmed in 90% of 
cases. The approach proposed in this study could facilitate timely treatment adaption through detection 
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I developed the intended clinical workflow and the methodology to quantify the dose 
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and statistical analyses. I, along with co-authors SM and RL developed the conclusions and 
refined the methods. I wrote this paper with modifications to structure, flow and readability 
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Background and purpose: Deformable image registration (DIR) facilitated dose reconstruction and 
accumulation can be applied to assess delivered dose and verify the validity of the treatment plan during 
treatment. This retrospective study used in silico deformations based on clinically observed anatomical 
changes as ground truth to investigate the uncertainty of reconstructed and accumulated dose in head-
and-neck radiotherapy (HNRT).  
 
Materials and methods: A planning CT (pCT), cone beam CT (CBCT) from week one of treatment 
and three later CBCTs were selected for 12 HNRT patients. These images were used to generate in 
silico reference CBCTs and deformation vector fields (DVFs) as ground truth with B-spline DIR. 
Inverse consistency (IC) of voxels was assessed by determining their net displacement after successive 
application of the forward and backward DVF. The reconstructed dose based on demons DIR was 
compared to the ground truth to assess the structure-specific uncertainties of this DIR algorithm for 
inverse consistent and inverse inconsistent voxels.  
 
Results:  
Overall, 98.5% of voxels were inverse consistent with the 95% level of confidence range for dose 
reconstruction of a single fraction equal to [-2.3%; +2.1%], [-10.2%; +15.2%] and [-9.5%; +12.5%] 
relative to their planned dose for target structures, critical organs at risk (OARs) and non-critical OARs, 
respectively. Inverse inconsistent voxels generally showed a higher level of uncertainty. 
 
Conclusion:  
The uncertainty in accumulated dose using DIR can be accurately quantified and incorporated in dose-
volume histograms (DVHs). This method can be used to prospectively assess the adequacy of target 
coverage during treatment in an objective manner.  
   







The introduction of intensity modulated radiotherapy has enabled highly conformal dose deliveries 
which allows dose reduction to organs at risk (OAR) and reduced treatment toxicity [21,191,192]. 
However with highly conformal dose distributions, non-rigid patient deformations (i.e., changes in 
patient pose, weight loss, tumor response, OAR shift and shrinkage) during treatment [78] may lead to 
unacceptable loss in target coverage or over-dosage to OARs [93]. Deformable image registration (DIR) 
facilitates dose reconstruction and subsequent accumulation of the reconstructed dose per fraction to 
assess total delivered dose to target volumes and OARs in the presence of these anatomical changes 
[58,107,139,142]. A commonly used dose reconstruction and accumulation procedure matches the 
planning computed tomography (pCT) image (source) to an image taken during treatment (target) using 
DIR. This match is described by a ‘forward’ deformation vector field (DVF). The plan (beam 
arrangement, monitor units, fluence maps) is then recalculated on the deformed pCT (dCT), and the 
resulting dose distribution is mapped back to the pCT using the inverse or ‘backward’ DVF. 
Alternatively, dose reconstruction can be done using Hounsfield unit (HU) corrected on-treatment 
images, and subsequently map the reconstructed dose to the pCT using DIR [199]. Intrinsic limitations 
of DIR algorithms [134,153] may cause displacement field errors (DFEs) in the ‘forward’ registration 
or inverse consistency errors (ICEs) in the ‘backward’ transformation [159]. These limitations 
specifically show up in areas of low image contrast and large anatomical changes and result in 
uncertainties in the reconstructed dose [145,162–165]. The suitability of DIR for accurate and precise 
dose accumulation is debated in the literature [143,166–169]. A standardized approach to assess the 
accuracy of DIR facilitated dose accumulation may encourage a large scale implementation. 
This investigation includes objectively assessing the adequacy of target coverage using DIR facilitated 
dose accumulation. This retrospective study was instigated as no literature exists on the accuracy of this 
specific approach. The objects of this study were to quantify the uncertainty in the reconstructed and 
accumulated dose [80] based on a DIR algorithm employed by Varian's SmartAdapt [135] specifically, 
and to provide a method to incorporate these results as a confidence interval in dose-volume histograms 









observed anatomical changes as ground truth to evaluate the dose accumulation uncertainty. This 
methodology could also be used to validate reconstructed and accumulated doses acquired with other 
DIR implementations.   
   






3.2 Materials and methods 
3.2.1 Patient group 
Twelve patients with cancers in the head-and-neck region that were previously treated radically were 
selected for this retrospective study. The patients’ characteristics are summarized in the Supplementary 
Data (A.1: Patient group). Each patient’s pCT was used to generate a retrospective volumetric 
modulated arc therapy (VMAT) plan (Eclipse Treatment Planning v11.6 - 13.7, Varian Medical 
Systems, Palo Alto CA, USA) using 3 mm PTV margin expansions (prescribed dose 54 Gy and 
simultaneous integrated boost volumes to 60 and 66 Gy in 30 fractions) optimized according to the 
planning protocol in the Supplementary Data (A.9: Planning protocol). The dose calculation grid size 
was 2.5 x 2.5 x 3.0 mm3. The pCT scans (Brilliance Big Bore; Philips Medical Systems, Eindhoven, 
The Netherlands) had a voxel size of 1.3 x 1.3 x 3.0 mm3. Patients were immobilized using a 2.4 mm 
Reloadable Head and Shoulder S-Frame Kevlar Mask (Q-Fix, Avondale PA, USA) and an individual 
head and shoulder support vacuum bag (Klarity Medical Products, Newark OH, USA). Daily (n = 30) 
cone beam computed tomography (CBCT) scans were acquired to verify patient treatment position. The 
CBCT scans with a voxel size of 0.5 x 0.5 x 2 mm3 were acquired prior to treatment using a Varian 
Truebeam (v2.0 or v2.5; Varian Medical Systems, Palo Alto CA, USA). For a minority of treatment 
fractions, CBCT scans were acquired on a Varian Clinac (v2.1) with a voxel size of 0.7 x 0.7 x 2.5 mm3. 










3.2.2 Intended clinical workflow 
The intended clinical workflow as displayed in Figure 3.1 uses DIR facilitated dose accumulation to 
objectively assess the appropriateness of the original treatment plan in the context of non-rigid patient 
deformations. First, a 6 degree of freedom (DOF) rigid bony anatomy registration of the CBCT and the 
pCT was performed. Second, the pCT is matched to the pre-treatment CBCT using Varian’s demons 
DIR [133,134] implementation in SmartAdapt (v.13.6, Varian Medical Systems, Palo Alto CA, USA) 
which produces the dCT and is described by a forward DVF. As dCTs encompass the correct HU 
calibration, they can be used to reconstruct the dose delivered during fraction f using the beam 
arrangement, monitor units and fluence maps from the original treatment plan. Third, the original 
treatment plan is recalculated on the dCT and the resulting dose distribution mapped back to the pCT 
space according to the inverse DVF producing the fraction-specific reconstructed dose. Fourth, the 
reconstructed dose distributions of successive fractions are accumulated. SmartAdapt does not facilitate 
dose accumulation and the intended workflow requires external software. Therefore, 3D Slicer (v4.8) 
which is available as freeware was used to accumulate the dose reconstructed for individual fractions 
[200,201]. 
Initial assessment of SmartAdapt’s forward and inverse (i.e., CBCT-to-pCT) registrations highlighted 
noticeable ICEs especially for large deformations and in areas of low CBCT contrast (Supplementary 
Data A.10: Symmetry and inverse consistency). A consequence of this shortcoming for this evaluation 
study would be that the resulting dose reconstruction errors would not be assigned to the same voxel as 
it originated from, which would invalidate the dose accumulation of the reconstructed dose of the 
individual fractions. It was therefore decided not to use the inverse or symmetric (i.e., interchanging the 
source and target image) DVF provided by SmartAdapt, but to generate a true inverse DVF to warp the 
reconstructed dose back to pCT space. This true inverse was calculated by inverting the voxel-specific 
displacement vector described by the Digital Imaging and Communications in Medicine (DICOM) 
deformable spatial registration module and was also done using 3D Slicer.  
 
 
   







3.2.3 Assessing the accuracy of the intended clinical workflow 
Figure 3.1b and Figure 3.1c detail the approach that was used to assess the accuracy of the dose 
reconstruction and accumulation. This approach included an initialization phase (Figure 3.1b) and a 
dose comparison phase (Figure 3.1c). The dose comparison phase was designed in such a way that it 
tests whether the clinical workflow can accurately reconstruct the delivered dose for a known reference 
deformation. These reference deformations were generated in silico during the initialization phase and 
were based on clinically observed deformations. The dose comparison phase included both a test branch 
(right-hand side; orange) and a reference branch (left-hand side; blue). The test branch is identical to 
the clinical workflow depicted in Figure 3.1a but uses the known reference deformation with respect to 
the pCT, 𝑑𝐶𝐵𝐶𝑇𝑓
𝑟𝑒𝑓
 as input. Exactly the same deformation vector field 𝐷𝑉𝐹𝑓
𝑟𝑒𝑓
that was used in the 
initialization phase to generate 𝑑𝐶𝐵𝐶𝑇𝑓
𝑟𝑒𝑓
 was applied throughout the reference branch of Figure 3.1c. 
In this way, the reference deformed dose distribution 𝑑𝐷𝐷𝑓
𝑟𝑒𝑓
that was produced by the reference branch 
could be used as the ground truth against which the deformed dose distribution generated in the test 
branch 𝑑𝐷𝐷𝑓
𝑡𝑒𝑠𝑡 was compared. 
 





of fraction f as input for the test branch in the dose comparison phase. The 
first step of this initialization phase comprised the creation of a virtual CBCT, 𝐶𝐵𝐶𝑇𝑝𝑙𝑎𝑛 which closely 
resembles the pCT. This was accomplished by DIR of the pCT and a selected CBCT that was acquired 
during the first week of treatment, 𝐶𝐵𝐶𝑇1𝑠𝑡 𝑤𝑒𝑒𝑘 using SmartAdapt. In the second step,  𝐷𝑉𝐹𝑓
𝑟𝑒𝑓
 was 
generated by matching  𝐶𝐵𝐶𝑇𝑝𝑙𝑎𝑛 to the CBCTs of treatment fractions f = 3, 16 and 29 using B-spline 
DIR. For the current study, the B-spline algorithm was used as the reference DIR algorithm as 
implemented within the Plastimatch [202] module of 3D Slicer [200,201] using a 2-stage, 2-resolution 
procedure (stage 1/2: image subsampling rate, 4,4,2/2,2,1; grid size, 100/50 mm; regularization, 0.005; 
landmark penalty, 0.005; max iterations, 100).  
 
The DVF was limited to the CBCT field of view (FOV) in the inferior-superior direction and is generally 










delivered in these regions can either not, or not accurately be mapped back to the pCT space. Therefore, 
pCT structures extending outside the superior-inferior extent of the CBCT FOV were cut back 5 mm 
from the average location of the superior-inferior borders. The in-plane extent of the CBCT FOV was 
large enough to include all structures in the anterior/posterior and left/right direction for all patients 
included in this study. 
 
 
















Figure 3.1: Framework used to estimate uncertainty in the reconstructed dose as obtained using the demons algorithm. 
Green, orange and blue outlines represent objects from the clinical workflow, the DIR workflow under investigation, and 
the reference standard generation, respectively. Panel (a): intended clinical workflow to accumulate dose; (b) initialization 
phase to generate an input CBCT for the DIR workflow under investigation in this study; (c) dose comparison phase showing 
the evaluation workflow as conducted in this study. The dashed gray lines in panel (b) and (c) indicate that these represent 
corresponding process steps. 
 
DIR = deformable image registration. pCT = planning computed tomography. CBCT = cone beam computed tomography 
dCBCT = deformed CBCT. dCT = deformed pCT. DVF = deformation vector field. DD = dose distribution. dDD = 











3.2.4 Voxel-specific evaluation of observed dose differences 
In-house developed software (MATLAB 2018b version 9.5, The MathWorks Inc.) was used to analyze 
the voxel-specific results of the reconstructed dose distributions 𝑑𝐷𝐷𝑓
𝑟𝑒𝑓
 and 𝑑𝐷𝐷𝑓
𝑡𝑒𝑠𝑡 of the dose 
comparison phase. First, the uncertainty in the test DIR workflow was assessed by considering the 
potential error contributions from both branches to the voxel-specific dose difference between the 
reconstructed dose distributions 𝑑𝐷𝐷𝑓
𝑟𝑒𝑓
 and 𝑑𝐷𝐷𝑓
𝑡𝑒𝑠𝑡. For that purpose, it was assumed that both 











  (5) 
Considering that the known reference deformation vector field 𝐷𝑉𝐹𝑓
𝑟𝑒𝑓
 was generated using the 
reference DIR algorithm, 𝐷𝐹𝐸𝑓
𝑟𝑒𝑓
 equals zero per definition. For each head-and-neck radiotherapy 
(HNRT) structure of interest, the total dose error in the test branch (𝑖. 𝑒. , 𝐷𝐹𝐸𝑓
𝑡𝑒𝑠𝑡 + 𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡
) was then 
calculated for each voxel and expressed as a percentage of the planned dose per fraction, 𝑡𝑜𝑡:  







𝑝𝑙𝑎𝑛 × 100%                          (6) 
The magnitude of 𝐼𝐶𝐸𝑓
𝑟𝑒𝑓




, and subtracting the result 
from 𝐷𝐷𝑓
𝑟𝑒𝑓









   
Figure 3.2: Schematic representation of the factors contributing to the total dose difference of a specific voxel (black square) 
between the test (orange pathway) and reference (light blue pathway) deformable image registration (DIR) dose 
reconstructions. The ‘forward’ registrations are shown by the solid arrows. The displacement field error (DFE) of the test 
registration (orange pathway) is exemplified by the top light blue and orange voxels not perfectly aligning. The ‘backward’ 
registration is shown by the dashed arrow. The inverse consistency error (ICE) of the test registration is exemplified by the 
bottom black and orange voxels not perfectly overlapping. 
 







3.2.5 Assessing DVH uncertainty in the clinical workflow based on the 
results of this study 
After each voxel's contribution to the reconstructed test dose uncertainty was determined as described 
above, each voxel was stratified by whether its forward displacement vector was inversely consistent 
(referred to as ‘inverse consistent voxels’ from this point onward) or not (‘inverse inconsistent voxels’). 
The methodology applied to make this distinction can also be applied in a clinical setting, and allows 
summation of the voxel-specific uncertainty over multiple fractions using the estimated uncertainty 
from this study based on this distinction. The displacement error 𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 was calculated by 
subsequently applying 𝐷𝑉𝐹𝑓
𝑡𝑒𝑠𝑡 and the inverse 𝐷𝑉𝐹𝑓
𝑡𝑒𝑠𝑡 provided by SmartAdapt to the pCT, and 
subtracting this result from the original pCT. Subsequently, an inverse consistency (IC) threshold equal 
to the size of one voxel of the dose calculation grid (i.e., 2.5 x 2.5 x 3.0 mm3), 𝑉𝑠𝑧, was used to 
distinguish between inverse consistent and inverse inconsistent voxels of 𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡. The IC rate was 
defined as the number of voxels meeting the IC threshold criterion divided by the total number of 
voxels, and was used to assess the validity of the dose reconstruction uncertainty estimates in this study. 
In a clinical setting, the IC rate could potentially be used as additional information to assess the validity 
of the reconstructed DVH. Considering that the dose distributions and dose gradients of various 
structures in HNRT are generally distinct, the dose reconstruction uncertainties were evaluated 
separately for each structure type. 
For each structure S, the dose reconstruction uncertainties of inverse consistent uc and inverse 
inconsistent ui voxels were estimated using the 95% percentile range of the distributions of ∆𝑡𝑜𝑡 in 
accordance with the Guide to the Expression of Uncertainty in Measurement (GUM) [196]. In addition, 
the upper and lower part of the 95% range were assessed separately to maintain the skewed, non-normal 
distributed character of ∆𝑡𝑜𝑡. For dose reconstruction in the intended clinical workflow, the 95% 
confidence interval of the accumulated 𝑑𝐷𝐷𝑓
𝑡𝑒𝑠𝑡 dose for a single voxel within structure S at fraction f, 
𝑢𝐴𝑓
𝑆 was calculated according to the following. 
Uncertainty summation in quadrature assuming a fraction-to-fraction normal distribution of u: 
 𝑢𝐴𝑓 [𝐺𝑦] = √∑ (𝐷𝑖
𝑟   .  𝑢)2
𝑓









For a system with two uncertainty levels this can be expanded into: 
  𝑢𝐴𝑓 [𝐺𝑦] = √∑ (𝐷𝑖
𝑟   .  𝑢)2
𝑓
𝑖=1         𝑢 =  {
𝑢𝑐      if  𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 < 𝑉𝑠𝑧
𝑢𝑖    if  𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 > 𝑉𝑠𝑧
    (7b) 
Expressed as a percentage of accumulated dose for separate upper and lower levels of uncertainty: 
  𝑢𝐴𝑓
𝑆+ [%] =  
√∑ (𝐷𝑖




𝑎 × 100%        𝑢 =  {
𝑢𝑐
𝑆+     if  𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 < 𝑉𝑠𝑧
𝑢𝑖
𝑆+   if  𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 > 𝑉𝑠𝑧
   (7c) 
𝑢𝐴𝑓
𝑆− [%] =  
√∑ (𝐷𝑖




𝑎  × 100%       𝑢 =  {
𝑢𝑐
𝑆−     if  𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 < 𝑉𝑠𝑧
𝑢𝑖
𝑆−   if  𝑑𝐼𝐶𝐸𝑓
𝑡𝑒𝑠𝑡 > 𝑉𝑠𝑧
   (7d) 
where 𝐷𝑖
𝑟 are the reconstructed doses of each fraction and 𝐷𝑓
𝑎  is the accumulated dose for fraction f. 
The 95% level of confidence for each dose level bin in the (cumulative) DVH of the accumulated dose 
was calculated by averaging the 𝑢𝐴𝑓 of all voxels with 𝐷𝑓
𝑎 equal to or larger than that dose level. As an 
example of incorporating the uncertainty in the accumulated dose as a 95% level of confidence interval 
in DVHs during treatment, the accumulated DVHs including the 95% confidence interval at fraction 30 
was calculated for the high-dose PTV, the high-dose clinical target volume (CTV) and the ipsilateral 
parotid gland (PG) as per the intended dose accumulation clinical workflow (Figure 3.1a) for patient 1.  
 








3.3.1 Voxel-specific evaluation 
Table 5 summarizes the averages and ranges of the IC rate for each of the 14 structures included in the 
analysis. In addition, Table 5 summarizes the averages and 95% percentile ranges of 𝑡𝑜𝑡 for both 
inverse consistent and inverse inconsistent voxels for all structures. The average IC rate for each 
structure was generally larger than 99% except for the brainstem planning risk volume (PRV), spinal 
cord PRV, brainstem, spinal cord and ipsilateral PG where the average IC rate was slightly lower but 
still larger than 94%. More detail about the IC rates for all patients’ structures can be found in the 
Supplementary Data (A.11: IC rates).  
The distributions of 𝑡𝑜𝑡 values for inverse consistent and inverse inconsistent voxels is shown in the 
histograms of Figure 3.3a and Figure 3.3b, respectively. Q-Q probability plots showed that 𝑡𝑜𝑡 was 
generally not normally distributed (Supplementary Data A.12: Q-Q probability plots). Therefore, the 
standard uncertainty (i.e., uc and ui) of the reconstructed dose was estimated using the 95% percentile 
range of these distributions rather than 1 standard deviation. For inverse consistent voxels, the median 
𝑡𝑜𝑡  over all structures was 0.0% with a 95% percentile range equal to (-3.6%; +4.6%). For inverse 
inconsistent voxels, the median 𝑡𝑜𝑡 was -0.1% with a 95% percentile range equal to (-10.7%; +10.5%).  
For individual structure types, the largest 95% percentile ranges of 𝑡𝑜𝑡 for both inverse consistent and 
inverse inconsistent voxels were observed for the brainstem (and brainstem PRV) and PGs. The 95% 
percentile ranges of 𝑡𝑜𝑡 for inverse consistent and inverse inconsistent voxels of the brainstem were (-
15.6%; +21.0%) and (-15.8%; +14.2%), respectively. For the ipsilateral PG, the 95% percentile range 
of 𝑡𝑜𝑡 for inverse consistent and inverse inconsistent voxels was (-10.5%; +14.4%) and (-18.8%; 
+8.1%), respectively. For the contralateral PG, these were (-10.4%; +12.7%) and (-23.5%; +4.5%), 
respectively. For all target structures (i.e., PTVs and CTVs), the largest 95% percentile ranges of 𝑡𝑜𝑡 
were (-3.1%; +2.7%) and (-6.1%; +3.0%) for inverse consistent and inverse inconsistent voxels, 
respectively. Individual structure distributions of 𝑡𝑜𝑡 are available in the Supplementary Data (A.13: 










Table 5: Structure-specific average and range for the inverse consistency (IC) rate, and median and 
95% percentile range of 𝑡𝑜𝑡for inverse consistent and inverse inconsistent voxels. PTV = planning 
target volume. CTV = clinical target volume. PRV = planning risk volume. PG = parotid gland. SMG 
= submandibular gland. 
  IC rate (%) 
Inverse consistent voxels 
tot (%) 
Inverse inconsistent voxels 
tot (%) 








11 99.1 85.6 – 100.0 0.0 -2.0; +1.6 0.2 -2.8; +7.7 
Intermediate-
dose PTV 
4 100.0 99.9 – 100.0 -0.1 -2.9; +1.4 0.2 -1.4; +1.4 
Low-dose 
PTV 
12 99.5 94.0 – 100.0 0.0 -3.1; +2.7 -0.4 -6.1; +3.0 
High-dose 
CTV 
11 99.1 85.3 – 100.0 0.1 -1.3; +1.5 0.2 -2.2; +4.0 
Intermediate-
dose CTV 
4 99.9 99.8 – 100.0 0.0 -1.7; +1.2 0.1 -1.5; +1.4 
Low-dose 
CTV 
12 99.4 91.2 – 100.0 0.0 -1.9; +2.0 -0.2 -4.5; +3.3 
Brainstem 
PRV 
12 96.9 73.3 – 100.0 0.8 -13.7; +19.5 -0.3 -15.8; +24.6 
Spinal cord 
PRV 
12 97.9 78.9 – 100.0 0.4 -6.7; +8.5 1.0 -8.4; +14.9 
Brainstem 12 94.1 64.2 – 100.0 1.0 -15.6; +21.0 0.0 -15.8; +14.2 
Spinal cord 12 97.1 71.9 – 100.0 0.4 -7.2; +9.0 0.9 -8.1; +15.8 
Ipsilateral 
PG 
14 96.8 26.3 – 100.0 0.6 -10.5; +14.4 -1.7 -18.8; +8.1 
Contralateral 
PG 
10 99.2 86.2 – 100.0 0.5 -10.4; +12.7 -6.8 -23.5; +4.5 
Ipsilateral 
SMG 
13 99.9 95.9 – 100.0 -0.1 -5.5; +3.3 0.7 -0.9; +1.3 
Contralateral 
SMG 
10 99.9 97.6 – 100.0 -0.1 -3.6; +5.5 -0.7 -6.4; +0.5 
























3.3.2 DVH uncertainty example 
Over all patients, 𝑢𝐴30 was (-0.4%; +0.3%), (-0.2%; +0.3%) and (-1.9%; +2.6%) for the inverse 
consistent voxels within the high-dose PTV, the high-dose CTV and ipsilateral PG, respectively. Note 
that as per Equation 7 (page 108), these structures’ ranges are approximately a factor five smaller than 
the ranges listed in Table 5. For inverse inconsistent voxels, 𝑢𝐴30 for these structures was (-0.5%; 
+1.4%), (-0.4%; +0.7%) and (-3.4%; +1.5%), respectively. 
For patient 1, the DVH metrics for the accumulated dose of the high-dose target volumes were 
significantly different at the 95% level of confidence compared to the planned values (Figure 3.4a). 
D98% (PTV) and D99% (CTV) were 97.8% and 99.5% of the planned values, respectively. The D50% values 
for the high-dose PTV and CTV accumulated dose values were both 100.4% of their planned D50%. The 
accumulated dose to the ipsilateral PG was only marginally higher than the planned dose (Figure 3.4b). 
Figure 3.5 shows the spatial distribution of the reconstructed dose uncertainty (i.e., 𝑡𝑜𝑡) at fractions 3 
and 29 for patient 1’s high-dose PTV and ipsilateral PG calculated over all voxels (left column), and 
for inverse consistent voxels only (right column). Typically, a high IC rate is observed for most 
structures as can be observed by comparing the left-hand and right-hand columns of Figure 3.5a-f. In 
addition, a low level of uncertainty in reconstructed dose is typically observed as highlighted in Figure 
3.5a-b and Figure 3.5e-f. In a small number of cases an uncertainty larger than 10% in the reconstructed 
dose was observed, as indicated by the region with the red color wash in Figure 3.5c and Figure 3.5d. 
The higher uncertainties in these cases were caused by DFEs of the test algorithm in high dose gradient 
regions and occurred independent of IC. Considerable reduction in the external contour and/or poor 
CBCT image contrast challenged the IC functionality of the test DIR algorithm and resulted in an 
exceptionally low IC rate of 26.3% for the ipsilateral PG at fraction 29 (Figure 3.5h). Further 
investigation found this large contour reduction between the pCT and 𝐶𝐵𝐶𝑇29 also challenged the 
reference algorithm, resulting in a non-realistic deformation 𝐷𝑉𝐹29
𝑟𝑒𝑓
 in the ipsilateral PG region. The 
test DIR was unable to reproduce this unrealistic reference deformation in an inverse consistent manner. 
The combination of a low IC rate, high dose gradient and notable DFEs resulted in distinctively higher 
uncertainty of the reconstructed structure dose for this fraction (Figure 3.5g). 
 









Figure 3.4: Dose-volume histogram (DVH) of the accumulated dose for patient 1’s high-dose CTV and 
PTV (a) and ipsilateral parotid gland (PG) (b) at the end of the 30 fraction treatment compared to the 
original planning DVHs. The accumulated D98% and D99% (red bullet points) of the high-dose PTV and 
CTV were significantly different at the 95% level of confidence from the planned values but still 97.8% 











Figure 3.5: 𝑡𝑜𝑡of all voxels (left column) and inverse consistent voxels only (right column) for patient 
1 at fraction 3 (a-d) and fraction 29 (e-h). The high-dose PTV (a,b,e,f) and ipsilateral parotid gland 
(c,d,g,h) are shown for a single axial slice. 
  
 








Accurate DIR facilitated dose accumulation for individual patients would be extremely useful to verify 
the adequacy of the delivered dose in the presence of non-rigid patient deformations (i.e., changes in 
patient pose, weight loss, tumor response, OAR shift and shrinkage) during treatment [139], and could 
provide an objective tool to decide whether treatment adaptation is required. In particular when a PTV 
margin reduction is implemented [1,3,4], loss in target coverage during treatment might occur more 
often and might become more relevant compared to an approach using standard PTV margins [110,142]. 
Furthermore, the application of DIR facilitated dose accumulation to monitor individual patients’ actual 
delivered dose during treatment can largely be automated and is therefore attractive from an economic 
and efficiency perspective. The current study was carried out for an image-guided radiotherapy (IGRT) 
workflow using the DIR algorithm available at our institute and was based on daily CBCT, but the 
approach can also be used for other workflows. For instance, the generation of an in silico ground truth 
as demonstrated here, including the procedure to generate a known CBCT deformation (Figure 3.1b) 
can also be used to validate other DIR algorithms. Alternatively, this procedure can be amended to 
validate DIR dose accumulation pathways that utilize other imaging schemes (i.e., not CT-to-CBCT). 
Limitations of the DIR facilitated dose reconstruction include reduced accuracy due to low image 
contrast and potential algorithm restrictions to recover large deformations [135]. In addition, DIR 
algorithms do generally assume that mass is conserved and are therefore not able to correctly replicate 
volume changes. In particular in high dose gradient areas, low image contrast and large anatomical 
changes may cause low IC rates and large DFEs in the DIR facilitated dose reconstruction and 
accumulation approach [139]. This study investigated the uncertainty in DIR facilitated dose 
reconstruction and accumulation, using in silico deformations based on clinically observed anatomical 
changes. By quantifying the observed dose reconstruction uncertainties for specific structures, and for 
inverse consistent and inverse inconsistent voxels separately, this data can be used in a prospective way. 
This application enables assessing the impact of anatomical changes to target coverage and/or OAR 
sparing at the 95% level of confidence during treatment.  
Many studies assessed the delivered dose based on dose reconstruction using on-treatment imaging 









accuracy of DIR [142,199], while only a few papers directly assessed the dose reconstruction accuracy 
[145,162,164,204]. To the best of our knowledge, there are no other studies that investigated a demons 
DIR pCT-CBCT workflow to assess the delivered dose during HNRT, included an uncertainty estimate 
based on clinically observed deformations as ground truth, and presented a methodology that can be 
used in a prospective way (i.e., included in on-treatment DVHs). 
 Using an IC threshold of one dose calculation voxel size, the IC rate was at least 95% for the majority 
of structures in this study. Only 8% of the 149 structures that were each analyzed for three fractions in 
this study had an IC rate less than 95% (Supplementary Data A.11: IC rates), with the majority of these 
cases observed for one specific patient. In particular the large external contour reduction of fraction 29 
for the ipsilateral PG of this patient as illustrated in Figure 3.5h likely resulted in the extremely low IC 
rate of 26.3%. The main purpose of the current study was to provide a robust estimate of the dose 
reconstruction uncertainty by separately assessing the uncertainty for inverse consistent and inverse 
inconsistent voxels for various structure types. However, for other DIR algorithms and/or other body 
sites, the dose reconstruction uncertainty for inverse inconsistent voxels may be much larger or more 
variable. In that case an alternative approach could be to use the IC rate in combination with an 
acceptance threshold for the IC rate that depends on the clinical risk associated with accepting an 
erroneous dose reconstruction. For implementation of this methodology in other departments, it is up 
to the discretion of the users to select an approach that works optimal for a specific application. 
Larger DFEs were specifically observed for brainstem and the PGs. Further investigation (data not 
shown) did not reveal a statistically significant trend of the DFE with the progress of treatment for the 
ipsilateral or contralateral PGs. It was therefore concluded that low image contrast in the CBCTs was a 
major contributor to the larger DFEs for these structures rather than contour or other anatomical 
changes. In spite of the lower IC rates and consequently higher estimated dose reconstruction 
uncertainty in these cases, the example DVHs in Figure 3.4 indicate that the accuracy of dose 
reconstruction appears to be sufficient for clinical application. Furthermore, it is anticipated that future 
improvements of the CBCT image quality such as the implementation of iterative reconstruction [205] 
will not only be beneficial for IGRT in general but may also increase the accuracy of dose 
 







reconstruction. Although it should be noted that the study by Veiga et al. found that CBCT image quality 
was sufficient for dose of the day calculations based on CT-to-CBCT DIR [206]. 
Both the reference DIR algorithm and the test DIR algorithm under investigation in this study do not 
have provisions to account for either the loss or increase of mass of structures. This is a limitation for 
uncertainty estimates in this study although the two algorithms likely respond differently to volume 
changes. Furthermore, volume changes will generally reduce the IC rate and result in a higher estimated 
dose reconstruction uncertainty in prospective applications. Thus, the impact of volume changes on the 
dose reconstruction accuracy is at least partially included in the uncertainty estimate. A previous study 
from our group [207] revealed that seven of the patients included in the current study showed a 
significant change in neck contour over the treatment course which could potentially have impacted the 
uncertainty estimate for the elective dose target volumes. Similarly, five patients showed at least a 25% 
decrease of PG volume but volume changes of the GTVs could not be determined due to CBCT image 
quality restrictions. Literature on the impact of volume changes on the accuracy of DIR based dose 
reconstruction is scarce but a short debate on this subject concluded that the impact was expected to be 
limited [167,168]. Future studies are required to quantitatively assess the impact on patient dosimetry 
of this limitation of the current DIR algorithms but would at least require high contrast imaging during 
treatment. 
The distinction between inverse consistent and inverse inconsistent voxels to estimate the uncertainty 
of the accumulated dose in the intended clinical workflow was based on the forward and inverse DVF 
as provided by SmartAdapt. However, the true inverse DVF was applied in the intended clinical 
workflow of Figure 3.1a to warp the reconstructed dose. The contribution to the uncertainty of the 
accumulated dose of inverse inconsistent voxels in prospective application of DIR based dose 
reconstruction in the intended clinical workflow will therefore be conservative. 
It should be noted that the degree to which the reference deformations of the in silico ground truth are 
representative is limited by the accuracy of the reference registrations (i.e., 𝐷𝑉𝐹𝑓
𝑟𝑒𝑓
) which in theory 
could reduce the applicability of the dose accumulation uncertainties derived here, and alternative DIR 
algorithms may be able to generate more representative DVFs [203,208]. However, perfectly accurate 









changes routinely seen during treatment and that the reconstructed dose of a test DIR algorithm (e.g., 
𝑑𝐷𝐷𝑓
𝑡𝑒𝑠𝑡) is evaluated against the reconstructed dose of the reference DIR algorithm (e.g., 𝑑𝐷𝐷𝑓
𝑟𝑒𝑓
). 
Degraded CBCT image quality, erroneous initial rigid alignment, large initial deformations, etc. could 
challenge the intrinsic accuracy of DIR algorithms which may lead to systematic residual deformable 
registration errors. If this occurs at the stages where the reference (ground truth) deformation is 
generated (Figure 3.1b), the impact of these phenomena on the clinical DIR workflow under 
investigation would not be fully assessed and could potentially create a bias in results. An extensive 
visual comparison of pCT and 𝐶𝐵𝐶𝑇𝑝𝑙𝑎𝑛 assess any systematic residual deformations showed that the 
CBCT image quality was generally degraded around dental implants due to differences in scatter, which 
obscured the comparison at some locations. Although no residual deformation errors were found, it 
cannot be excluded that the dose reconstruction error of the DIR algorithm under investigation around 
dental fillings is larger than estimated in the current study. In addition, a difference in tongue position 
between pCT and 𝐶𝐵𝐶𝑇𝑝𝑙𝑎𝑛 was observed due to swallowing, but this was for one patient only and it 
is therefore unlikely that this created a bias in results. Further investigation using a considerably less 
representative CBCT of the first week of treatment as ‘worst’ case (i.e., notable swallowing differences 
relative to the pCT) to generate an alternative 𝐶𝐵𝐶𝑇𝑝𝑙𝑎𝑛 resulted in very comparable 95% percentile 
ranges of 𝑡𝑜𝑡. Therefore, the impact of residual differences between the pCT and 𝐶𝐵𝐶𝑇𝑝𝑙𝑎𝑛 on the 
estimated dose reconstruction uncertainty are estimated to be negligible. Comparison of 𝑑𝐶𝐵𝐶𝑇𝑓
𝑟𝑒𝑓
 and 
𝐶𝐵𝐶𝑇𝑓 did reveal some residual deviations at a number of locations but these were generally smaller 
than a dose calculation voxel. However, these residual deformations were not systematic in nature, and 
it is therefore estimated that a bias in results due to DIR limitations in this part of the workflow is 
negligible. 
The dose difference 𝑡𝑜𝑡 was not available for those voxels which were cut from structures extending 
outside the superior-inferior extent of the CBCT due to the limited CBCT FOV. However, it is 
reasonable to assume that the measured structure-specific 95% percentile range of 𝑡𝑜𝑡  is representative 
for the actual 95% percentile range considering that it is unlikely that residual deformations and dose 
reconstruction errors will be different outside the CBCT FOV, and that the 𝑡𝑜𝑡  values were assessed 
over multiple patients. 
 







Two studies [145,162] have evaluated uncertainties in the dose reconstruction and accumulation process 
for HNRT specifically. The study of Veiga et al. [145] compared these uncertainties for four DIR 
algorithms and five HNRT patients based on CT-to-CBCT registration. These DIR algorithms 
represented three different implementations of B-spline which were compared against the results 
obtained using a symmetric B-spline registration parameterized by a stationary velocity field. The latter 
algorithm was chosen as the reference algorithm for that study due to its inverse and symmetry 
consistency which are properties theoretically associated with physically plausible patient deformations 
during treatment [130,131,146]. However, no ground truth was defined which may have confounded 
the reconstructed dose comparison. The best performing DIR algorithm in this study recorded a root 
mean square (RMS) dose difference of 1.6% and a 95% percentile range of ±1.4% with respect to the 
prescribed dose for all voxels encompassed by the 95% isodose surface. This is very comparable to the 
results of our study where the median 𝑢𝑐 for the high-dose PTV was 0.0% with a 95% percentile range 
equal to (-2.0%; +1.6%).  
The study of Rigaud et al. [162] compared ten DIR approaches to register the planning CT with weekly 
repeat CTs for 15 HNRT patients. The uncertainty in dose accumulation was then assessed based on 
the registration errors of 14 landmarks as identified by an expert. Of the 10 DIR approaches in this 
study, the B-spline DIR algorithm utilizing mutual information on filtered CTs performed best with an 
average dose difference error of 1.7% and a 95% percentile range of ±3.8% relative to the planned dose, 
respectively. Again, this compares well with the results of our study where the overall median 𝑢𝑐 was 
0.0% with a 95% percentile range equal to (-3.6%; +4.6%).  
This study assessed the structure-specific uncertainties in DIR based dose reconstruction during HNRT 
using in silico deformations based on clinically observed anatomical changes as ground truth. This 
uncertainty was quantified both for inverse consistent and inverse inconsistent voxels, as well as the 
average IC rate for each structure. This data can be used in a prospective way to estimate the accuracy 
of DIR based dose reconstruction and provides a method to objectively assess the adequacy of treatment 
in the context of anatomical changes or variations in patient positioning. The results of this study suggest 

























4 DOSE ACCUMULATION TO ASSESS THE VALIDITY OF TREATMENT 
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treatment plans with reduced margins in radiotherapy of head and neck cancer. In publication 






I applied the methodology that I developed in Chapter Three to simulate the intended clinical 
workflow for HNRT at the WBCC. I collected all patient data, performed all tasks within the 
treatment planning system, wrote all the MATLAB scripts for data analysis and performed all 
tasks within Slicer. I performed all the mathematics for the statistical analyses. I, along with 
co-authors SM and RL developed the conclusions and refined the methods. I wrote this paper 
with modifications to structure, flow and readability from SM and RL. 
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Background and purpose: Literature has reported reduced treatment toxicity in head-and-neck 
radiotherapy (HNRT) when reducing the planning target volume (PTV) margin from 5 to 3 mm but 
loco-regional control was not always preserved. This study used deformable image registration (DIR)-
facilitated dose accumulation to assess clinical target volume (CTV) coverage in the presence of 
anatomical changes. 
 
Materials and methods: VMAT plans for 12 patients were optimized using 3 or 5 mm PTV and 
planning risk volume (PRV) margins. The planning computed tomography (pCT) scan was registered 
to each daily cone beam CT (CBCT) using DIR. The inverse registration was used to reconstruct and 
accumulate dose (𝐷𝑎𝑐𝑐). CTV coverage was assessed using the dose-volume histogram (DVH) 
metric 𝐷99%
𝑎𝑐𝑐  and by individual voxel analysis. Both approaches included an uncertainty estimate using 
the 95% level of confidence.  
 
Results: 𝐷99%
𝑎𝑐𝑐  was less than 95% of the prescribed dose 𝐷𝑝𝑟𝑒𝑠𝑐 for three cases including only one case 
where this was at the 95% level of confidence. However for many patients, the accumulated dose 
included a substantial volume of voxels receiving less than 95% 𝐷𝑝𝑟𝑒𝑠𝑐 independent of margin 
expansion, which predominantly occurred in the subdermal region. Loss in target coverage was very 
patient specific but tightness of target volume coverage at planning was a common factor leading to 
underdosage. 
 
Conclusion: This study agrees with previous literature that PTV/PRV margin reduction did not 
significantly reduce CTV coverage during treatment, but also highlighted that tight coverage of target 
volumes at planning increases the risk of clinically unacceptable dose delivery. Patient specific 
verification of dose delivery assessing the dose delivered to each voxel is recommended.   
 








The introduction of intensity modulated radiotherapy has enabled highly conformal dose deliveries 
which allow dose reduction to organs at risk (OARs), and result in reduced treatment toxicity 
[21,191,192]. These highly conformal treatments require image-guided radiotherapy (IGRT) to warrant 
accurate patient positioning and monitoring of changes in patient anatomy [86]. Planning target volume 
(PTV) margins are applied to target volumes [170] during treatment planning to account for 
uncertainties such as patient positioning, geometrical accuracy of the treatment machine and 
geometrical uncertainties of target volume definition. The presence of these uncertainties have also 
prompted a recommendation to apply a planning risk volume (PRV) margin to critical OARs [42]. PTV 
and PRV margins of 5 mm are commonly applied in head-and-neck radiotherapy (HNRT) 
[171,209,210]. However, PTV margin recipes [35,36] do not account for non-rigid anatomy changes 
(i.e., changes in patient pose, weight loss, tumor response, OAR shift and shrinkage) which are 
commonly observed in HNRT [78,79,207]. Nevertheless, two groups have reported favorable toxicity 
profiles while maintaining good two-year loco-regional (LR) control rates after reducing the PTV 
margin from 5 to 3 mm [1–3]. More recently, a third study by Franzese et al. [4] reported a significant 
difference in the two-year LR control rates between patients treated with 5 or 3 mm PTV margins. In 
the latter study, a 3 mm PTV margin was associated with a decreased rate of LR control. A retrospective 
study by van Kranen et al. [142] found a slight increase in the risk of clinical target volume (CTV) 
underdosage when reducing the PTV margin from 5 to 3 mm while a similar study by Wu et al [110] 
concluded that the coverage of the CTVs at the end of treatment was not affected by a PTV margin 
reduction. Considering these differing results, further investigation of risk factors that could jeopardize 
a patient’s CTV coverage and/or critical OAR avoidance in a reduced margin setting is warranted. 
This study utilized deformable image registration (DIR) facilitated dose accumulation to objectively 
assess the adequacy of target coverage, critical OAR avoidance and non-critical OAR sparing when 
either 5 or 3 mm PTV and PRV margins were applied. In addition, the occurrence, location and trends 
where CTV coverage and critical OAR avoidance could be at risk was investigated. This study 









changes during HNRT when margins are reduced [110,142]. While used retrospectively in this study, 
the presented dose accumulation analysis is primarily intended for prospective clinical application.  
 







4.2 Materials and methods 
4.2.1 Treatment immobilization, planning and on-treatment imaging 
Twelve patients with cancers in the head-and-neck region that were previously treated radically were 
selected for this study. The patients’ characteristics are summarized in Supplementary Data A.1: Patient 
group. The planning computed tomography (pCT) scans (Brilliance Big Bore; Philips Medical Systems, 
Eindhoven, The Netherlands) had a voxel size of 1.3 x 1.3 x 3.0 mm3. Patients were immobilized using 
a 2.4 mm Reloadable Head and Shoulder S-Frame Kevlar Mask (Q-Fix, Avondale PA, USA) and an 
individual head and shoulder support vacuum bag (Klarity Medical Products, Newark OH, USA). 
 
Each patient’s pCT was used to generate two volumetric modulated arc therapy (VMAT) plans (Eclipse 
Treatment Planning, Varian Medical Systems, Palo Alto CA, USA) using either 5 or 3 mm PTV and 
PRV margin expansions from the CTVs and critical OARs (i.e., brainstem and spinal cord), 
respectively. Plan optimization was carried out using the protocol in Supplementary Data A.9: Planning 
protocol, using a dose calculation grid size of 2.5 x 2.5 x 3.0 mm3. For eleven patients, a 5 mm expansion 
of the gross tumor volume (GTV) was used to generate the high-risk CTV with a prescribed dose of 66 
Gy in all but one case where a compartmentalization approach [34] was used. For one patient with a 
benign tumor, the prescribed dose to the target volume was 54 Gy and the CTV was created by a 3 mm 
expansion of the GTV (see Supplementary Data A.1: Patient group and A.14: Structures available for 
analysis). For four patients, an intermediate-risk CTV was defined with a prescribed dose of 60 Gy to 
include anatomical structures with a high probability of infiltration based on positron-emission 
tomography (PET) imaging and experience of the radiation oncologist. The low-risk CTV included 
structures as per The Danish Head and Neck Cancer Group (DAHANCA) consensus guidelines [176] 
and was planned to 54 Gy. All plans used two full arcs to create a highly conformal dose distribution 
around the 54 Gy low-risk CTV and simultaneous integrated boost volumes to 60 and 66 Gy in 30 
fractions. To achieve similar plans in terms of conformity and avoid a bias in the plan comparison, the 
first author (NL) generated each patient’s 3 and 5 mm plan in immediate succession. All plans fulfilled 
the departmental criteria for treatment plan acceptance which are based on the studies of Doornaert et 
al. [47] and Verbakel et al. [29] and adhere to ICRU guidelines [211]. Plans were reviewed by a senior 









In a small number of cases where a CTV was located superficially within 3 mm of the external contour 
without the use of bolus, that CTV was cropped 3 mm from the external contour for plan evaluation 
and dose accumulation analysis with “virtual bolus” being applied during plan optimization to moderate 
the fluence in the skin region [212]. In those cases, the treating radiation oncologist omitted the use of 
bolus to reduce the risk of severe skin toxicity. PTVs that were located within 3 mm of the external 
contour were cropped back 3 mm from the skin for plan evaluation after optimization.  
 
Daily (n = 30) cone beam computed tomography (CBCT) scans were acquired to verify patients’ 
treatment position. The CBCT scans with a voxel size of 0.5 x 0.5 x 2 mm3 were acquired prior to 
treatment using a Varian Truebeam (v2.0 or v2.5; Varian Medical Systems, Palo Alto CA, USA). For 
a minority of treatment fractions, CBCT scans were acquired on a Varian Clinac (v2.1) with a voxel 
size of 0.7 x 0.7 x 2.5 mm3. All patients consented to their data being used for retrospective audits 
conform the guidelines of the local ethics committee. 
 
4.2.2 Dose accumulation and uncertainty estimation 
The total delivered dose at each successive fraction was calculated according to the DIR facilitated dose 
accumulation workflow previously described [213]. In summary, first a 6 degree of freedom rigid bony 
anatomy registration of the CBCT and the pCT was performed. Second, the pCT was deformed to match 
the anatomy of each daily CBCT using Varian’s demons DIR implementation in SmartAdapt (SA) 
(v.13.6, Varian Medical Systems, Palo Alto CA, USA), which produced a deformed pCT (dCT) and a 
‘forward’ deformation vector field (DVF). Third, the original treatment plan was recalculated on the 
dCT using the beam arrangement, monitor units and fluence maps from the original treatment plan. The 
resulting dose distribution was mapped back to the pCT space according to the true inverse DVF, 
producing the fraction-specific reconstructed dose. Fourth, the reconstructed dose distributions of 
successive fractions were accumulated. The true inverse DVF calculation and dose accumulation of the 
individual fraction reconstructed doses was carried out using 3D Slicer (v4.8) which is available as 
freeware [200,201].  
 
 







The uncertainty in the dose accumulation procedure was assessed in a previous study [213] by 
comparing DIR facilitated dose accumulation using SA with the results of an in silico model based on 
clinically observed deformations as ground truth. These differences were separately calculated for 
inverse consistent and inverse inconsistent voxels. The distinction between those voxels was made by 
successive application of the forward DVF and inverse DVF and classifying the net shifts larger than 
one dose calculation voxel as inverse inconsistent. These results from the previous study were 
subsequently used in the current study to calculate the dose reconstruction uncertainties of inverse 
consistent uc and inverse inconsistent ui voxels. The 95% level of confidence of the accumulated dose 
for a single voxel within structure S at fraction f, 𝑢𝐴𝑓
𝑆 is: 
𝑢𝐴𝑓
𝑆+ [%] =  
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where 𝐷𝑖
𝑟 are the reconstructed doses of each fraction and 𝐷𝑓
𝑎  is the accumulated dose for fraction f. 
The 95% level of confidence for each dose bin in the (cumulative) DVH of the accumulated dose was 
calculated by averaging 𝑢𝐴𝑓 of all voxels with 𝐷𝑓
𝑎 equal to or larger than that dose level.  
 
4.2.3 Dose analysis  
The accumulated dose at the end of treatment, 𝐷𝑎𝑐𝑐  was analyzed for target volumes and OARs as 
detailed in Supplementary Data A.14: Structures available for analysis for both 5 and 3 mm margin 
expansion plans. The difference between the planned dose 𝐷𝑝𝑙𝑎𝑛 and 𝐷𝑎𝑐𝑐 was defined as the change 
in dose, 𝐷. From this point onward, DVH dose metrics of 𝐷𝑝𝑙𝑎𝑛, 𝐷𝑎𝑐𝑐 and 𝐷 will be expressed using 
subscripts. For example, 𝐷99%
𝑎𝑐𝑐  refers to the minimum accumulated dose delivered to 99% of the volume. 
Target coverage of the PTV was assessed using D98% to be consistent with both our department protocol 
and existing literature [23,211]. The CTV coverage was quantified using D99% to enable direct 
comparison of our results with those reported by van Kranen et al. [142]. However, DVH metrics 









specifically for large target volumes, a clinically relevant loss in sub-volume coverage may not be 
detected. Therefore, CTV coverage was also assessed by recording the number of voxels where 
𝐷𝑝𝑙𝑎𝑛 and 𝐷𝑎𝑐𝑐 were less than 95% of 𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% confidence level. In addition, a more in-depth 
investigation was conducted to quantitatively assess coverage near the skin considering that target 
coverage was often already tight during treatment planning in this region. Specifically, the dependence 
of target coverage both during planning and treatment on the minimum distance between the CTV and 
skin was investigated. For that purpose, local volumes of approximately 0.5 cm3 were defined at the 
point of minimum distance between the high-dose (HD) CTV and skin. A detailed methodology how 
the local volumes were constructed is provided in Supplementary Data A.15: Generation of local 
volumes. 
 
4.2.4 Statistical analyses 
The normality of the distributions of the DVH parameters 𝐷𝑝𝑙𝑎𝑛, 𝐷𝑎𝑐𝑐  and the difference 𝐷 between 
these metrics for the two margin expansions’ structures were tested using Q-Q plots and Shapiro-Wilk 
tests as detailed in Supplementary Data A.16: Normality tests. Unless stated otherwise, two-tailed 
paired Student’s t-tests at a 5% level of significance were conducted for normally distributed metrics. 
The number of cases where 𝐷 was outside the 95% level of confidence, i.e., when the 95% CI of 𝐷𝑎𝑐𝑐 
did not include 𝐷𝑝𝑙𝑎𝑛, was defined as . The number of cases where a CTV 𝐷99%
𝑎𝑐𝑐  was less than 95% 
of 𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% level of confidence was defined as .   
 








4.3.1 Target volumes 
No significant difference was observed between the coverage of target volumes for the two margin 
expansions at planning (Table 6) due to the minimum requirement for 𝐷98%
𝑝𝑙𝑎𝑛
 of the PTVs in the applied 
planning protocol (Supplementary Data A.9: Planning protocol). There was also no significant 
difference between the observed 𝐷𝑎𝑐𝑐 during treatment for the two margin expansions, except for the 
low-dose (LD) target volumes LD-CTV and LD-PTV (Table 6). The average loss in target volume 
coverage during treatment relative to 𝐷𝑝𝑙𝑎𝑛, 𝐷, over all patients was significantly different between 5 
and 3 mm margin expansions for the HD-CTV (p = 0.04), LD-CTV (p = 0.01) and intermediate-dose 
(ID) PTV (p = 0.03), although these differences were small. Example cases where the HD-CTV 
coverage during treatment was either well preserved or not are presented in Figure 4.1a and Figure 4.1b, 
respectively. A loss in coverage at the 95% level of confidence (i.e., ) was observed for at least 75% 
of all CTVs. However for only three cases, 𝐷99%
𝑎𝑐𝑐  was less than 95% of the prescribed dose 𝐷𝑝𝑟𝑒𝑠𝑐. For 
only one case (i.e., ), this dose difference was at the 95% level of confidence. 
 
Table 7 further details the number of voxels with less than 95% of 𝐷𝑝𝑟𝑒𝑠𝑐 for the HD-CTVs and ID-
CTVs in conjunction with the observed CTV 𝐷99% for individual patients. It shows that for a majority 
of patients, either one or both margin expansion plans included voxels that received less than 95% 
𝐷𝑝𝑟𝑒𝑠𝑐  during treatment, and that this already occurred during treatment planning for many cases. In 
four patients, the voxels in the HD-CTV that received less than 95% 𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% confidence level 
were located in the subdermal region (Patients 1, 10-12). For these cases, both the PTV and the CTV 
were not fully covered by the 95% isodose at planning except for one case (patient one; 3 mm plan) 
where the CTV was covered at planning. For patient three, progressive anatomical changes during 
treatment resulted in a small number of voxels (n = 4) at the superior side of an involved node (level 
2a) receiving less than 95% 𝐷𝑝𝑟𝑒𝑠𝑐. For patient seven, voxels in the HD-CTV receiving less than 95% 
𝐷𝑝𝑟𝑒𝑠𝑐 were located in the posterior soft palate where target volume coverage was already tight during 
planning (95% 𝐷𝑝𝑟𝑒𝑠𝑐 isodose situated midway between the PTV and CTV). For the ID-CTV, voxels 









For patient six, this underdosage was present at the left posterior aspect of the mandible where target 
volume coverage was tight during planning as well. 
 
Further investigation of the relation between target coverage at the end of treatment and coverage at 
treatment planning showed that there was no obvious correlation between the HD-CTV 𝐷99%
𝑎𝑐𝑐  and the 
HD-PTV 𝐷98%
𝑝𝑙𝑎𝑛
 (Figure 4.2a). There appeared to be a correlation between the HD-CTV 𝐷99%
𝑎𝑐𝑐  and HD-
CTV 𝐷99%
𝑝𝑙𝑎𝑛
 which were approximately equal for cases where 𝐷99%
𝑝𝑙𝑎𝑛
 was larger than 98% 𝐷𝑝𝑟𝑒𝑠𝑐 (Figure 
4.2b). For the two patients where 𝐷99%
𝑝𝑙𝑎𝑛
 was smaller than 98% 𝐷𝑝𝑟𝑒𝑠𝑐, both margin expansion plans 
exhibited a larger drop in coverage during treatment in the superficial region. There was no obvious 
correlation between the planned and received dose for individual voxels (Figure 4.3). This was further 
illustrated by the analysis of the local target coverage near the skin. Figure 4.4 shows that overall, a 
lower 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 was obtained for the local CTVs that were closer to the skin. In addition, less superficial 
CTVs generally showed a slight increase in target coverage whereas the local CTVs more proximal to 
the skin displayed either preservation or a considerable drop in local coverage during treatment. These 
trends were very similar for both margin expansions and were independent of the magnitude of the 
contour change. 
 







Table 6: Structure-specific average and range for the planned, accumulated and  doses. HD = high-dose. ID = intermediate-dose. LD = low-dose. CTV = clinical target volume. PTV = planning target volume. SC 
= spinal cord. BS = brainstem. PRV = planning risk volume. PG = parotid gland. SMG = submandibular gland. Ips. = ipsilateral. Contra. = contralateral. Dplan = planned dose. Dacc = accumulated dose. 𝐷 = 
change in dose = Dacc - Dplan. D99% = dose to 99% of volume. D98% = dose to 98% of volume. D0.1cc= minimum dose to 0.1 cm3 of the volume receiving the highest dose. Dmean = mean dose.  = number of cases where 
𝐷 was outside the 95% level of confidence.  = number of cases where 𝐷99%
𝑎𝑐𝑐  was less than 95% of the prescribed dose at the 95% level of confidence.*Indicates a statistically significant difference. 
    𝑫𝒑𝒍𝒂𝒏 [Gy]  𝑫𝒂𝒄𝒄 [Gy]  D [Gy]   
Metric Structure n 
PTV/PRV 
expansion 
Median Range p-value  Median Range p-value  Median Range p-value   
D99% HD-CTV  11 
3 mm 65.1 63.6 – 65.7 
0.66 
 65.0 62.7 – 65.9 
0.24 
 -0.3 -1.7 – 0.6 
0.04* 
9  1  
5 mm 65.0 63.7 – 65.9  65.4 62.0 – 66.3  0.3 -2.2 – 0.7 10  0  
 ID-CTV 4 
3 mm 60.1 59.0 – 60.4 
0.91 
 60.2 58.9 – 60.4 
0.37 
 0.1 -0.3 – 0.2 
0.44 
3 0  
5 mm 60.0 59.6 – 60.2  60.2 59.8 – 60.6  0.4 -0.4 – 0.6 4 0  
 LD-CTV 12 
3 mm 53.5 52.3 – 54.1 
0.08 
 53.3 52.0 – 54.4 
< 0.01* 
 -0.1 -1.0 – 0.3 
0.01* 
9 0  
5 mm 53.7 52.5 – 54.6  54.1 52.4 – 55.1  0.2 -0.8 – 0.6 10 0  
                 
D98% HD-PTV  11 
3 mm 63.5 62.7 – 64.2 
0.23 
 62.0 59.8 – 63.3 
0.66 
 -1.4 -3.1 – -0.4  
0.08 
11  
5 mm 63.4 62.8 – 63.6  62.5 59.8 – 63.2  -0.9 -3.0 – -0.3 11  
 ID-PTV 4 
3 mm 57.6 57.1 – 58.2 
0.53 
 56.3 55.5 – 56.8 
0.12 
 -1.4 -1.8 – -0.9 
0.03* 
4  
5 mm 57.6 57.2 – 57.7  56.7 56.3 – 56.9  -0.8 -1.2 – -0.7 4  
 LD-PTV 12 
3 mm 51.7 51.3 – 53.4 
0.11 
 50.2 49.0 – 52.0 
0.05* 
 -1.5 -2.9 – -0.5 
0.14 
12  
5 mm 52.0 51.4 – 53.5  50.6 50.0 – 52.0  -1.3 -2.2 – -0.7 12  
                 
D0.1cc SC  12 
3 mm 34.1 19.4 – 43.4 
0.63 
 34.5 19.9 – 42.5 
0.54 
 -0.1 -1.0 – 1.0 
0.33 
6  
5 mm 36.0 23.5 – 42.3  36.1 24.1 – 41.8  0.1 -0.8 – 1.2 3  
 BS  12 
3 mm 37.1 30.0 – 51.9 
0.63 
 37.7 30.1 – 51.5 
0.58 
 0.2 -2.1 – 1.7 
0.41 
5  
5 mm 35.6 27.1 – 52.4  35.4 26.5 – 52.3  0.1 -1.4 – 1.1 2  
                
D0.1cc SC PRV 12 
3 mm 38.7 21.1 – 45.2 
0.03* 
 38.7 21.4 – 43.9 
0.04* 
 -0.7 -1.6 – 1.0 
0.83 
10  
5 mm 42.1 26.6 – 47.4  41.3 26.7 – 47.9  -0.3 -2.7 – 0.5 7  
 BS PRV 12 
3 mm 41.5 33.7 – 52.9 
0.02* 
 41.3 32.6 – 52.7 
< 0.01* 
 0.3 -1.1 – 2.3 
0.60 
2  
5 mm 45.3 36.5 – 60.7  45.5 35.8 – 61.1  -0.4 -0.9 – 2.6 1  
                
Dmean Ips. PG 14 
3 mm 28.0 14.1 – 43.6 
< 0.01* 
 28.8 14.1 – 43.0 
< 0.01* 
 0.4 -0.7 – 2.1 
0.57 
5  
5 mm 31.9 16.8 – 50.0  33.4 16.7 – 49.4  0.4 -0.6 – 2.1 5  
 Contra. PG 10 
3 mm 17.1 4.5 – 32.8 
< 0.01* 
 17.9 4.6 – 32.2 
< 0.01* 
 0.1 -0.6 – 1.2 
0.71 
7  
5 mm 21.8 5.2 – 37.2  22.7 5.3 – 36.7  0.2 -0.9 – 1.3 6  
                 
Dmean Ips. SMG 13 
3 mm 63.5 1.1 – 65.8 
0.01 
 62.8 1.2 – 66.0 
< 0.01* 
 0.0 -1.7 – 0.7 
0.17 
6  
5 mm 64.1 1.5 – 66.1  64.0 1.6 – 66.2  0.1 -1.8 – 0.7 7  
 Contra. SMG 9 
3 mm 50.7 0.7 – 55.5 
0.04* 
 50.5 0.7 – 55.9 
0.03* 
 0.0 -1.1 – 1.3 
0.74 
6  









Figure 4.1: Dose-volume histograms (DVHs) of 𝐷𝑝𝑙𝑎𝑛 and 𝐷𝑎𝑐𝑐 for the high-dose clinical target volume (CTV) 
of patient 8 (a) and patient 10 (b). In contrast to (a), a CTV underdosage is observed for case (b) when utilizing 
3 and 5 mm planning target volume (PTV) margin plans at the 95% level of confidence (b). 𝐷𝑝𝑙𝑎𝑛 = planned 
dose. 𝐷𝑎𝑐𝑐 = accumulated dose. D99% = dose to 99% of volume. 𝐷𝑝𝑟𝑒𝑠𝑐= prescribed dose.  
 
 








Table 7: Target coverage for individual patients’ high-dose (HD) and intermediate-dose (ID) clinical 
target volume (CTV). Dplan = planned dose. Dacc = accumulated dose. Dpresc = prescribed dose. D99% = 
minimum dose received by 99% 
 
 





D99% [Gy]  
(95% level of confidence) 
    𝑫𝒑𝒍𝒂𝒏 𝑫𝒂𝒄𝒄 𝑫𝒑𝒍𝒂𝒏 𝑫𝒂𝒄𝒄 
HD-CTV 
95% Dpresc 
= 62.7 Gy 
1 88.0 
3 mm  6* 64.8 64.5 (-0.13; +0.15) 
5 mm 15* 17* 64.3 64.1 (-0.13; +0.15) 
        
3 57.1  
3 mm  4*  64.7 65.3 (-0.13; +0.15) 
5 mm   65.0 65.7 (-0.13; +0.15) 
         
 
4 43.6 
3 mm   65.2 64.8 (-0.13; +0.15) 
 5 mm   65.2 65.6 (-0.13; +0.15) 
         
 
5 56.1 
3 mm   65.1 65.5 (-0.13; +0.15) 
 5 mm   65.1 65.7 (-0.13; +0.15) 
         
 
6 42.4 
3 mm   65.7 65.3 (-0.13; +0.15) 
 5 mm   65.1 65.4 (-0.13; +0.15) 
         
 
7 112.4 
3 mm  58* 64.6 63.9 (-0.13; +0.15) 
 5 mm  36* 64.6 64.9 (-0.13; +0.15) 
         
 
8 46.4 
3 mm   65.4 65.6 (-0.13; +0.15) 
 5 mm   65.8 66.0 (-0.13; +0.15) 
         
 
9 88.5 
3 mm   65.5 65.9 (-0.13; +0.16) 
 5 mm   64.6 65.1 (-0.13; +0.15) 
         
 
10 57.2 
3 mm 19* 127* 64.4  62.7 (-0.13; +0.15)± 
 5 mm 35* 175*  64.2  62.0 (-0.13; +0.15)* 
         
 
11 219.3 
3 mm 71* 77* 65.2 65.0 (-0.13; +0.15) 
 5 mm 12* 27* 65.9 66.3 (-0.14; +0.16) 
         
 
12 66.1 
3 mm 58* 99* 63.6  62.8 (-0.13; +0.15)± 
 5 mm 37* 86*  63.7 63.0 (-0.13; +0.15) 
        
ID-CTV 
95% Dpresc 
= 57.0 Gy 
6 78.3 
3 mm  4*  60.0 60.3 (-0.16; +0.11)  
5 mm   59.6 60.0 (-0.16; +0.11) 
       
9 211.3 
3 mm 4* 9* 60.2 60.4 (-0.16; +0.11) 
5 mm   60.0 60.4 (-0.16; +0.11) 
        
 
10 171.1 
3 mm  13* 60.4 60.1 (-0.16; +0.11) 
 5 mm  2*  60.0 60.6 (-0.16; +0.11) 
        
 
12 113.8 
3 mm 4* 13* 59.0 58.9 (-0.16; +0.11) 
 5 mm  2*  60.2 59.8 (-0.16; +0.11) 
† 1 cm3 includes 189 voxels   * Dose less than 95% Dpresc at the 95% level of confidence 













Figure 4.2: Plots of dose-volume histograms (DVH) metrics of interest for the high-dose (HD) clinical 
target volume (CTV) and planning target volume (PTV) when utilizing 3 or 5 mm planning target 
volume (PTV) and planning risk volume (PRV) margin plans. 𝐷𝑝𝑙𝑎𝑛 = planned dose. 𝐷𝑎𝑐𝑐 = 
accumulated dose. D99% = dose to 99% of volume. D98% = dose to 98% of volume. 𝐷𝑝𝑟𝑒𝑠𝑐= prescribed 
dose. 
 







Figure 4.3: Plot of individual voxels within the high-dose clinical target volumes (CTVs) of all patients 
when utilizing 3 or 5 mm planning target volume (PTV) and planning risk volume (PRV) margin plans. 
𝐷𝑝𝑙𝑎𝑛 = planned dose. 𝐷𝑎𝑐𝑐 = accumulated dose. 𝐷𝑝𝑟𝑒𝑠𝑐= prescribed dose. 
Figure 4.4: Progression of the minimum planned dose 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 to the minimum accumulated dose 𝐷𝑚𝑖𝑛
𝑎𝑐𝑐  for local 
clinical target volumes (CTVs) near the skin for 3 and 5 mm planning target volume (PTV)/planning risk volume 
(PRV) margin plans. 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 is plotted as a function of the minimum distance between the CTV and skin. 𝐷𝑚𝑖𝑛
𝑎𝑐𝑐  is 
plotted as a function of the minimum distance between the CTV and skin, and the local shift of the skin at the end of 







































Application of reduced PTV/PRV margins had a beneficial impact on the dosimetry for OARs (Table 
6). A significantly different 𝐷0.1𝑐𝑐
𝑝𝑙𝑎𝑛
 was achieved for the spinal cord (SC) PRV and brainstem (BS) PRV 
with 3 mm margin expansions. In addition, a compromise between target coverage and maximum dose 
to the BS PRV due to their proximity could be avoided for one patient by using 3 mm margin 
expansions, whereas a higher dose than the tolerance for the BS PRV had to be accepted to obtain 
sufficient target coverage both for the clinical plan and for the 5 mm plan in this study. More detail on 
the change in dosimetry of OARs during treatment for individual cases is provided in Supplementary 
Data A.17: Individual patient OAR dosimetry. A significantly different 𝐷𝑚𝑒𝑎𝑛
𝑝𝑙𝑎𝑛
 could be obtained using 
3 mm margin expansions for all salivary glands. The commonly used cut-off point in normal tissue 
complication probability (NTCP) models [25,59] stating that the PG 𝐷𝑚𝑒𝑎𝑛
𝑝𝑙𝑎𝑛
 should be preferably less 
than 26 Gy was achieved in 8 and 14 cases (Supplementary Data A.1: Patient group) for 5 and 3 mm 
margin expansions, respectively. The change in PG mean dose during treatment was generally less than 
1 Gy and not significantly different for the two margin expansions (Supplementary Data A.17: 

























The current study used DIR-facilitated dose accumulation to assess the actually delivered dose in the 
presence of anatomical changes, and the impact of a reduced PTV margin on the robustness of target 
coverage for anatomical changes. The CTV coverage 𝐷99%
𝑎𝑐𝑐  was found to be similar for both margin 
expansions and for only one case, this was less than 95% of the prescribed dose 𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% level 
of confidence. However for many cases, the accumulated dose included a substantial volume of voxels 
receiving less than 95% 𝐷𝑝𝑟𝑒𝑠𝑐 independent of margin expansion. This predominantly occurred in the 
subdermal region.   
 
Whether or not a PTV margin reduction is safe depends on many department-specific factors and can 
ultimately only be established by reviewing clinical results. Chen et al. [1,2] reported a 78% and 80% 
three-year LR control rate for the patient groups treated with 5 and 3 mm PTV margins, respectively (p 
= 0.75). Similarly, Navran et al. [3] reported that the two-year LR control rates equal to 79.2% and 
79.9% for patients treated with 5 and 3 mm PTV margins, respectively, were not significantly different 
(p = 1.0). In contrast to the previous two groups, Franzese et al. [4] found a significant difference (p = 
0.045) in LR control rates which were 87.8% and 72.6% for patients treated with 5 and 3 mm PTV 
margins at two-year follow-up, respectively. Unfortunately, the above clinical results studies did not 
have a common approach to GTV to CTV margins, treatment adaptation, and treatment plan acceptance 
criteria. It is therefore not possible to conclude what caused the mixed clinical results and whether a 
PTV margin reduction is generally safe remains equivocal. The retrospective DIR-based dose 
accumulation studies by van Kranen et al. [142] and Wu et al [110] investigated the impact of 
anatomical changes to the dose delivery during modulated HNRT for different PTV margin expansions. 
Both studies used DVH metrics to assess the planned and delivered dose and, well aligned with the 
results of the current study, both studies reported a reduction in OAR dose with reduced margin 
expansions and a limited change in target coverage as indicated by DVH metrics. The study by van 
Kranen et al. [142] which used dose accumulation based on DIR of daily CBCT images reported a CTV 
𝐷99%









respectively. The study by Wu et al. [110] used dose accumulation based on weekly re-CTs included 
eleven patients. This study concluded that the coverage of the CTVs at the end of treatment was not 
affected by anatomical changes based on the ratio of multiple DVH metrics relative to the corresponding 
planning metrics. It should be noted that the current study and those by van Kranen et al. [142] and Wu 
et al. [110] may be restricted by limitations of DIR in the presence of mass and density changes 
[139,143,166–169]. The impact of this limitation is partially included in the dose accumulation 
uncertainty estimate that was used in the current study [213]. In addition, the current study and similar 
retrospective studies [110,142] only evaluated the plan robustness for anatomical changes during 
treatment. A full PTV margin estimate should include all geometrical uncertainties as sufficiently 
described in literature [35,36,170]. Due to the absence of a golden standard for delineation accuracy 
and limited knowledge on microscopic tumor spread for different tumor types [37,214,215], the only 
way to fully assess the validity of applied treatment margins is by pattern of failure studies or a review 
of clinical results as exemplified in refs [1–4] which must include consistent volume definitions 
[34,216]. However, we recommend that more comprehensive information is provided in review of 
clinical results studies including a voxel-based analysis of the actually delivered dose. 
 
The initial analysis of target coverage based on DVH metrics in the current study suggested that 5 and 
3 mm PTV margin plans have similar target coverage with only one 5 mm treatment plan where the 
target coverage was below the rejection criterion 𝐷99%
𝑎𝑐𝑐 < 95% 𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% level of confidence 
(Table 6). However, a full analysis of the dose delivered to each voxel (Table 7) highlighted potentially 
clinically significant underdosage in many cases both for 3 mm and 5 mm margin expansions. DVH 
metrics inherently lack spatial information regarding the dose distribution within a volume of interest 
[190] and commonly refer to percentages instead of absolute volumes. Specifically for larger target 
volumes, underdosage of the high- and intermediate-risk target volumes may not be detected by using 
DVH metrics as criterion. Therefore, a voxel-specific analysis of the entire target volume as is presented 
in the current study is preferred. 
 
 







For the majority of cases with voxels receiving less than 95% 𝐷𝑝𝑟𝑒𝑠𝑐, these voxels were located in the 
dermal region. Pattern of failure studies in literature that did explicitly document the locations of 
marginal loco-regional recurrence (LRR) indicated that these occur relatively frequently in the 
subcutaneous/dermal region. Specifically, subcutaneous/dermal recurrences constituted 45% (4/9) [1], 
60% (3/5) [217], 100% (1/1) [218] and 22% (2/9) [219] of the marginal LRRs in these reports. No 
dermal recurrences were observed for the patients included in the current study (median follow up 32 
months, range 7 – 44 months). Further retrospective review of the study cases by the most senior 
clinician of our department involved in HNRT revealed that in some cases the observed underdosage 
of specific voxels in this study could potentially be clinically relevant. However, in most cases the CTV 
contour near the skin might have been slightly too generous with contour extension beyond the platysma 
and the observed underdosage of specific voxels in this study might not be clinically relevant for those 
cases. It should be noted that a slightly less generous CTV contour would also have resulted in a 
different treatment plan with likely one or more locations presenting a compromise in target coverage. 
As per the current departmental procedure, this study applied “virtual bolus” during plan optimization 
when CTVs extended into the dermal region [212] to moderate the fluence in the skin region and reduce 
the risk of severe skin toxicity. This approach commonly results in tight target coverage near the skin 
but is generally accepted by the treating clinician as compromise rather than using bolus on treatment 
unless the skin itself is at risk.  
 
For 3D-conformal radiation treatments, the accuracy of the accumulated skin dose is limited by the 
uncertainty in the calculated dose in the buildup region [220]. However for VMAT treatments in this 
study, the dose to skin could be regarded as exit dose because the majority of dose to the skin was 
delivered through medial beam angles. Using the methodology previously developed for time-resolved 
point dose QC to assess the TPS calculated dose per control point [221], it could be demonstrated that 
~80% of the dose delivered to 40 superficial HD-CTV points with Dacc < 95% Dpresc was deposited at 
beam angles where the effective depth was larger than or equal to 4 mm. More detail on this analysis is 
provided in Supplementary Data A.18: Time-resolved point dose QC analysis. In general, full scatter 









patient. Therefore, the exit dose follows the normal percentage depth dose curve and can be accurately 
calculated [220,222,223]. The accuracy of the skin dose calculation could also be limited by uncertainty 
in the Hounsfield units (HUs) of the most superficial voxels within the body contour [224]. 
Supplementary Material A.19: HU override analysis details the results of planning simulations using 
an HU override equal to the average HU value ± 100 for these voxels. The HD-CTV doses were assessed 
for both HU values and the largest resulting 95% percentile range of the difference was ~1% 𝐷𝑝𝑟𝑒𝑠𝑐. It 
is therefore reasonable to assume that any uncertainty in the HU of superficial regions has minimal 
impact on the observed values of HD-CTV 𝐷𝑎𝑐𝑐, which were as low as ~85% 𝐷𝑝𝑟𝑒𝑠𝑐 (Figure 4.3). 
 
In the current study, loss in CTV coverage was very patient specific and appeared to be independent of 
margin expansion. Specifically for superficial HD-CTVs, the loss in local target coverage occurred 
more frequently in regions near the skin, but appeared not to be correlated with the magnitude of 
anatomical changes. In general, multiple mechanisms play a role in target coverage differences between 
planning and treatment. The interplay between local fluence, dose delivered per gantry angle, 
contribution of scatter and anatomical changes prohibited a clear identification of risk factors for 
individual patients that may be prone to a loss in target coverage during treatment. Nevertheless, it was 
clear that target coverage at treatment planning was an important factor considering that changes in 
patient anatomy on treatment are more likely to result in a decrease in target coverage when it was 
already marginal or compromised during the treatment preparation stage. It is recommended to assess 
target coverage using a voxel-based approach and not exclusively rely on DVH metrics. In principle 
this is not different from a slice-by-slice review of the 3D dose distribution before acceptance at 
treatment preparation by the treating radiation oncologist. However, manual review of the delivered 
dose after each fraction would be very laborious and automated processing of results using a voxel 
based analysis would be preferable for efficiency reasons.  
 
In addition to increased sparing of salivary glands as described by many other studies [58,110,142], this 
study also highlighted the increased avoidance of the critical OARs with reduced PTV margins. As the 
 







minimum distance between the HD-CTV and BS decreased, a higher 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 to the local PTV was 
generally achievable with 3 than with 5 mm margins (Supplementary Data A.17: Individual patient 
OAR dosimetry). Comparably, as the minimum distance between the HD-CTV and BS decreased a 
lower 𝐷𝑚𝑎𝑥
𝑝𝑙𝑎𝑛
 to the local PRV was generally achievable with 3 mm margins (Supplementary Data A.17: 
Individual patient OAR dosimetry). The compromise to the local BS PRV 𝐷𝑚𝑎𝑥
𝑝𝑙𝑎𝑛
 as required for the 5 
mm margin plan for patient ten was not necessary for the 3 mm plan.  
 
In summary, a PTV/PRV margin reduction from 5 to 3 mm itself did not change the plan robustness for 
anatomical changes during treatment. However, a considerable loss in CTV coverage was observed for 
some patients irrespective of the margin expansion. Although this was very patient specific, it was 
specifically observed when target coverage at treatment planning was already tight. Patient-specific 
verification of dose delivery during treatment is therefore recommended, for instance using the DIR-



















The motivation for conducting the body of research detailed in this dissertation was to demonstrate that 
a safe PTV margin reduction from 5 to 3 mm is feasible by developing a quality management “safety 
net” for patients who may be at risk of unacceptable loss in target coverage and/or overdosage to normal 
tissues. The use of a reduced 3 mm PTV margin is likely to improve patient toxicity results [1–4]. An 
emphasis on safe PTV margin reduction is particularly warranted considering that an equivalent LR 
control rate was not maintained for one [4] of three groups that have clinically implemented reduced 
PTV margins [1–4], and that the frequency of loss in target coverage during treatment may slightly 
increase with reduced mm PTV margins [142]. It is important to optimise the PTV margin so 
appropriate target coverage is achieved while simultaneously ensuring the margins are not overly 
generous resulting in unnecessary toxicity for patients.  
 
PTV margins do not standardly account for non-rigid anatomy changes (e.g., changes in patient pose, 
weight loss, tumour response, OAR shift, OAR shrinkage) commonly observed during HNRT which 
can undermine the planned dose objectives. Therefore, a loss in target coverage could occur more often 
and may become more relevant with reduced mm PTV margins. The premise of developing the quality 
management “safety net” in the research described in this dissertation was to enable the monitoring and 
quantification of a patient’s dosimetry in the presence of anatomical changes. Monitoring the delivered 
dose during treatment would allow detection of unacceptable loss in target coverage and/or overdosage 
to OARs. Ultimately, identifying patients at risk would facilitate timely and appropriate ART. Broadly, 
the “safety net” was required to (a) quantify and separate the different modes of non-rigid anatomical 
change; and (b) quantify the dosimetric impact of non-rigid deformations. The studies included in the 
 







research described in this dissertation were undertaken to build the quality management “safety net”, 
and resulted in a series of papers for publication which were reproduced in Chapters Two, Three and 
Four (at the time of this dissertation’s submission Chapter Two has been published, Chapter Three has 
been accepted and is an article in press and Chapter Four is in peer-review). The Sections 5.2-5.4 of 
the current Discussion chapter detail the “safety net” requirement that each study aimed to achieve and 
the rationale for conducting each study in the context of the wider body of literature. In addition, further 
considerations that are relevant to each study which were not provided in the corresponding discussion 
Sections (i.e., 2.4, 3.4 and 4.4) are put forward. Section 5.5 presents a collective summary of the 
individual studies to show how they constitute a coherent body of research and the current Discussion 
chapter concludes with a consideration of future perspectives. 
 
5.2 Monitoring anatomical changes of individual patients using statistical process 
control during head-and-neck radiotherapy 
The study described in Chapter Two aimed to develop a method to quantify and separate the different 
modes of non-rigid anatomical change that can occur during treatment, the “safety net” requirement (a). 
A large number of previous studies have successfully quantified non-rigid deformations in HNRT 
[78,81–84,91,95,98,225,226]. These studies include the quantification of daily positioning inaccuracies 
[81–85], investigations of the change in volume and neck diameter of various HN sub-regions as a 
surrogate of weight change [78,93,95,226], and investigations of structures’ volumetric changes 
[79,91,98]. However, the analyses in these studies were either carried out manually which would make 
their clinical implementation impractical from an economic and efficiency perspective, or did not 
provide a method of detecting systematic changes. SPC (Sub-section 2.2.5) is widely used in 
manufacturing as a quality management tool and recently, its use in radiotherapy for quality assurance 
has been discussed [188]. Control charts, also known as process-behaviour charts, are frequently used 
to examine and monitor process time trends [189,227]. Natural variation will occur in even the most 
well controlled processes. Discrimination of natural and exceptional variation is governed by a single 









interpreted as exceptional variation and the cause should be investigated. The unambiguous instructions 
surrounding control chart initialisation and interpretation allow time trends to be reviewed in a 
standardised way. 
 
The feasibility study in Chapter Two was the first study to investigate the suitability of DIR and EWMA 
SPC charts to assess trends for individual patients during HNRT. Specifically, DIR and EWMA SPC 
charts were used to objectively quantify, monitor and separate individual patients’ non-rigid 
deformations. A standardised approach to quantify patient deformations with an estimated robustness 
derived from comprehensive uncertainty analyses was utilised. Trends in patient positioning 
reproducibility occurring before the end of treatment week four were confirmed in 24% of cases when 
SPC process limits were used, whereas absolute BA structure deviations could be confirmed in 82% of 
cases when an a priori 2 mm clinical limit was used. SPC process limits were useful to detect trends of 
changes of the treatment-region volume, PGs shrinkage, and PG shifts occurring before the end of 
treatment week four which could be confirmed in 90% of cases.  
 
The main challenge encountered in the study in Chapter Two was defining the exact moment a patient 
positioning deviation trend exceeded the SPC control limits at a certain statistical confidence interval. 
This was particularly applicable to shallow trends with narrow process limits in spite of their sub-
millimetre accuracies. For these cases, the relatively large uncertainties in both the DIR derived EWMA 
statistics and the EWMA process limits precluded trend confirmation at a 90% confidence level. The 
main contributors to the total uncertainty in the DIR derived EWMA statistics were the uncertainty in 
the DIR algorithm, and the uncertainty when copying structures to the CBCT from the dCT 
(Supplementary Data A.2: Uncertainty analysis). The accuracy of the DIR algorithm will likely be 
improved by the application of local rigidity constraints to BA structures to reduce the impact of “creep” 
[197,198] while an improved level of uncertainty when copying structures to the CBCT from the dCT 
is expected with improved image resolution of the planning CT, particularly in the z direction. The 
uncertainty in the EWMA process limits was caused by the uncertainty in the standard deviation of the 
reference period (uncertainty in σ, equation 4 page 79) only, because the other variables determining 
 







the process limits are constants. The uncertainty in the EWMA process limits was therefore directly 
proportional to the variation in the reference period. Efforts to reduce the uncertainty in the EWMA 
process limits could focus on defining the optimal length of the reference period which is likely to be 
structure- and patient-specific. The study in Chapter Two used the first week of treatment, fractions 1-
5, as the reference period length to represent a “stable” process. However, the first week of treatment 
may not always appropriately represent a stable process as potential trends for some structures and for 
some patients could already be occurring. Investigating the methods that were proposed in the current 
paragraph to reduce uncertainty and optimise the EWMA reference period may indeed develop 
structure-specific clinical limits which may then demonstrate the efficacy of SPC to timely indicate 
ART. 
 
Considering the difficulty with shallow trends and narrow SPC process limits as described in the 
preceding paragraph, the study in Chapter Two found it more efficient to apply a clinical limit to ‘flag’ 
patient positioning deviations that may have a clinical impact during treatment. In that study, a generic 
a priori 2 mm clinical limit was used for all BA structures. However, on clinical implementation, the 
clinical limit should ideally be individually set for each BA structures’ deviations and for each patient 
based on expected impact to target coverage and/or OAR sparing. To further clarify, it helps to realise 
that BA deviations are essentially surrogates for the non-rigid positioning of target volumes and the 
extent to which a target volume may abut or even contain a BA structure needs consideration. For 
example, a target volume immediately adjacent to C1-C3 that also encapsulates the entire mandible is 
likely to have a clinically relevant change in dosimetry as the mandible deviation reaches the size of the 
PTV margin expansion. Whereas for a target volume immediately adjacent to C1-C3 extending only 
midway to the mandible, the same mandible deviation magnitude is less likely to cause a clinically 
relevant change in dosimetry.  
 
The study in Chapter Two successfully developed a method to quantify and separate the different modes 
of non-rigid anatomical change. However, non-rigid deformation trends exceeding an SPC process or 









interpretation rules. Chapter Two set the platform required to investigate the dosimetric impact of the 
observed non-rigid deformations in an effort to show the efficacy of SPC to timely indicate required 
ART. 
 
5.3 Quantifying the dose accumulation uncertainty after deformable image 
registration in head-and-neck radiotherapy 
DIR-facilitated dose reconstruction and accumulation allows estimation of the actually delivered dose 
in the presence of anatomical changes during HNRT [139]. DIR-facilitated dose accumulation was 
therefore identified as a tool that could quantify the dosimetric impact of non-rigid deformations, the 
“safety net” requirement (b). However, the validation of DIR for this purpose is challenging because a 
comprehensive ground truth when dealing with patient data does not yet exist [130]. In the absence of 
a comprehensive ground truth, a number of studies [136,145,164,228–230] have validated the 
accumulated dose using physical or simulated phantoms with known DVFs. However, the reference 
deformations in these studies were not always clinically realistic. Other groups have indirectly estimated 
the uncertainty in the accumulated dose by modelling DIR uncertainties as multivariate Gaussian 
distributions [231,232]. As discussed in the DIR for dose accumulation review of Chetty et al. [139], 
specific aspects of DIR-facilitated dose accumulation that can impact the accumulated dose have been 
investigated by various authors, i.e.,: the choice of DIR algorithm and parameters [145,162,230,233], 
the ROI selected to generate the DVF [228], the dose grid resolution [234], the inverse consistency of 
the DVF [159,165] and the principles of mass and energy conservation [229,235]. Current literature 
encourages research that validates DIR-facilitated dose accumulation in the setting of clinical realism 
[139], in particular for patients exhibiting mass/density changes during treatment [169].  
 
As it was considered whether it was possible to utilise DIR-facilitated dose accumulation to assess the 
delivered dose in HNRT using the DIR application available at the WBCC, it was recognised that the 
factors which may impact the accumulated dose mentioned in the preceding paragraph are algorithm, 
treatment site and potentially department specific, and should be explored. To the best of the author’s 
 







knowledge, no previous study has evaluated the uncertainty in the proposed dose accumulation clinical 
workflow with subsequent incorporation in DVHs. The study in Chapter Three was conducted to 
address this knowledge gap, and the general recommendation of the literature mentioned in the previous 
paragraph [139,169]. 
 
The retrospective study in Chapter Three utilised in silico deformations based on clinically observed 
anatomical changes as ground truth to evaluate the dose accumulation uncertainty. In order to assess 
the structure-specific uncertainties of the demons DIR algorithm for inverse consistent and inverse 
inconsistent voxels, the reconstructed dose based on demons DIR was compared to a ground truth 
reconstructed dose distribution based on B-spline DIR. The inverse consistency of voxels was assessed 
by determining their net displacement after successive application of the forward and backward DVF.  
Over all patient structures included in this study, 98.5% of voxels were inverse consistent with a 95% 
level of confidence range for dose reconstruction of a single fraction relative to their planned dose equal 
to [-2.3%; +2.1%], [-10.2%; +15.2%] and [-9.5%; +12.5%] for target structures, critical OARs and non-
critical OARs, respectively. As per Equation 7 (page 108), the uncertainty in the accumulated dose for 
these structures was [-0.4%; +0.4%], [-1.9%; +2.8%] and [-1.7%; +2.3%] at the end of treatment, 
respectively. Inverse inconsistent voxels generally showed a higher level of uncertainty (Table 5). 
Quantification of the uncertainty in DIR-facilitated dose accumulation allowed incorporation of a 95% 
confidence interval in DVHs. The methodology developed in Chapter Three can be used to 
prospectively assess the adequacy of target coverage during treatment and decide whether a re-plan is 
necessary in an objective manner. Furthermore, the methodology described in Chapter Three can also 
be used to validate reconstructed and accumulated doses acquired with other DIR implementations and 
imaging schemes. 
 
Currently, the suitability of DIR for accurate and precise dose accumulation is debated in the literature 
[139,143,166–169,236] which may be contributing to the absence of a large scale clinical 
implementation. The primary limitation of most currently available DIR algorithms causing the debate 









occurring during treatment. This is particularly applicable to regressing tumours but also some normal 
tissues, such as the PGs where a significant reduction in volume is often observed during HNRT 
[79,207]. Historically, intensity-based DIR algorithms do not have provisions to account for loss of 
tissue [167,168] and generally attempt to align the border of the original structure to the border of the 
structure that has partially dissolved/shrunken during treatment by “squeezing” voxels together. 
Consequently, two different voxels of the original structure may both be directed to a single voxel of 
the dissolved/shrunken structure. In that case, the reconstructed dose in the partially dissolved/shrunken 
structure is imposed back on the initial structure, irrespective of how the structure has actually changed. 
This would impose that same dose to all voxels of the initial structure which would create energy, and 
violate the principle that energy should be conserved [167,168]. In addition to the principle of energy 
conservation limitation, DIR-facilitated dose accumulation does not standardly consider individual 
cells’ response to radiation exposure [139]. There are two modes of cellular tumour regression that are 
important in this context: elastic and inelastic [237]. Elastic regression refers to the process whereby all 
tissue (tumour and normal) retreats concentrically with the tumour border including any subclinical 
microscopic malignant disease [237]. Inelastic regression is the case where the tumour boundary retreats 
concentrically but independently of the surrounding normal tissue, potentially leaving pockets of 
subclinical microscopic malignant disease [237]. An example of inelastic regression can be observed 
for HN SCC patients with extracapsular spread present in metastatic lymph nodes [238,239]. For both 
elastic and inelastic regression modes, DIR algorithms with a strict one-to-one voxel map (as a surrogate 
for cell-to-cell) functionality that also facilitates tissue loss will likely provide a better estimate of the 
accumulated dose. The appropriateness of DIR-facilitated dose accumulation in the presence of 
mass/density changes specifically on the study in Chapter Three was discussed in Section 3.4 where it 
was concluded that the impact of volume changes on the dose reconstruction accuracy was at least 
partially included in the uncertainty estimate. This conclusion was appropriate considering that in silico 
deformations based on clinically observed anatomical changes were used as ground truth. The workflow 
for dose accumulation first described in Chapter Three was used in Chapter Four to objectively assess 
the adequacy of target coverage during treatment for a reduced PTV margin setting. 
 
 







5.4 Individual patient dose accumulation assessing the validity of reduced PTV 
and PRV margin plans in head-and-neck radiotherapy 
The study described in Chapter Four utilized DIR-facilitated dose accumulation to objectively assess 
the adequacy of target coverage, critical OAR avoidance and non-critical OAR sparing when either 5 
or 3 mm PTV and PRV margins were applied and as a result, the dosimetric impact of the non-rigid 
deformations was investigated which was the “safety net” requirement (b). To be consistent with the 
scarce body of literature regarding the robustness of treatment plans for anatomical changes during 
HNRT when margins are reduced [110,142], target coverage, critical OAR avoidance and non-critical 
OAR sparing was first quantified with DVH metrics. However, DVH metrics inherently lack spatial 
information regarding the dose distribution within a volume of interest [190] and for large target 
volumes, a clinically relevant loss in local sub-volume coverage may not be detected. Therefore, a more 
in-depth voxel-specific investigation was conducted. To the best of the author’s knowledge, no previous 
study has reported on the application of a DIR-facilitated dose accumulation voxel-specific analysis for 
a reduced PTV/PRV margin setting. Using DVH metrics and the 95% C.I. derived as described in 
Chapter Three, a statistically significant underdosage (defined by a CTV 𝐷99%
𝑎𝑐𝑐  being less than 95% of  
𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% confidence level) was observed in one case only while for two other cases, the 
underdosage was borderline significant. However a voxel-based analysis showed that for many cases, 
the accumulated dose included a substantial volume of voxels receiving an underdosage. Loss in target 
coverage was independent of margin expansion and very patient specific with tightness of target volume 
coverage at planning was a common factor leading to underdosage. While used retrospectively in the 
study in Chapter Four, the presented dose accumulation analysis is primarily intended for prospective 
clinical application.   
 
As introduced in Section 1.7 classical PTV margin recipe calculations [35,36] yield CTV to PTV margin 
expansions of 6-9 mm, even when non-rigid deformations are ignored and low estimates for the 
uncertainty in target volume delineation are used. Despite this, PTV margins of 5 mm are commonly 









up to 78-88% are commonly reported [1–3,53,62]. Furthermore, the studies of Chen et al. [1,2] and 
Navran et al. [3] have clinically implemented reduced PTV margins from 5 to 3 mm and reported 
equivalent two- and three-year LR control rates and overall survival between the two margin 
expansions. It should also be mentioned that most treatment failures occur in field while recurrences 
within or near the PTV margin are relatively rare [172,173]. Specifically in HNRT there are a numbers 
of reasons that might explain the contradiction between 6-9 mm PTV margin calculations [170] and 
favourable outcomes using a 3-5 mm PTV margin: (1) The margin around the GTV which defines the 
CTV and accounts for microscopic spread might be too generous [214,215]. A lack of consensus on the 
appropriate CTV expansion exists in the literature [32–34,218,240,241]; (2) PTV margin recipes do not 
account for the presence of an intermediate-risk PTV in HNRT which usually embeds the high-dose 
PTV and primary tumour. This intermediate-risk PTV is irradiated to a lower dose level and provides a 
dose bath which may partially compensate geometrical misses; (3) As noted by Van Kranen et al. [142], 
a patient’s deformations could shift a CTV into an adjacent PTV in cases of multiple CTVs or concave 
target volumes; (4) Volume loss of the treatment region (e.g. weight loss, tumour and/or salivary gland 
shrinkage) could move CTV boundaries further into the high-dose region; (5) The planned dose 
distribution does not conform perfectly to the PTV, i.e., the volume treated to 95% of the prescribed 
dose is larger than the PTV contour. The latter can be observed in Figure 1.4 where the 95% isodose 
colourwashes do not conform perfectly to the high-dose PTV contours shown in red.  
 
Treatment plan optimisation and evaluation is typically directed by constraints and objectives in order 
to achieve satisfactory doses to targets and normal tissues [45]. The constraints and objectives are 
generally based on models of TCP and NTCP. These models are themselves normally based on 
treatment outcomes with dose and volume data from the planned dose distribution [114]. However as 
well-documented in the literature [58,80], the planned dose is not always equal to the dose that is 
actually delivered due to changes in a patient’s positioning and/or anatomy during treatment. 
Consequently, the constraint and objective thresholds may not be appropriate benchmarks to assess the 
actually delivered dose or to determine those patients for treatment adaption. Accurate and precise DIR-
facilitated dose accumulation could be used to quantify the actually delivered dose which may in turn 
 







be used to update control and complication models [242]. In agreement with the literature [58,80], the 
results in Chapter Four (Error! Reference source not found.) found a significant difference between 
the planned and actually delivered doses in the majority of cases. However, the change in coverage in 
terms of absolute dose was relatively small. It is therefore unlikely that NTCP models can be updated 
in a pragmatic manner based on results such as those in Chapter Four considering the uncertainty 
intervals in NTCP models [25,59] are often larger than the change in coverage that was observed. Using 
the PGs as an example, the study of Hunter et al. [60] found differences between planned and delivered 
𝐷𝑚𝑒𝑎𝑛 doses (-4.9 to +8.4 Gy, median difference +2.2 Gy) in the majority of PGs were small relative 
to the standard deviation of the dose-saliva data, suggesting that ART is not likely to gain measurable 
salivary output improvement in most cases. These differences were observed at first treatment, 
indicating potential benefit for more complex setup corrections or adaptive interventions in the minority 
of patients with large deviations detected early by CBCT. It is likely than a more effective gain in PG 
function after HNRT will be achievable with margin reduction as opposed to ART. In the results in 
Chapter Four the commonly used cut-off point in NTCP models [25,59] stating that the PG 𝐷𝑚𝑒𝑎𝑛
𝑝𝑙𝑎𝑛
 
should be preferably less than 26 Gy was achieved in 8 and 14 cases (Supplementary Data A.1: Patient 
group) for 5 and 3 mm margin expansions, respectively. 
 
It should be realised that the study in Chapter Four as well as the two comparable studies that have 
been previously mentioned [110,142] evaluated treatment plan robustness in the presence of anatomical 
changes only, and did not consider other treatment related uncertainties, such as geometrical accuracy 
of the treatment machine and geometrical uncertainty of the target volume definition. In contrast to the 
latter two studies [110,142], the study in Chapter Four evaluated the delivered dose to the CTVs and 
PTVs. Considering that the application of a PTV margin is to ensure the CTV receives adequate dose 
in the presence of all treatment related uncertainties it was relevant to assess both CTV and PTV 










Chapter Four was successful in quantifying the dosimetric impact of non-rigid changes in patient 
anatomy and did so by assessing target coverage, critical OAR avoidance and non-critical OAR sparing 
when either 5 or 3 mm PTV and PRV margins were used on a patient-specific basis. The results in 
Chapter Four indicated that PTV/PRV margin reduction did not significantly reduce CTV coverage 
during treatment. However, patient-specific verification of the dose delivered to each voxel was 
recommended, irrespective of margin expansion, considering that assessment of the target coverage 
using DVH parameters only was not sufficient. 
 
5.5 Collective summary 
The three studies in this dissertation were successful in developing the quality management “safety net” 
by demonstrating the feasibility of prospectively applying the tools to monitor non-rigid anatomical 
changes and delivered dose. More specifically, the study in Chapter Two presented methodology to 
detect systematic anatomical changes occurring during treatment and the studies in Chapters Three and 
Four provided a means to accumulate dose after each fraction to decide whether treatment adaption is 
required. It was initially intended to further extend the “safety net” by directly linking the results in 
Chapters Two and Four in an effort to generate generic guidelines to select and/or predict patients for 
timely and appropriate treatment adaption using SPC. Objective and generally applicable guidelines to 
select patients who will benefit from treatment adaptation are generally lacking [79,115] and while 
some studies have investigated the appropriate timing of a scheduled treatment adaption [127,243], 
commonly the decision to adapt treatment is based on manual ad hoc IGRT review in which treatment 
staff qualitatively address patient deformations (weight loss, tumour regression, positioning 
reproducibility, etc.) [93,119–121]. However considering that loss in target coverage was found to be 
very patient specific in the results in Chapter Four, the development of generic guidelines for timely 
and appropriate treatment adaption using SPC could not be demonstrated. The following paragraph 











In total, eight patients had an underdosage (Error! Reference source not found.; Section 4.2.1) which 
was defined by an individual CTV voxel’s accumulated dose being significantly less than 95% of 
𝐷𝑝𝑟𝑒𝑠𝑐. The underdosages for five of these patients occurred in the subdermal aspect of the CTV region 
while the remaining three underdosages which were non-subdermal occurred in the posterior soft palate, 
the superior aspect of a level 2a node and the left anterior aspect of the mandible. In an effort to develop 
the generic guidelines to select patients for ART, the SPC trends for these eight patients were further 
scrutinised. A systematic change in the neck volume occurring before the end of treatment week four 
was confirmed in seven patients. However, these seven patients only included two patients who had a 
subdermal underdosage and two patients who had non-subdermal underdosage. Therefore, 
approximately 50% of systematic changes in the neck region volume occurred independently of an 
underdosage. To further illustrate the ambiguity when attempting to establish a potential correlation 
between underdosage and treatment volume change, it should be noted that 40% (6/15) of the HD or 
ID-CTVs already had an underdosage at planning (Error! Reference source not found.) for at least one 
of the margin expansion plans. In addition, despite patient one exhibiting the largest local contour 
reduction of all patients, the neck region volume of patient one remained ‘in-control’ from an SPC 
perspective throughout treatment. Further investigation found wider process control limits for patient 
one compared to the other patients, owing to a larger variation in the reference period. Absolute 
deviations for those BA structures most proximal to the underdosed CTVs were also investigated. Three 
of the patients with subdermal underdosage had a BA deviation exceed the 2 mm clinical limit before 
the end of treatment week four for their most proximal BA structure (mandible or hyoid). However, the 
remaining two patients’ deviation of their most proximal structure, C3-C5, did not exceed the clinical 
limit. While the results for the former three patients are encouraging it should be stated that 67% (2/3) 
of the patients who did not have a HD-CTV underdosage had their most proximal BA structure’s 
deviation (mandible) exceed the clinical limit. Similarly ambiguous results were obtained for the three 
patients with non-subdermal underdosages where only 33% (1/3) of the most proximal BA structure’s 
deviation exceeded the clinical limit. The feasibility of using SPC detected systematic changes in 
anatomy as a risk factor for CTV underdosage was unable to be demonstrated in a consistent and 










The patient-specific nature of loss in target coverage hampered the development of generic guidelines 
for ART based on changes in patient positioning or anatomy changes. However, the DIR-facilitated 
dose accumulation approach that was developed did provide a means to objectively decide whether 
ART is necessary for individual patients. There are two modes of ART that could apply the developed 
dose accumulation methodology: online and offline [114,244,245]. An online ART approach could 
evaluate the delivered dose and correct the dosimetric impact of complex anatomical changes by re-
optimising the plan on the dCT of the pre-treatment CBCT with subsequent delivery. However, the 
burdensome workload [246] and technological requirements [115] make it unlikely that such an online 
ART will be implemented on a large scale in the near future. Further discussion of online ART is 
provided in Sub-section 5.6.2 below. In contrast to online ART, it is possible that an offline ART 
procedure based on the DIR-facilitated dose accumulation methodology demonstrated in Chapters 
Three and Four could be implemented in the near future. Retrospective dose reconstruction would be 
conducted at the end of each treatment fraction with subsequent evaluation of the accumulated dose. 
Evaluation of the accumulated dose with concurrent consideration of the anticipated dose that will be 
delivered in the remaining treatment fractions would then facilitate the decision to adapt treatment. The 
plan re-optimisation could be conducted on the dCT with subsequent delivery occurring as soon as 
quality assurance protocols have been completed. 
 
5.6 Future perspectives 
The research described in this dissertation aimed to demonstrate that a safe PTV margin reduction from 
5 to 3 mm is feasible at the WBCC. In addition, the research aimed to contribute to the wider body of 
HNRT literature and knowledge regarding the optimal treatment margin and DIR-facilitated dose 
accumulation. Sub-sections 5.6.1 and 5.6.2 discuss treatment margin optimisation and DIR-facilitated 
dose accumulation, respectively, and are presented in the context of the research described in this 
dissertation and future developments. 
 
 







5.6.1 Treatment margin optimisation 
Chapter Four found that both 5 and 3 mm margin plans for VMAT HNRT are generally robust for 
anatomical changes which suggests the possibility of further PTV margin reduction. The retrospective 
DIR-facilitated dose accumulation studies by van Kranen et al. [142] and Wu et al [110] investigated 
the impact of anatomical changes to the dose delivery during modulated HNRT for 5, 3 and 0 mm PTV 
margin expansions. The study of Wu et al [110] found that the coverage of CTVs at the end of treatment 
was not affected by anatomical changes based on the ratio of multiple DVH metrics relative to the 
corresponding planning metrics for all PTV margin expansions. The study by van Kranen et al. [142] 
found that 27% (20/73) of CTVs were underdosed (𝐷99%
𝑎𝑐𝑐  less than 95% of 𝐷𝑝𝑟𝑒𝑠𝑐) for a 0 mm PTV 
margin expansion while for a 3 mm expansion, this occurred in only 3% (2/73) of CTVs. Based on the 
findings of the two preceding studies [110,142] and the results in Chapter Four, it seems likely that the 
PTV margin may be further optimisable to an expansion less than 3 mm. However, it is worth reiterating 
that a direct comparison of the results in these three studies is not possible due to differing analyses that 
were used to quantify the CTV coverage. Furthermore, all three studies mentioned in this paragraph so 
far evaluated treatment plan robustness in the presence of anatomical changes only and did not consider 
other treatment related uncertainties such as the geometrical accuracy of the treatment machine and the 
geometrical uncertainty of the target volume definition. Reducing the PTV margin based on the 
improvement of one aspect of the treatment, such as the robustness of plans for anatomical changes, 
could still be dangerous and may lead to CTV underdosage if the additional treatment related 
uncertainties are not considered.  
 
In addition to the lack of consensus on the optimal PTV margin expansion in HNRT, a lack of consensus 
on the optimal CTV margin also exists [1–4,32–34,171,193,218,240,241,247]. Both of these 
ambiguities may at least partially be due to the uncertainty in GTV definition, which is seldom 
quantified. Unfortunately, studies using histopathological validation (the gold standard) [37,38,214] to 
assess the target volume definition uncertainty are limited, owing to their complexity. The 









reduce the uncertainty in target definition without considerably increasing physicians' workloads. A 
further reduction to the target volume definition uncertainty may be achieved with the routine inclusion 
of high-contrast MRI scans [250] and PET [251] images in the contouring process as they are generally 
considered to reduce the variation [252]. Although it should be noted that geometric distortions [253] 
and non-standardised imaging sequences [254] can restrict the effective use of MRI for target 
delineation. A current recommendation is that GTV delineation should be conducted on the pCT rigidly 
registered to an MRI scan that is also acquired in the treatment position [255,256]. However the 
availability of a diagnostic position MRI scan, not to mention a treatment position MRI scan, is not 
standardly available in all centres. Encouragingly, a recent study by Chuter et al. [257] found that the 
deformable registration of MRI scan acquired in the diagnostic position to the pCT facilitated a 
significant improvement in GTV delineation accuracy compared to contouring solely on the pCT. This 
finding could strengthen the case for departments to routinely include MRI scans. The use of artificial 
intelligence (AI) for structure definition [258], and in radiation oncology in general [259,260] is 
currently a “hot topic”. While promising methods such as those developed by Huang et al. [258] have 
demonstrated automatic AI delineation of the GTV with high accuracy and efficiency, AI methods for 
structure definition in general differ in performance [261] and can struggle in regions of homogeneous 
image contrast [262]. In these cases, incomplete and inaccurate definitions can be generated which 
require laborious manual correction. Nevertheless, the use of AI for structure definition seems to be a 
promising tool to assist the clinician in HN cancer management in the future [263,264]. 
 
Improvements in the accuracy of target volume definition may lead to more favourable patient outcomes 
but a definitive proof of safe PTV margin reduction is likely to only be achieved by reporting clinical 
results in conjunction with a comprehensive description of all relevant treatment details. For example, 
plan design, constraint adoption, prioritisation of OARs and target coverage, technical aspects of 
treatment accuracy, robustness of the planning solution for anatomical changes and patient positioning 
accuracy are aspects of treatment which can all influence treatment outcomes [5] irrespective of the 
accuracy of target volume definition. Clinical results reports should also standardly include the locations 
of recurrences and use consistent definitions for recurrence locations to increase insight of how 
 







treatment margins can be optimised. In literature, a "marginal recurrence" has been defined by 20% to 
95% of the LRR volume falling within the planned dose 95% isodose line [265] but also if 20% to 95% 
of the LRR volume was within the CTV [266]. It is recommended that future studies reporting on 
marginal recurrences use isodose lines of the DIR-facilitated accumulated dose distribution to define 
LRR locations. In addition, the actually delivered doses to the recurrence volumes as assessed by dose 
accumulation should be recorded which may increase insight into the variation of patient-specific 
tumour radio-sensitivity [267,268]. 
 
5.6.2 DIR-facilitated dose accumulation  
In Chapter Three the intended clinical workflow based on DIR-facilitated dose accumulation to assess 
the actually delivered dose was defined and was subsequently found to be sufficiently accurate to assess 
the adequacy of treatment. This finding adds to a growing body of literature showing that DIR-
facilitated dose accumulation is a tool that can be used to quantify the delivered dose [166,204,269]. 
The novel quantification technique developed in Chapter Three may draw greater attention to the 
accuracy and precision of DIR-facilitated dose accumulation, potentially progressing its clinical 
application and assisting to resolve the appropriateness of DIR-facilitated dose accumulation debate  
[139,143,166–169,236]. Considering the results in Chapter Three and the previously mentioned 
literature [166,204,269], DIR-facilitated dose accumulation can be utilised to objectively decide 
whether ART is necessary for individual patients. It is likely that a fully online ART procedure that 
includes online evaluation of the delivered dose (DIR-facilitated), re-planning [114,245] and 
subsequent delivery will be the standard of radiotherapy in the future. In fact, the integration of MRI 
with linear accelerators has already shown the feasibility of daily online re-planning [270] and 
improvements to the plan optimisation time [271] are expected to reduce the longer associated treatment 
times. An additional advantage to the online ART procedure is that a further reduction to the PTV 
margin can be achieved [272,273]. However, a number of limitations of DIR-facilitated dose 
accumulation still remain which are likely to restrict a large scale implementation of fully online ART 










In general, DIR algorithms disregard changes occurring within target volumes and normal tissues at the 
cellular level, in particular for situations of mass and density alteration. Currently, the addition of local 
rigidity constraints [197,198] and constraints on inverse consistency and symmetry [147,148] more 
accurately inform the DVF regularisation but the inclusion of models describing tumour and normal 
tissue progression [274,275] is recommended for inclusion in future DIR algorithms. This limitation 
may itself represent an unacceptable level of risk to manufacturers. Furthermore, the technological 
demands of a fully online ART procedure are non-trivial in the context of a standard radiotherapy centre 
[114,139]. Another limitation of DIR-facilitated dose accumulation in an online ART procedure is that 
the accumulated dose will require immediate radiation oncologist review and approval. This 
requirement is likely to represent a prohibitively large increase in clinicians’ workloads for large scale 
implementation. In the immediate future, studies (including Chapter One) that have attempted to predict 
patients for ART [79,92,104,127,207,276] will still be beneficial to gain understanding on where 
specific ART approaches are necessary or on when specific anatomical changes lead to a clinically 
irrelevant change in dosimetry. 
 
As DIR-facilitated dose accumulation becomes more routine in the clinical setting, it must be realised 
that the validation of this method is not trivial and will increase the demand on department resources. 
The increase in complexity of the tools informing online ART must be met with comprehensive 
understanding of the limitations and clinical risk associated with these novel techniques. It is up to the 






















This dissertation aimed to enable a safe PTV margin reduction in HNRT by investigating the application 
of DIR in combination with EWMA SPC charts and DIR-facilitated dose accumulation to identify 
patients who may be at risk of unacceptable loss in target coverage and/or overdosage to normal tissues. 
EWMA SPC enabled detection of systematic anatomical changes and DIR-facilitated dose 
accumulation was sufficiently accurate to assess the adequacy of the delivered dose. The patient-
specific nature of target coverage loss prevented the definition of generic guidelines for ART based on 
observed anatomical changes or patient positioning trends. However, the developed DIR-facilitated 
dose accumulation workflow will facilitate the creation of generic guidelines to objectively decide 
whether treatment adaptation is necessary for individual patients. Both 5 and 3 mm margin plans for 
VMAT HNRT were found to be robust for anatomical changes, while tight- or under-coverage of target 
volumes already present at the treatment planning stage turned out to be an important factor that may 
impact target coverage and potentially result in clinically unacceptable dose delivery. Assessment of 
the target coverage using DVH parameters only was not sufficient and patient-specific verification of 
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A.1: Patient group 
 
Twelve patients with cancers in the head-and-neck region that were previously treated radically were 
selected for this research. The planning computed tomography (pCT) scans (Brilliance Big Bore; Philips 
Medical Systems, Eindhoven, The Netherlands) had a voxel size of 1.3 x 1.3 x 3.0 mm3. Patients were 
immobilized using a 2.4 mm Reloadable Head and Shoulder S-Frame Kevlar Mask (Q-Fix, Avondale 
PA, USA) and an individual head and shoulder support vacuum bag (Klarity Medical Products, Newark 
OH, USA). Daily (n = 30) cone beam computed tomography (CBCT) scans were acquired to verify 
patient treatment position. The CBCT scans with a voxel size of 0.5 x 0.5 x 2 mm3 were acquired prior 
to treatment using a Varian Truebeam (v2.0 or v2.5; Varian Medical Systems, Palo Alto CA, USA). 
For a minority of treatment fractions, CBCT scans were acquired on a Varian Clinac (v2.1) with a voxel 
size of 0.7 x 0.7 x 2.5 mm3. All patients consented to their data being used for retrospective audits. 
 
Table A.1: Clinical and disease characteristics of patient cohort. 
Characteristic Number 
Number of patients 12 
Primary site 
    Tonsil 
    Nasopharynx 
    Oropharynx 







    T1 
    T2 
    T3 
    T4 








    Yes 




Weight at treatment planning (kg) 
    Range 
    Mean 
 
53.2 – 141.3 
75.2 
Age (years) 
    Range 
    Mean 
 
40 – 80 
62.8 
Sex 
    Male 














Figure A.1: Average planned dose-volume histogram (DVH) parameter over all patients with either 3 or 5 mm 
planning target volume (PTV) and planning risk volume (PRV) margins. PG = parotid gland. SMG = submandibular 









Table A.2: Patient-specific dose volume histogram (DVH) metrics detailing the planned dose in Gy for each structure of interest using 3 mm planning target volume 
(PTV) margins. CTV = clinical target volume. PRV = planning risk volume. PG = parotid gland. SMG = submandibular gland. D99% = minimum dose to 99% of volume. 
D98% = minimum dose to 98% of volume. Dmean= mean dose. D0.1cc = maximum dose to 0.1 cubic centimeters. 
  
 Patient 1 2 3 4 5 6 7 8 9 10 11 12 median range 
Structure DVH parameter               
CTV 54 D99% 53.5 52.7 53.4 53.9 52.3 54.1 53.2 53.5 54.1 53.8 53.6 53.0 53.5 52.3 – 54.1 
CTV 60 D99%      60.0   60.2 60.4  59.0 60.1 59.0 – 60.4 
CTV 66 D99% 64.8  64.7 65.2 65.1 65.7 64.6 65.4 65.5 64.4 65.2 63.6 65.1 63.6 – 65.7 
PTV 54 D98% 52.2 51.5 51.5 51.3 51.8 53.0 51.7 53.4 51.5 51.3 52.2 51.7 51.7 51.3 – 53.4 
 PTV 60 D98%      58.2   57.7 57.1  57.4 57.6 57.1 – 58.2 
PTV 66 D98% 63.8  63.6 63.1 64.2 63.5 62.9 63.7 64.1 62.7 63.3 63.2 63.5 62.7 – 64.2 
Spinal cord  D0.1cc 43.4 19.4 38.8 31.4 34.2 40.5 38.9 34.1 33.7 31.4 36.0 32.3 34.1 19.4 – 43.4 
Brainstem D0.1cc 35.7 51.9 37.9 30.6 38.0 30.0 39.1 35.8 38.5 37.1 37.1 35.2 37.1 30.0 – 51.9 
Spinal cord  PRV D0.1cc 44.5 21.1 40.5 34.8 34.8 45.2 41.4 45.2 39.0 34.5 38.4 35.3 38.7 21.1 – 45.2 
Brainstem PRV D0.1cc 38.3 52.9 43.6 33.7 40.3 36.0 45.3 36.9 41.6 45.7 41.4 41.5 41.5 33.7 – 52.9 
Ipsilateral PG Dmean 27.4 14.1 24.4 24.6 34.4 30.8 36.2 34.5 28.6 20.2 27.2 43.6 
28.0 14.1 – 43.6 
        36.2  20.1    
Contralateral PG Dmean 25.2 4.5 25.9 24.0 32.8 6.5  4.8  18.0 16.1 4.6 17.1 4.5 – 32.8 
Ipsilateral SMG Dmean 64.7 1.1 58.4 63.5 63.7 63.5 42.2 64.6 65.8 52.4  64.5 
63.5 1.1 – 65.8 
        43.6  58.5    









Table A.3: Patient-specific dose volume histogram (DVH) metrics detailing the planned dose in Gy for each structure of interest using 5 mm planning target volume 
(PTV) margins. CTV = clinical target volume. PRV = planning risk volume. PG = parotid gland. SMG = submandibular gland. D99% = minimum dose to 99% of volume. 
D98% = minimum dose to 98% of volume. Dmean= mean dose. D0.1cc = maximum dose to 0.1 cubic centimeters. 
 Patient 1 2 3 4 5 6 7 8 9 10 11 12 median range 
Structure DVH parameter               
CTV 54 D99% 53.4 52.5 53.6 54.0 52.8 53.6 54.3 53.8 54.6 54.0 54.0 53.2 53.7 52.5 – 54.6 
CTV 60 D99%      59.6   60.0 60.0  60.2 60.0 59.6 – 60.2 
CTV 66 D99% 64.3  65.0 65.2 65.1 65.1 64.6 65.8 64.6 64.2 65.9 63.7 65.0 63.7 – 65.9 
PTV 54 D98% 52.0 51.5 51.6 52.7 51.4 53.0 51.9 53.5 52.4 52.0 52.6 51.6 52.0 51.4 – 53.5 
 PTV 60 D98%      57.7   57.6 57.2  57.5 57.6 57.2 – 57.7 
PTV 66 D98% 63.4  63.5 63.6 63.6 62.9 62.8 63.1 63.2 62.8 63.6 63.6 63.4 62.8 – 63.6 
Spinal cord  D0.1cc 42.3 23.5 37.5 32.7 32.2 36.5 42.0 35.6 29.1 34.0 36.5 37.6 36.0 23.5 – 42.3 
Brainstem D0.1cc 42.1 52.4 34.2 30.6 36.6 27.7 27.1 36.5 37.9 45.8 34.7 32.6 35.6 27.1 – 52.4 
Spinal cord  PRV D0.1cc 45.3 26.6 42.0 37.8 36.9 42.3 47.4 42.3 40.8 44.4 41.4 46.5 42.1 26.6 – 47.4 
Brainstem PRV D0.1cc 44.3 53.3 47.3 36.5 41.2 42.6 46.2 42.6 46.3 60.7 43.7 46.5 45.3 36.5 – 60.7 
Ipsilateral PG Dmean 30.8 16.8 27.1 27.2 36.2 33.0 42.3 35.3 26.3 26.1 35.9 50.0 
31.9 16.8 – 50.0 
        46.2  25.5    
Contralateral PG Dmean 26.8 6.4 26.7 26.1 37.2 8.9  5.2  22.1 21.5 8.6 21.8 5.2 – 37.2 
Ipsilateral SMG Dmean 64.1 1.5 59.2 65.2 64.4 64.4 47.4 66.1 65.2 56.3  66.0 
64.1 1.5 – 66.1 
        48.0  61.5    









A.2: Uncertainty analysis 
 
Supplementary Data A.2 details sources of uncertainty that were identified in this work and how they 
were assessed. For complete comprehension of the uncertainty quantification, the reader is directed to 
the GUM guidelines [196].  
 
List of abbreviations  
BA = bony anatomy (e.g., C1-C3, C3-C5, C5-C7, mandible, etc…) 
PG = parotid gland 
DIR = deformable image registration 
MMR = manual method of registration 
pCT = planning computed tomography 
dCT = deformed computed tomography 
CBCT = cone beam computed tomography 
HR = high resolution 
SD = standard deviation 
N = sample size 
 
Parameters used in this work following GUM guidelines 
𝐷𝑓
𝐵𝐴 = the measurand estimating BA/PG deviation relative to C1-C3 at fraction f  
𝑉𝑓
𝑃𝐺 = the measurand estimating PG/neck volume at fraction f 
 
c(𝑇𝑥,𝑓
𝐵𝐴) = sensitivity coefficient for change in centroid position of BA/PG in x plane at fraction f 
c(𝑉𝑃𝐺) = sensitivity coefficient for volume of PG/neck structure  
 
u(𝑇𝑥,𝑎
𝐵𝐴) = uncertainty component a for change in centroid position of BA/PG in x plane 
u(𝑉𝑎
𝑃𝐺) = uncertainty component a for volume of PG/neck structure 
 
uc(𝑇𝑥
𝐵𝐴) = combined uncertainty for change in centroid position of BA/PG in x plane 
uc(𝑉𝑃𝐺) = combined uncertainty for volume of PG/neck structure  
 
𝑢𝑜,𝑓(𝐷𝑓
𝐵𝐴) = overall uncertainty for BA/PG deviation measurand at fraction f 
𝑢𝑜,𝑓(𝑉𝑓
𝑃𝐺) = overall uncertainty for PG/neck volume measurand at fraction f 
 
kp = coverage factor determining level of confidence  


























𝑃𝐺 = volume recorded in MATLAB analysis 
 
c(𝑇𝑥,𝑓



































































c(𝑉𝑃𝐺) ≡ ∂𝑉𝑃𝐺/∂𝑉𝑃𝐺= 1 
 
The combined uncertainty was calculated for each measurand input variable (i.e., 
𝑇𝑥,𝑓
𝐵𝐴, 𝑇𝑧,𝑓
𝐶1−𝐶3, 𝑒𝑡𝑐 … ) and are detailed in the following tables of Supplementary Data B. The overall 
uncertainty for each fraction f’s measurand was then calculated using:   
 
𝑢𝑜,𝑓(𝐷𝑓





The overall uncertainty for each fraction was then multiplied by a coverage factor of 1.645 (90% level 
of confidence) to give an expanded uncertainty. The coverage factor was chosen after Shapiro–Wilk 
tests were unable to reject normality of the measurands’ distributions. Finally, the expanded uncertainty 
was used as the uncertainty associated with the metrics of interest used in Equation 3 (page 79) of the 
dissertation. Note that combined uncertainties of each measurand input variable are identical for every 
fraction. The fraction-varying sensitivity coefficients give rise to different overall uncertainties for the 
same BA region of the same patient. 
 
The uncertainties associated with 𝜇0 and 𝜎 of Equation 4 (page 79) of the dissertation were the standard 
error of the reference period and the standard error of the reference period’s SD multiplied by a coverage 










Uncertainties in metrics of interest derived with DIR and MMR are established following the same 
methodology as described above, however note the differences in uncertainty components in the 
following tables. 
 
List of tables  
A.2.1.1: DIR uncertainty components for change in centroid position of C1-C3 in each anatomical plane 
A.2.1.2: DIR uncertainty components for change in centroid position of C3-C5 in each anatomical plane 
A.2.1.3: DIR uncertainty components for change in centroid position of C5-C7 in each anatomical plane 
A.2.1.4: DIR uncertainty components for change in centroid position of mandible in each anatomical plane 
A.2.1.5: DIR uncertainty components for change in centroid position of maxilla in each anatomical plane 
A.2.1.6: DIR uncertainty components for change in centroid position of base of skull in each anatomical plane 
A.2.1.7: DIR uncertainty components for change in centroid position of hyoid in each anatomical plane 
A.2.1.8: DIR uncertainty components for change in centroid position of occipital in each anatomical plane 
A.2.1.9: DIR uncertainty components for change in centroid position of larynx in each anatomical plane 
 
A.2.2.1: MMR uncertainty components for change in centroid position of C1-C3 in each anatomical plane 
A.2.2.2: MMR uncertainty components for change in centroid position of C3-C5 in each anatomical plane 
A.2.2.3: MMR uncertainty components for change in centroid position of C5-C7 in each anatomical plane 
A.2.2.4: MMR uncertainty components for change in centroid position of mandible in each anatomical plane 
A.2.2.5: MMR uncertainty components for change in centroid position of maxilla in each anatomical plane 
A.2.2.6: MMR uncertainty components for change in centroid position of base of skull in each anatomical plane 
A.2.2.7: MMR uncertainty components for change in centroid position of hyoid in each anatomical plane 
A.2.2.8: MMR uncertainty components for change in centroid position of occipital in each anatomical plane 
A.2.2.9: MMR uncertainty components for change in centroid position of larynx in each anatomical plane 
 
A.2.3.1:  DIR uncertainty components for change in centroid position of PGs in each anatomical plane 
 
A.2.4.1:  DIR uncertainty components for change in volume of PGs  
A.2.4.2: DIR uncertainty components for change in volume of neck 
 
















Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐶1−𝐶3) Uncertainty in DIR algorithm 0.18 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝐶1−𝐶3) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.16 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝐶1−𝐶3) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.18 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝐶1−𝐶3) Conversion to HR for dCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝐶1−𝐶3) Conversion to HR for pCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝐶1−𝐶3) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝐶1−𝐶3) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝐶1−𝐶3) Uncertainty in DIR algorithm 0.11 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝐶1−𝐶3) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.10 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝐶1−𝐶3) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.12 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝐶1−𝐶3) Conversion to HR for dCT structure 0.03 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝐶1−𝐶3) Conversion to HR for pCT structure 0.03 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝐶1−𝐶3) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝐶1−𝐶3) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝐶1−𝐶3) Uncertainty in DIR algorithm 0.25 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝐶1−𝐶3) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.31 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝐶1−𝐶3) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.32 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝐶1−𝐶3) Conversion to HR for dCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝐶1−𝐶3) Conversion to HR for pCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝐶1−𝐶3) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝐶1−𝐶3) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙


























Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐶3−𝐶5) Uncertainty in DIR algorithm 0.11 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝐶3−𝐶5) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.20 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝐶3−𝐶5) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.23 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝐶3−𝐶5) Conversion to HR for dCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝐶3−𝐶5) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝐶3−𝐶5) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝐶3−𝐶5) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝐶3−𝐶5) Uncertainty in DIR algorithm 0.35 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝐶3−𝐶5) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.09 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝐶3−𝐶5) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.19 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝐶3−𝐶5) Conversion to HR for dCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝐶3−𝐶5) Conversion to HR for pCT structure 0.03 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝐶3−𝐶5) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝐶3−𝐶5) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝐶3−𝐶5) Uncertainty in DIR algorithm 0.23 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝐶3−𝐶5) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.19 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝐶3−𝐶5) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.34 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝐶3−𝐶5) Conversion to HR for dCT structure 0.07 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝐶3−𝐶5) Conversion to HR for pCT structure 0.03 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝐶3−𝐶5) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝐶3−𝐶5) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙




























Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐶5−𝐶7) Uncertainty in DIR algorithm 0.08 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝐶5−𝐶7) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.28 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝐶5−𝐶7) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.31 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝐶5−𝐶7) Conversion to HR for dCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝐶5−𝐶7) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝐶5−𝐶7) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝐶5−𝐶7) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝐶5−𝐶7) Uncertainty in DIR algorithm 0.44 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝐶5−𝐶7) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.21 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝐶5−𝐶7) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.28 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝐶5−𝐶7) Conversion to HR for dCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝐶5−𝐶7) Conversion to HR for pCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝐶5−𝐶7) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝐶5−𝐶7) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝐶5−𝐶7) Uncertainty in DIR algorithm 0.41 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝐶5−𝐶7) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.33 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝐶5−𝐶7) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.30 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝐶5−𝐶7) Conversion to HR for dCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝐶5−𝐶7) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝐶5−𝐶7) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝐶5−𝐶7) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙




























Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Uncertainty in DIR algorithm 0.62 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.10 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.28 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Conversion to HR for dCT structure 0.11 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Conversion to HR for pCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Uncertainty in DIR algorithm 0.47 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.34 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.26 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Conversion to HR for dCT structure 0.09 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Uncertainty in DIR algorithm 0.40 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.21 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.25 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Conversion to HR for dCT structure 0.07 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Conversion to HR for pCT structure 0.03 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙


























Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Uncertainty in DIR algorithm 0.43 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.34 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.56 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Conversion to HR for dCT structure 0.13 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Conversion to HR for pCT structure 0.14 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Uncertainty in DIR algorithm 0.55 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.36 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.30 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Conversion to HR for dCT structure 0.07 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Conversion to HR for pCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Uncertainty in DIR algorithm 1.02 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.70 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.34 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Conversion to HR for dCT structure 0.08 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Conversion to HR for pCT structure 0.08 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙



























Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐵𝑂𝑆) Uncertainty in DIR algorithm 0.47 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝐵𝑂𝑆) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.36 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝐵𝑂𝑆) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.70 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝐵𝑂𝑆) Conversion to HR for dCT structure 0.13 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝐵𝑂𝑆) Conversion to HR for pCT structure 0.12 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝐵𝑂𝑆) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝐵𝑂𝑆) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝐵𝑂𝑆) Uncertainty in DIR algorithm 0.44 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝐵𝑂𝑆) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.86 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝐵𝑂𝑆) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.34 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝐵𝑂𝑆) Conversion to HR for dCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝐵𝑂𝑆) Conversion to HR for pCT structure 0.06 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝐵𝑂𝑆) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝐵𝑂𝑆) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝐵𝑂𝑆) Uncertainty in DIR algorithm 0.90 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝐵𝑂𝑆) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.34 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝐵𝑂𝑆) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.30 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝐵𝑂𝑆) Conversion to HR for dCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝐵𝑂𝑆) Conversion to HR for pCT structure 0.03 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝐵𝑂𝑆) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝐵𝑂𝑆) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙


























Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
ℎ𝑦𝑜𝑖𝑑
) Uncertainty in DIR algorithm 0.90 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.42 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
1.07 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
ℎ𝑦𝑜𝑖𝑑
) Conversion to HR for dCT structure 0.22 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
ℎ𝑦𝑜𝑖𝑑
) Conversion to HR for pCT structure 0.21 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
ℎ𝑦𝑜𝑖𝑑
) Uncertainty in DIR algorithm 0.77 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.60 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.53 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
ℎ𝑦𝑜𝑖𝑑
) Conversion to HR for dCT structure 0.13 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
ℎ𝑦𝑜𝑖𝑑
) Conversion to HR for pCT structure 0.13 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
ℎ𝑦𝑜𝑖𝑑
) Uncertainty in DIR algorithm 0.10 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.37 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.19 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
ℎ𝑦𝑜𝑖𝑑
) Conversion to HR for dCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
ℎ𝑦𝑜𝑖𝑑
) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points


































Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Uncertainty in DIR algorithm 1.72 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.21 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.51 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Conversion to HR for dCT structure 0.15 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Conversion to HR for pCT structure 0.14 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Uncertainty in DIR algorithm 1.00 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.24 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.39 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Conversion to HR for dCT structure 0.11 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Conversion to HR for pCT structure 0.06 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Uncertainty in DIR algorithm 1.54 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.09 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.25 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Conversion to HR for dCT structure 0.07 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Conversion to HR for pCT structure 0.03 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
































Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑙𝑎𝑟𝑦𝑛𝑥
) Uncertainty in DIR algorithm 0.38 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.37 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.60 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝑙𝑎𝑟𝑦𝑛𝑥
) Conversion to HR for dCT structure 0.29 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝑙𝑎𝑟𝑦𝑛𝑥
) Conversion to HR for pCT structure 0.21 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝑙𝑎𝑟𝑦𝑛𝑥
) Uncertainty in DIR algorithm 0.18 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.57 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.33 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝑙𝑎𝑟𝑦𝑛𝑥
) Conversion to HR for dCT structure 0.19 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝑙𝑎𝑟𝑦𝑛𝑥
) Conversion to HR for pCT structure 0.22 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝑙𝑎𝑟𝑦𝑛𝑥
) Uncertainty in DIR algorithm 0.08 
SD of differences between centroids of manually 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.23 
SD of differences between centroids of pCT and CBCT 




Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.23 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝑙𝑎𝑟𝑦𝑛𝑥
) Conversion to HR for dCT structure 0.09 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝑙𝑎𝑟𝑦𝑛𝑥
) Conversion to HR for pCT structure 0.11 
SD of differences between centroids of HR and non-HR 




Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points




Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points




































Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐶1−𝐶3) Inter-observer variation in match result 0.51 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑥,𝑏
𝐶1−𝐶3) 












𝐶1−𝐶3) Inter-observer variation in match result 0.33 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑦,𝑏
𝐶1−𝐶3) 












𝐶1−𝐶3) Inter-observer variation in match result 0.24 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑧,𝑏
𝐶1−𝐶3) 





















𝑪𝟏−𝑪𝟑) = 0.90 mm 
 
 






Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐶3−𝐶5) Inter-observer variation in match result 0.19 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑥,𝑏
𝐶3−𝐶5) 












𝐶3−𝐶5) Inter-observer variation in match result 0.34 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑦,𝑏
𝐶3−𝐶5) 












𝐶3−𝐶5) Inter-observer variation in match result 0.20 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑧,𝑏
𝐶3−𝐶5) 







































Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐶5−𝐶7) Inter-observer variation in match result 0.29 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑥,𝑏
𝐶5−𝐶7) 












𝐶5−𝐶7) Inter-observer variation in match result 0.28 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑦,𝑏
𝐶5−𝐶7) 












𝐶5−𝐶7) Inter-observer variation in match result 0.25 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑧,𝑏
𝐶5−𝐶7) 





















𝑪𝟓−𝑪𝟕) = 0.90 mm 
 
 






Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Inter-observer variation in match result 0.62 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑥,𝑏
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 












𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Inter-observer variation in match result 0.40 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑦,𝑏
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 












𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) Inter-observer variation in match result 0.73 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑧,𝑏
𝑚𝑎𝑛𝑑𝑖𝑏𝑙𝑒) 






































Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Inter-observer variation in match result 0.16 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑥,𝑏
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 












𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Inter-observer variation in match result 0.15 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑦,𝑏
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 












𝑚𝑎𝑥𝑖𝑙𝑙𝑎) Inter-observer variation in match result 0.24 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑧,𝑏
𝑚𝑎𝑥𝑖𝑙𝑙𝑎) 





















𝒎𝒂𝒙𝒊𝒍𝒍𝒂) = 0.90 mm 
 
 






Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝐵𝑂𝑆) Inter-observer variation in match result 0.12 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑥,𝑏
𝐵𝑂𝑆) 












𝐵𝑂𝑆) Inter-observer variation in match result 0.12 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑦,𝑏
𝐵𝑂𝑆) 












𝐵𝑂𝑆) Inter-observer variation in match result 0.25 
SD of differences between match of two observers (authors 
NL and RL. N = 117) 
u(𝑇𝑧,𝑏
𝐵𝑂𝑆) 





















𝑩𝑶𝑺) = 0.90 mm 
 
 













Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
ℎ𝑦𝑜𝑖𝑑
) Inter-observer variation in match result 0.25 
SD of differences between match of two observers (authors 


















) Inter-observer variation in match result 0.33 
SD of differences between match of two observers (authors 


















) Inter-observer variation in match result 0.41 
SD of differences between match of two observers (authors 





























) = 0.96 mm 
 
 






Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙
) Inter-observer variation in match result 0.33 
SD of differences between match of two observers (authors 


















) Inter-observer variation in match result 0.41 
SD of differences between match of two observers (authors 


















) Inter-observer variation in match result 0.34 
SD of differences between match of two observers (authors 


















































Source of uncertainty 
Value 
(mm) 
How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑙𝑎𝑟𝑦𝑛𝑥
) Inter-observer variation in match result 0.43 
SD of differences between match of two observers (authors 


















) Inter-observer variation in match result 0.50 
SD of differences between match of two observers (authors 


















) Inter-observer variation in match result 1.27 
SD of differences between match of two observers (authors 










































Tables A.2.3.X  
 





Source of uncertainty Value (mm) How uncertainty was assessed 
u(𝑇𝑥,𝑎
𝑃𝐺) Uncertainty in DIR algorithm 0.11 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑥,𝑏
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.12 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑐
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.12 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑥,𝑑
𝑃𝐺) Conversion to HR for dCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑒
𝑃𝐺) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑥,𝑓
𝑃𝐺) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑥,𝑔
𝑃𝐺) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(x grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑎
𝑃𝐺) Uncertainty in DIR algorithm 0.10 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑦,𝑏
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.13 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑐
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.29 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑦,𝑑
𝑃𝐺) Conversion to HR for dCT structure 0.07 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑒
𝑃𝐺) Conversion to HR for pCT structure 0.05 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑦,𝑓
𝑃𝐺) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
 (y grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑦,𝑔
𝑃𝐺) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(y grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑎
𝑃𝐺) Uncertainty in DIR algorithm 0.10 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑇𝑧,𝑏
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from pCT to 
CBCT 
0.20 
SD of differences between centroids of pCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑐
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
0.27 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑇𝑧,𝑑
𝑃𝐺) Conversion to HR for dCT structure 0.07 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑒
𝑃𝐺) Conversion to HR for pCT structure 0.08 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
u(𝑇𝑧,𝑓
𝑃𝐺) 
Grid size uncertainty of copying structure 
from pCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√pCT no.of points
    (N = 120) 
u(𝑇𝑧,𝑔
𝑃𝐺) 
Grid size uncertainty of copying structure 
from dCT to CBCT 
< 0.01 
(z grid resolution of CBCT √3⁄ )
√dCT no.of points
    (N = 120) 
 
uc(𝑻𝒙




















Tables A.2.4.X  




Source of uncertainty 
Value 
(cm3) 
How uncertainty was assessed 
u(𝑉𝑎
𝑃𝐺) Uncertainty in DIR algorithm 0.30 
SD of differences between centroids of manually 
adapted DIR and DIR structures (N = 6) 
u(𝑉𝑏
𝑃𝐺) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
1.37 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑉𝑐
𝑃𝐺) Conversion to HR for dCT structure 0.04 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
 








Source of uncertainty 
Value 
(cm3) 
How uncertainty was assessed 
u(𝑉𝑎
𝑛𝑒𝑐𝑘) Uncertainty in DIR algorithm 4.20 
Estimated uncertainty of 2% of average neck volume 
over all patients 
u(𝑉𝑏
𝑛𝑒𝑐𝑘) 
Capping and other aspects (excl. grid size 
uncert.) when copying structure from dCT to 
CBCT 
8.09 
SD of differences between centroids of dCT and CBCT 
structures correcting for grid size uncertainty (N = 30) 
u(𝑉𝑐
𝑛𝑒𝑐𝑘) Conversion to HR for dCT structure 0.25 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
 










Source of uncertainty 
Value 
(cm3) 
How uncertainty was assessed 
u(𝑉𝑎
𝐶2) Inter-observer variation in volume definition 0.50 
SD of differences between match of two observers 
(authors NL and RL. N = 117) 
u(𝑉𝑏
𝐶2) Conversion to HR for dCT structure 0.01 
SD of differences between centroids of HR and non-HR 
structures (N = 24) 
 












A.3: SPC results 
 
Table A.3.1: Fraction numbers when exponentially weighted moving average (EWMA) statistics exceeded process limits. EWMA statistics are calculated from data 
acquired using deformable image registration (DIR). (IC= in control; NA = not assessed; PG = parotid gland; BOS = base of skull; Occ = occipital bone; Max = 



























1 13 30 IC 15 12 13 IC 9 11, 9 - 8, 9 - IC 
2 28 IC 9 NA NA NA NA 15 - 9, 9 - 11, 10 10 ↑ 
3 IC IC IC IC 30 16 IC 18 19, IC - 10, 8 - 12 ↓ 
4 30 30 30 18 19 IC 18 22 30, IC - 17, 15 - 17 ↑ 
5 13 20 11 15 NA 23 NA 11 14, 20 - 9, 9 - 10 ↓ 
6 19 20 NA IC IC 17 IC 17 14 22 8 9 24 ↓ 
7 25 IC NA IC NA 23 25 IC 18 7 11 12 NA 
8 IC 10 12 11 NA IC 20 8 13, 15 - 20, 11 - 9 ↓ 
9 12 9 IC IC NA 11 20 IC 13 18 12 21 IC 
10 IC 25 15 13 18 14 NA 17 18 24 9 20 14 ↓ 
11 IC 9 8 10 14 12 14 IC IC, 11 - 21, 12 - 18 ↓ 
12 IC 20 23 14 13 16 IC IC 12 9 8 12 15 ↓ 
IC% 42% 25% 30% 36% 14% 18% 44% 33% 18% 0% 0% 0% 18% 











A.4: Individual patient 90% level of confidence SPC results 
Table A.4.1: Fraction number when exponentially weighted moving average (EWMA) statistics exceeded process limits before the end of treatment week 4 shown in 
boldface. Fraction number when the accuracy interval exceeded the process limits 90% level of confidence shown in parentheses. EWMA parameters are established 
from deformable image registration (DIR) raw data. (No entry = in control or exceeded control after treatment week 4; NA = not assessed; PG = parotid gland; BOS 

























1 13 (X)   15 (27) 12 (20) 13 (X)  9 (14) 
11 (13) 













10 (15) ↑ 
3      16 (X)  18 (X) 19 (25)  
10 (15) 
8 (12) 
 12 (X) ↓ 
4    18 (29) 19 (30)  18 (X)    
17 (X) 
15 (X) 
 17 (26) ↑ 






 10 (23) ↓ 
6 19 (X) 20 (X) NA   17 (X)  17 (25) 14 (20)  8 (19) 9 (16)  
7   NA  NA    18 (29) 7 (19) 11 (16) 12 (21) NA 






 9 (13) ↓ 
9 12 (X) 9 (X)   NA 11 (26) 20 (X)  13 (15) 18 (23) 12 (19)   
10   15 (X) 13 (X) 18 (X) 14 (X) NA 17 (X) 18 (24)  9 (14) 20 (24) 14 (27) ↓ 
11  9 (X) 8 (X) 10 (X) 14 (X) 12 (14) 14 (X)  11 (28)  12 (20)  18 (28) ↓ 
12  20 (X)  14 (23) 13 (20) 16 (X)   12 (17) 9 (X) 8 (12) 12 (18) 15 (22) ↓ 
Nr of cases  0/4 0/6 0/5 3/7 3/5 2/7 0/4 3/7 12/13 4/5 14/16 6/6 7/8 
Efficiency 0% 0% 0% 43% 60% 29% 0% 43% 92% 80% 88% 100% 88% 
95% CI 0-13% 0-8% 0-10% 0-87% 7-100% 0 - 69% 0 -13% 0% -87% 74-100% 35-100% 68-100% 92-100% 58-100% 









A.5: Individual patient 90% level of confidence clinical limit results 
Table A.5.1: Fraction number when exponentially weighted moving average (EWMA) statistics exceeded the 2 mm clinical limit during the first 4 weeks of treatment 
shown in boldface. Fraction number when the accuracy interval 2 mm clinical limit shown in parentheses. EWMA parameters are established from deformable image 
registration (DIR) raw data. (No entry = deviations within 2 mm or exceeded control after treatment week 4; NA = not assessed; BOS = base of skull; Occ = occipital; 













1     19 (21) 1 (1) 1 (1) 10 (14) 
2 1 (1) 1 (X) 1 (1) NA NA NA NA 1 (1) 
3 1 (1)     1 (3) 1 (1)  
4 1 (X)    1 (18) 1 (17) 1 (9)  
5   11 (X)  NA 1 (13) NA  
6   NA   1 (17) 1 (17)  
7   NA  NA 1 (1) 1 (1) 1 (X) 
8     NA 1 (1) 1 (1)  
9 1 (12)    NA  1 (19) 1 (18) 
10      1 (1) NA  
11      1 (1) 1 (1)  
12     1 (1)  1 (X) 9 (X) 
Nr of cases 3/4 0/1  1/2  0/0 3/3 9/9 8/9 3/5 
Efficiency 75% 0% 50% NA 100% 100% 89% 60% 











A.6: Differences between E0 values of SPC charts based on DIR or MMR 
 
Table A.6.1: Deformation (mm) of the exponentially weighted moving average (EWMA) reference period E0, acquired with deformable image registration (DIR). (NA 


















1 1.0 1.1 1.0 1.2 1.7 5.1 3.9 1.9 
2 2.5 2.0 2.6 NA NA NA NA 4.0 
3 2.7 1.3 1.3 1.2 1.6 3.1 3.4 1.1 
4 2.2 0.9 1.7 1.3 2.2 2.3 2.5 1.3 
5 1.2 1.9 2.0 1.2 NA 2.5 NA 1.2 
6 1.7 1.4 NA 0.9 1.0 2.1 2.7 1.3 
7 1.7 0.9 NA 1.2 NA 4.1 5.9 2.5 
8 1.7 0.7 1.2 1.1 NA 3.4 2.8 1.4 
9 2.2 1.5 1.2 1.4 NA 1.5 2.1 2.1 
10 1.5 0.8 0.8 0.8 1.0 5.7 NA 0.9 
11 1.2 1.5 1.4 1.1 1.6 3.0 3.9 1.8 
12 1.7 1.0 0.9 1.6 2.5 1.5 2.2 1.9 











Table A.6.2: Deformation (mm) of the exponentially weighted moving average (EWMA) reference period E0, acquired with the manual method of registration (MMR). 

















1 1.2 1.1 2.3 1.4 2.6 4.6 4.8 3.5 
2 2.5 1.9 3.8 NA NA NA NA 5.3 
3 1.3 1.1 2.2 1.5 2.3 3.5 2.3 1.5 
4 1.1 0.7 2.0 1.2 1.8 2.2 1.9 1.4 
5 1.8 1.4 1.7 1.6 NA 2.0 NA 1.9 
6 0.6 0.8 NA 1.0 1.3 2.4 3.0 1.6 
7 2.0 1.2 NA 1.0 NA 3.4 4.6 2.6 
8 1.6 0.6 1.5 1.2 NA 3.9 3.0 2.2 
9 1.3 1.5 2.1 1.5 NA 2.0 2.1 2.8 
10 1.0 0.8 1.0 0.9 1.2 6.7 NA 1.3 
11 1.4 1.1 1.7 1.6 2.0 2.0 2.6 2.1 
12 1.1 1.3 1.6 1.5 2.0 1.8 1.9 2.1 











Table A.6.3: Differences in deformation (mm) of the exponentially weighted moving average (EWMA) reference periods E0, acquired with deformable image registration 
(DIR) and the manual method of registration (MMR). (NA = not assessed; BOS = base of skull; Occ = occipital bone; Max = maxilla. *indicates a significant difference 

















1 -0.2 0.0 -1.2 -0.2 -0.9 0.5 -0.9 -1.5 
2 0.0 0.1 -1.2 NA NA NA NA -1.3 
3 1.4 0.1 -0.9 -0.3 -0.7 -0.4 1.1 -0.4 
4 1.1 0.3 -0.3 0.2 0.4 0.1 0.6 -0.1 
5 -0.6 0.5 0.2 -0.5 NA 0.5 NA -0.7 
6 1.1 0.6 NA -0.1 -0.2 -0.3 -0.3 -0.4 
7 -0.3 -0.3 NA 0.2 NA 0.7 1.3 -0.1 
8 0.0 0.1 -0.2 -0.1 NA -0.5 -0.2 -0.8 
9 0.9 -0.1 -0.9 -0.1 NA -0.4 0.0 -0.6 
10 0.5 0.0 -0.1 -0.1 -0.2 -1.1 NA -0.4 
11 -0.2 0.4 -0.3 -0.6 -0.3 0.9 1.3 -0.3 
12 0.5 -0.3 -0.7 0.0 0.5 -0.3 0.3 -0.2 
Mean 
difference 











A.7: Average parotid shift and volume EWMA 
 






































A.8: Radiation oncologist PG review 
 
Table A.8.1: Summary of Dice similarity coefficient (DSC) and Hausdorff distance (HD) metrics 
evaluating the deformed parotid gland (PG) contours. Deformed PG contours were evaluated against 
















0.40 – 2.47 cm 
 
 
Table A.8.2: Patient-, fraction- and parotid gland-specific Dice similarity coefficient (DSC) and 
Hausdorff distance (HD) metrics evaluating the deformed parotid gland (PG) contours. Deformed PG 
contours were evaluated against independent radiation oncologist re-contours. 
Patient, CBCT fraction, parotid gland DSC HD (cm) 
1, CBCT10, left parotid 0.90 0.48 
1, CBCT20, left parotid 0.87 1.02 
1, CBCT30, left parotid 0.86 0.47 
2, CBCT10, left parotid 0.78 1.03 
2, CBCT20, left parotid 0.73 1.29 
2, CBCT30, left parotid 0.74 1.21 
3, CBCT10, left parotid 0.88 0.72 
3, CBCT20, left parotid 0.87 0.44 
3, CBCT30, left parotid 0.85 0.46 
4, CBCT10, left parotid 0.87 0.76 
4, CBCT20, left parotid 0.85 1.11 
4, CBCT30, left parotid 0.84 1.05 
5, CBCT10, left parotid 0.72 1.25 
5, CBCT20, left parotid 0.70 1.44 
5, CBCT30, left parotid 0.62 1.61 
6, CBCT10, left parotid 0.81 0.81 
6, CBCT20, left parotid 0.86 1.08 
6, CBCT30, left parotid 0.74 1.65 
7, CBCT10, left parotid 0.87 0.48 
7, CBCT20, left parotid 0.79 1.02 
7, CBCT30, left parotid 0.64 1.07 
8, CBCT10, left parotid 0.85 1.11 
8, CBCT20, left parotid 0.82 0.96 
8, CBCT30, left parotid 0.77 1.17 
9, CBCT10, left parotid 0.81 0.89 
9, CBCT20, left parotid 0.82 0.99 
9, CBCT30, left parotid 0.77 0.70 
10, CBCT10, left parotid 0.92 0.41 
10, CBCT20, left parotid 0.89 0.61 
10, CBCT30, left parotid 0.90 0.41 










11, CBCT20, left parotid 0.91 0.46 
11, CBCT30, left parotid 0.82 0.67 
12, CBCT10, left parotid 0.88 1.28 
12, CBCT20, left parotid 0.86 1.54 
12, CBCT30, left parotid 0.83 0.90 
1, CBCT10, right parotid 0.92 0.90 
1, CBCT20, right parotid 0.89 0.62 
1, CBCT30, right parotid 0.89 0.45 
2, CBCT10, right parotid 0.77 0.87 
2, CBCT20, right parotid 0.68 0.94 
2, CBCT30, right parotid 0.70 0.88 
3, CBCT10, right parotid 0.87 0.61 
3, CBCT20, right parotid 0.87 0.59 
3, CBCT30, right parotid 0.83 0.59 
4, CBCT10, right parotid 0.84 0.80 
4, CBCT20, right parotid 0.84 0.77 
4, CBCT30, right parotid 0.84 1.06 
5, CBCT10, right parotid 0.77 1.15 
5, CBCT20, right parotid 0.69 1.86 
5, CBCT30, right parotid 0.69 1.60 
6, CBCT10, right parotid 0.79 1.67 
6, CBCT20, right parotid 0.79 1.63 
6, CBCT30, right parotid 0.79 1.37 
7, CBCT10, right parotid 0.85 0.71 
7, CBCT20, right parotid 0.82 0.69 
7, CBCT30, right parotid 0.70 1.39 
8, CBCT10, right parotid 0.83 1.27 
8, CBCT20, right parotid 0.81 1.60 
8, CBCT30, right parotid 0.80 1.26 
9, CBCT10, right parotid 0.79 2.14 
9, CBCT20, right parotid 0.82 2.47 
9, CBCT30, right parotid 0.85 0.91 
10, CBCT10, right parotid 0.91 0.42 
10, CBCT20, right parotid 0.90 0.50 
10, CBCT30, right parotid 0.90 0.47 
11, CBCT10, right parotid 0.89 0.61 
11, CBCT20, right parotid 0.89 0.42 
11, CBCT30, right parotid 0.84 1.15 
12, CBCT10, right parotid 0.83 0.98 
12, CBCT20, right parotid 0.79 0.79 

















A.9: Planning protocol 
 
Table A.9.1: Dose-volume objectives used in treatment plan optimization. 
 
Dose-volume metrics 
 D0.1cc = minimum dose to 0.1 cm
3 of the volume that receives the highest dose 
 Dmax = maximum dose 
Dmean = mean dose  
D98%= minimum dose to 98% of the volume  
D99%= minimum dose to 99% of the volume  
PRV = planning risk volume. A 3 mm PRV was used 
PTV = planning target volume  
CTV = clinical target volume 
GTV = gross tumor volume 
 




Structure Dose-volume objective Priority 
Target structures   
          PTVs (high-, intermediate- and       
low-risk) 
D98% ≥ 95% prescribed dose 




          CTVs (high-, intermediate- and       
low-risk) 
D99% ≥ 95% prescribed dose 




          GTV D99% ≥ 95% prescribed dose 




Organs at risk   
          Brain stem PRV D0.1cc < 54 Gy High 
          Spinal cord PRV D0.1cc < 50 Gy High 
          Optic nerve/chiasm PRV D0.1cc < 55 Gy High 
          Parotid glands 
                  -Ipsilateral 
                  -Contralateral 
 
Dmean < 26 Gy [25,59] 




          Submandibular glands 
                  -Ipsilateral 
                  -Contralateral 
 
Dmean < 39 Gy [277] 




          Oral cavity*  Dmean < 35 Gy [2] Medium 
          Pharyngeal constrictor muscles* Dmean < 50 Gy [45] Low 






































Figure A.10.1: 3D vector of residual deformations after applying the SmartAdapt (SA) acquired forward deformation vector field (DVF) and subsequent inverse (left 
columns) or symmetric (right columns) DVF registration. Structures of interest in head-and-neck radiotherapy (HNRT) are shown for patient 1 at fraction 29 and 
patient 4 at fraction 3 to exemplify the residual deformation errors. In general, the symmetric registrations had larger residual deformations relative to the inverse 
registrations. A notable inverse consistency error was present for patient 1’s ipsilateral PG and high-dose PTV. PG = parotid gland. PRV = planning risk volume. PTV 









A.11: IC rates 
Table A.11.1: Structure- and fraction-specific inverse consistency (IC) rates [%] for patients 1 – 6. PTV = planning target volume. CTV = clinical target volume. PRV 
= planning risk volume. PG = parotid gland. SMG = submandibular gland. 
 Patient 1 2 3 4 5 6 
 fraction 3 16 29 3 16 29 3 16 29 3 16 29 3 16 29 3 16 29 
High-dose 
PTV 
 98.0 87.6 85.6    100 100 100 100 100 99.9 100 100 100 100 100 100 
Intermediate-
dose PTV 
                   
Low-dose 
PTV 
 97.5 94.1 94.0 100 100 99.7 100 100 100 100 99.9 99.9 100 100 100 99.9 99.9 99.9 
High-dose 
CTV 
 98.4 86.8 85.3    100 100 100 100 100 99.8 100 100 100 100 100 100 
Intermediate-
dose CTV 
                   
Low-dose 
CTV 
 98.0 91.4 91.2 100 100 100 100 100 100 100 100 99.9 100 100 100 100 100 100 
Brainstem 
PRV 
 86.8 94.9 97.0 99.8 98.1 96.9 100 73.3 100 99.9 99.1 97.6 99.8 98.8 99.6 96.4 87.3 95.9 
Spinal cord 
PRV 
 78.9 100 99.9 98.5 95.3 98.8 99.4 100 99.3 95.9 96.3 93.7 99.5 97.6 99.9 100 100 100 
Brainstem   64.2 84.6 93.7 99.8 98.4 98.9 100.0 64.2 100.0 98.4 93.9 90.8 99.7 97.8 99.3 98.1 83.2 94.1 
Spinal cord   71.9 100.0 99.7 94.6 90.5 96.2 99.2 100.0 98.2 94.7 96.1 91.6 99.8 96.2 100.0 98.9 98.1 96.5 
Ipsilateral 
PG 
 99.4 42.5 26.3 100 99.3 100 100 100 100 100 100 100 100 100 100 99.7 100 100 
                    
Contralateral 
PG 
 94.6 96.0 86.2 99.9 99.8 99.9 100 100 100 100 100 100 100 100 100 100 100 100 
Ipsilateral 
SMG 
 99.8 95.9 98.9 100 100 100 100 100 100 100 100 100 100 100 100    
                    
Contralateral 
SMG 









Table A.11.2: Structure- and fraction-specific inverse consistency (IC) rates [%] for patients 7 – 12. PTV = planning target volume. CTV = clinical target volume. PRV 
= planning risk volume. PG = parotid gland. SMG = submandibular gland. 
 
 Patient 7 8 9 10 11 12 
 fraction 3 16 29 3 16 29 3 16 29 3 16 29 3 16 29 3 16 29 
High-dose PTV  99.9 99.7 99.7 100 100 100 99.9 99.8 99.8 100 100 100 99.9 100 100 100 100 100 
Intermediate-dose PTV  100 100 100 100 100 100 99.9 99.9 99.9 100 100 100       
Low-dose PTV  100 100 100 100 99.9 100 99.8 99.6 99.6 100 100 99.9 99.7 99.9 99.9 99.5 99.7 99.9 
High-dose CTV  100 99.8 99.8 100 100 100 99.8 99.7 99.7 100 100 100 100 100 100 100 100 100 
Intermediate-dose CTV  100 99.9 99.9 100 100 100 99.9 99.8 99.8 100 100 100       
Low-dose CTV  100 100 99.9 100 100 100 99.8 99.7 99.7 100 100 99.9 99.9 99.9 99.9 99.8 99.8 99.9 
Brainstem PRV  96.8 96.3 99.6 100 100 100 98.1 98.9 99.8 99.9 99.6 95.9 95.4 95.6 95.6 98.6 97.1 99.9 
Spinal cord PRV  98.1 99.9 99.9 99.9 99.8 99.9 98.3 98.4 97.3 100 99.4 99.5 95.4 92.8 94.1 100 100 100 
Brainstem  95.5 92.6 98.3 100.0 99.9 100.0 93.9 95.3 97.9 100.0 100.0 98.7 83.6 80.7 96.1 97.8 97.1 100.0 
Spinal cord  98.8 99.8 99.9 100.0 100.0 100.0 98.0 98.7 96.8 100.0 99.6 100.0 94.8 92.6 92.7 100.0 100.0 100.0 
Ipsilateral PG  100 99.9 99.8 100 100 100 100 99.9 100 100 100 100 99.9 99.4 100 100 99.7 99.9 
        100 100 100    99.4 99.9 99.5    
Contralateral PG  100 100 100 100 100 100    100 100 100    100 99.9 99.9 
Ipsilateral SMG  100 100 100 100 100 100 100 100 100 100 100 100 99.9 99.9 100 100 100 100 
        100 100 100    100 100 100    





















































































































































































































































































































































































































































































































































A.13: Histograms of 𝑡𝑜𝑡  
Figure A.13.1: Histogram showing the distribution of 𝑡𝑜𝑡 for the high-dose planning target volume (PTV) of all patients for inverse consistent 













Figure A.13.2: Histogram showing the distribution of 𝑡𝑜𝑡 for the intermediate-dose planning target volume (PTV) of all patients for inverse 















Figure A.13.3: Histogram showing the distribution of 𝑡𝑜𝑡 for the low-dose planning target volume (PTV) of all patients for inverse consistent 













Figure A.13.4: Histogram showing the distribution of 𝑡𝑜𝑡 for the high-dose clinical target volume (CTV) of all patients for inverse consistent 











Figure A.13.5: Histogram showing the distribution of 𝑡𝑜𝑡 for the intermediate-dose clinical target volume (CTV) of all patients for inverse 













Figure A.13.6: Histogram showing the distribution of 𝑡𝑜𝑡 for the low-dose clinical target volume (CTV) of all patients for inverse consistent 













Figure A.13.7: Histogram showing the distribution of 𝑡𝑜𝑡 for the brainstem planning risk volume (PRV) of all patients for inverse consistent 












Figure A.13.8: Histogram showing the distribution of 𝑡𝑜𝑡 for the spinal cord planning risk volume (PRV) of all patients for inverse consistent 












Figure A.13.9: Histogram showing the distribution of 𝑡𝑜𝑡 for the brainstem of all patients for inverse consistent (left) and inverse inconsistent 











Figure A.13.10: Histogram showing the distribution of 𝑡𝑜𝑡 for the spinal cord of all patients for inverse consistent (left) and inverse 













Figure A.13.11: Histogram showing the distribution of 𝑡𝑜𝑡 for the ipsilateral parotid gland (PG) of all patients for inverse consistent (left) and 













Figure A.13.12: Histogram showing the distribution of 𝑡𝑜𝑡 for the contralateral parotid gland (PG) of all patients for inverse consistent (left) 













Figure A.13.13: Histogram showing the distribution of 𝑡𝑜𝑡 for the ipsilateral submandibular gland (SMG) of all patients for inverse consistent 





























Figure A.13.14: Histogram showing the distribution of 𝑡𝑜𝑡 for the contralateral submandibular gland (SMG) of all patients for inverse 












A.14: Structures available for analysis 
 
Table A.14: Patient-specific structure count and structure-specific dose-volume histogram (DVH) 
analysis parameter. CTV = clinical target volume. PTV = planning target volume. PRV = planning risk 
volume. PG = parotid gland. SMG = submandibular gland. D99% = minimum dose to 99% of volume. 












             
CTV 54 D99% X X X X X X X X X X X X 12 
CTV 60 D99%      X   X X  X 4 
CTV 66 D99% X  X X X X X X X X X X 11 
PTV 54 D98% X X X X X X X X X X X X 12 
 PTV 60 D98%      X   X X  X 4 
PTV 66 D98% X  X X X X X X X X X X 11 
Spinal cord D0.1cc X X X X X X X X X X X X 12 
Brainstem D0.1cc X X X X X X X X X X X X 12 
Spinal cord PRV D0.1cc X X X X X X X X X X X X 12 
Brainstem PRV D0.1cc X X X X X X X X X X X X 12 
Ipsilateral PG Dmean X X X X X X X X X X X X 14 
        X  X     
Contralateral PG Dmean X X X X X X  X  X X X 10 
Ipsilateral SMG Dmean X X X X X X X X X X  X 13 
        X  X     
Contralateral SMG Dmean X X X X X X  X  X X  9 





























Figure A.15.1: Generation of the local skin clinical target volume (CTV). (a) A 1 cm diameter sphere (green contour) 
was generated at the point of minimum distance between the CTV (red contour) and skin (pink contour). (b) The sub-
volume of the sphere that overlapped with the CTV was defined as the local skin CTV. The 3 mm planning target volume 
(PTV) margin is shown by the orange contour. Note that the PTV and CTV are both cropped 3 mm back from the skin 

































Figure A.15.2: Generation of the local critical organ at risk (OAR) volumes. (a) Two 1 cm diameter spheres (green 
contour and teal contour) were generated. One sphere was centred on the high-dose clinical target volume (CTV) (red 
contour) boundary and one sphere on the brainstem (blue contour) boundary at the point of minimum distance between 
the CTV and brainstem. (b) The sub-volumes of the spheres that overlapped with the brainstem and CTV were defined as 
the local brainstem and local CTV, respectively. The sub-volumes of the spheres that overlapped with the planning risk 
volume (PRV) margin (magenta contour) and planning target volume (PTV) margin (orange contour) were defined as 
the local PRV and local PTV, respectively. The generation of the local volumes was repeated for 5 mm PRV/PTV margin 

















A.16: Normality tests 
 
The planned, accumulated and 𝐷 DVH parameters were tested for normality for the LD-CTVs (i.e., 
CTV 54), HD-CTVs (i.e., CTV 66) and the ipsilateral PGs. It was determined that the planned, 
accumulated and 𝐷 DVH parameters were not always normally distributed and further normality tests 
of these parameters for the remaining structures was not conducted. However, the differences between 
the DVH parameters of the 5 and 3 mm plans were normally distributed. Supplementary Material E.1 
presents the normality results for the planned, accumulated and 𝐷 DVH parameters for the LD-CTV, 
HD-CTV and the ipsilateral PG. Supplementary Material E.2 presents the results of the normality tests 
for the differences between the DVH parameters of the 5 and 3 mm plans. Q-Q plots and Shapiro-Wilk 
tests were used to test for normality and are presented below. 
 
 
Supplementary Material E.1 
3mm_pln = Treatment plan with 3 mm PTV margins; the planned dose 
3mm_acc = Treatment plan with 3 mm PTV margins; the accumulated dose 
3mm_dD = Treatment plan with 3 mm PTV margins; the change in dose (i.e., acc – pln) 
 
5mm_pln = Treatment plan with 5 mm PTV margins; the planned dose 
5mm_acc = Treatment plan with 5 mm PTV margins; the accumulated dose 





3mm_pln 5mm_pln 3mm_acc 5mm_acc 3mm_dD 5mm_dD
W-stat 0.943525 0.967372 0.95848 0.896318 0.909193 0.848788
p-value 0.545042 0.881424 0.761936 0.142176 0.208325 0.035471
alpha 0.05 0.05 0.05 0.05 0.05 0.05















































































































































3mm_pln 5mm_pln 3mm_acc 5mm_acc 3mm_dD 5mm_dD
W-stat 0.936317 0.966111 0.863591 0.854681 0.944933 0.727134
p-value 0.478216 0.844804 0.06409 0.049112 0.580096 0.001048
alpha 0.05 0.05 0.05 0.05 0.05 0.05






































































































































QQ Plot - 5mm_dD
Shapiro-Wilk Test
3mm_pln 5mm_pln 3mm_acc 5mm_acc 3mm_dD 5mm_dD
W-stat 0.98194 0.956513 0.979519 0.960808 0.913207 0.926384
p-value 0.984517 0.665489 0.971924 0.736383 0.175411 0.271321
alpha 0.05 0.05 0.05 0.05 0.05 0.05














































































































































CTV54_pln CTV60_pln CTV66_pln PTV54_pln PTV60_pln PTV66_pln SpCPRV_pln BSPRV_pln Ips PG_pln Con PG_pln Ips SMG_pln Con SMG_pln
W-stat 0.9573515 0.7172207 0.97271705 0.9093418 0.8282964 0.9358162 0.935636113 0.89209911 0.96779665 0.94315548 0.922820162 0.85795049
p-value 0.7454602 0.0180998 0.91255958 0.2092412 0.1634032 0.4726295 0.443686319 0.12541955 0.84587468 0.588629064 0.273753477 0.091079879
alpha 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
normal yes no yes yes yes yes yes yes yes yes yes yes







CTV_54_pln = Differences between the D99% of the 5 and 3 mm planned doses for the LD-CTV 
CTV_60_pln = Differences between the D99% of the 5 and 3 mm planned doses for the ID-CTV 
CTV_66_pln = Differences between the D99% of the 5 and 3 mm planned doses for the HD-CTV 
PTV_54_pln = Differences between the D98% of the 5 and 3 mm planned doses for the LD-PTV 
PTV_60_pln = Differences between the D98% of the 5 and 3 mm planned doses for the ID-PTV 
PTV_66_pln = Differences between the D98% of the 5 and 3 mm planned doses for the HD-PTV 
SpCPRV_pln = Differences between the D0.1cc of the 5 and 3 mm planned doses for the spinal cord PRV 
BSPRV_pln = Differences between the D0.1cc of the 5 and 3 mm planned doses for the brainstem PRV 
Ips PG_pln = Differences between the Dmean of the 5 and 3 mm planned doses for the ipsilateral parotid gland 
Con PG_pln = Differences between the Dmean of the 5 and 3 mm planned doses for the contralateral parotid gland 
Ips SMG_pln = Differences between the Dmean of the 5 and 3 mm planned doses for the ipsilateral submandibular gland 



















































































































































































































































































CTV54_acc CTV60_acc CTV66_acc PTV54_acc PTV60_acc PTV66_acc SpCPRV_acc BSPRV_acc Ips PG_acc Con PG_acc Ips SMG_accCon SMG_acc
W-stat 0.9431502 0.94510135 0.96321135 0.9128057 0.86540617 0.894349 0.93870526 0.8046968 0.9728651 0.93631702 0.92437968 0.82682767
p-value 0.5 0.7 0.8 0.2 0.3 0.2 0.5 0.0 0.9 0.5 0.3 0.0
alpha 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05







CTV_54_acc = Differences between the D99% of the 5 and 3 mm accumulated doses for the LD-CTV 
CTV_60_acc = Differences between the D99% of the 5 and 3 mm accumulated doses for the ID-CTV 
CTV_66_acc = Differences between the D99% of the 5 and 3 mm accumulated doses for the HD-CTV 
PTV_54_ acc = Differences between the D98% of the 5 and 3 mm accumulated doses for the LD-PTV 
PTV_60_acc = Differences between the D98% of the 5 and 3 mm accumulated doses for the ID-PTV 
PTV_66_acc = Differences between the D98% of the 5 and 3 mm accumulated doses for the HD-PTV 
SpCPRV_acc = Differences between the D0.1cc of the 5 and 3 mm accumulated doses for the spinal cord PRV  
BSPRV_acc = Differences between the D0.1cc of the 5 and 3 mm accumulated doses for the brainstem PRV 
Ips PG_acc = Differences between the Dmean of the 5 and 3 mm accumulated doses for the ipsilateral parotid gland 
Con PG_acc = Differences between the Dmean of the 5 and 3 mm accumulated doses for the contralateral parotid gland 
Ips SMG_acc = Differences between the Dmean of the 5 and 3 mm accumulated doses for the ipsilateral submandibular gland 












































































































































































































































































CTV_54_dD = Differences between the D99% of the 5 and 3 mm 𝐷 i.e., change in dose for the LD-CTV 
CTV_60_dD = Differences between the D99% of the 5 and 3 mm 𝐷 i.e., change in dose for the ID-CTV 
CTV_66_dD = Differences between the D99% of the 5 and 3 mm 𝐷 i.e., change in dose for the HD-CTV 
PTV_54_dD = Differences between the D98% of the 5 and 3 mm 𝐷 i.e., change in dose for the LD-PTV 
PTV_60_dD = Differences between the D98% of the 5 and 3 mm 𝐷 i.e., change in dose for the ID-PTV 
PTV_66_dD = Differences between the D98% of the 5 and 3 mm 𝐷 i.e., change in dose for the HD-PTV 
SpCPRV_dD = Differences between the D0.1cc of the 5 and 3 mm 𝐷 i.e., change in dose for the spinal cord PRV  
BSPRV_dD = Differences between the D0.1cc of the 5 and 3 mm 𝐷 i.e., change in dose for the brainstem PRV 
Ips PG_dD = Differences between the Dmean of the 5 and 3 mm 𝐷 i.e., change in dose for the ipsilateral parotid gland 
Con PG_dD = Differences between the Dmean of the 5 and 3 mm 𝐷 i.e., change in dose for the contralateral parotid gland 
Ips SMG_dD = Differences between the Dmean of the 5 and 3 mm 𝐷 i.e., change in dose for the ipsilateral submandibular gland 
Con SMG_dD = Differences between the Dmean of the 5 and 3 mm 𝐷 i.e., change in dose for the contralateral submandibular gland 
Shapiro-Wilk Test
CTV54_dD CTV60_dD CTV66_dD PTV54_dD PTV60_dD PTV66_dDSpCPRV_dDBSPRV_dDIps PG_dDCon PG_dDIps SMG_dDCon SMG_dD
W-stat 0.854907 0.920262 0.937703 0.928113 0.871635 0.859572 0.888629 0.91328 0.912086 0.729235 0.958837 0.924056
p-value 0.0 0.5 0.5 0.4 0.3 0.1 0.1 0.2 0.2 0.0 0.7 0.4
alpha 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05

















































































































































































































































































Figure A.17.1: Scatter plots of the planned dose subtracted from the accumulated dose, D for the 12 patients’ 
organs at risk (OARs) when utilizing 3 or 5 mm planning target volume (PTV) and planning risk volume (PRV) 
margins. PG = parotid gland. SMG = submandibular gland. D0.1cc= minimum dose to 0.1 cm
3 of the volume that 
receives the highest dose. Dmean = mean dose. 95% level of confidence shown by error bars.  













Figure A.17.2 shows that a higher 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 to the local PTV (open markers) was achievable with 3 mm 
compared to 5 mm margin expansions in particular if the minimum distance between HD-CTV and 
BS was 10 mm or less. There was insufficient data in this range to decide whether this trend was also 
present for target volumes near the SC (Figure A.17.2b). Figure A.17.2a-b clearly show that the local 
CTV 𝐷𝑚𝑖𝑛
𝑎𝑐𝑐  (solid markers) was well above 95% of 𝐷𝑝𝑟𝑒𝑠𝑐 for both locations irrespective of the 
achieved local minimum PTV dose for both margin expansions. Very similar results can be observed 
for the maximum dose to the OARs and corresponding PRVs (Figure A.17.2c-d). In one case (patient 
ten), a compromise to the local BS PRV 𝐷𝑚𝑎𝑥
𝑝𝑙𝑎𝑛
 (62.6 Gy; tolerance dose 54 Gy) was required for the 5 
mm expansion to achieve sufficient PTV coverage during treatment planning. It should be reiterated 
that this compromise was not necessary for the 3 mm margin expansion and that 𝐷𝑚𝑎𝑥
𝑎𝑐𝑐  to the actual 








 A.17.2: The minimum planned 𝐷𝑚𝑖𝑛𝑝𝑙𝑎𝑛 and accumulated dose 𝐷𝑚𝑖𝑛𝑎𝑐𝑐  for the local PTV and CTV respectively using 3 and 5 mm planning target volume (PTV)/planning risk 
volume (PRV) margin plans, plotted as a function of the minimum distance (𝑑𝑚𝑖𝑛) between the clinical target volume (CTV) and brainstem (BS) (a) and spinal cord (SC) (b). 
The maximum planned 𝐷𝑚𝑎𝑥
𝑝𝑙𝑎𝑛
 and accumulated dose 𝐷𝑚𝑎𝑥
𝑎𝑐𝑐  for the local PRV and BS/SC respectively using 3 and 5 mm PTV/PRV margin plans, plotted as a function of the 














Figure G.1: Average percentage dose deposited at VMAT control points where effective depth 
(depending on beam angle) was larger than d for 40 points within the superficial aspect of the HD-CTV 





















A.19: HU override analysis 
 
Results of TPS calculations using a HU override equal to +/- 100 HU of the most superficial 4 mm 
within the body contour. The analysis was conducted for the four patients where a HD-CTV superficial 
underdosage was observed. First, the voxel-specific dose difference between the +/- 100 HU for each 
voxel of the HD-CTV was recorded. Second, the 95% percentile range of the voxel-specific dose 
differences was used to estimate the uncertainty in the dose calculation due to potential uncertainty in 
the HUs. The largest 95% percentile range (patient 12; 0.68 Gy; ~1% 𝐷𝑝𝑟𝑒𝑠𝑐) was used in the statement 
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Introduction Reduced treatment toxicity while maintaining equivalent local-regional control 
rates have been reported when reducing PTVs from 5 to 3 mm for Head and Neck radiation 
oncology [1,2]. However, many treatment aspects should be carefully considered before the 
PTV margin can be amended. This study investigates the application of deformable image 
registration (DIR) and Statistical Process Control (SPC) to quantify deformation, i.e., changes 
in patient pose and anatomy during treatment as a first step in developing a safety net for PTV 
margin reduction. 
 
Method This retrospective study includes 12 patients who received planning computed 
tomography (pCT) and daily CBCTs to verify their positioning. DIR of the pCT-to-CBCTs was 
performed and the relative position of nine bony anatomy (BA) structures of the head and neck 
region and the volume of a pre-defined neck region 𝑉𝑛
𝐷𝐼𝑅 were investigated. The DIR results 
were validated against manual registration of the BA structures and assessment of a neck 
volume. Exponentially Weighted Moving Average (EWMA) SPC charts were used to 
investigate trends in patient positioning accuracy and volume change of the neck. Future 
results to be included in this study will analyse trends of parotid gland changes using SPC, 




Results Preliminary results showed that the overall mean difference between DIR and manual 
registration was 0.0 mm with a random variation and systematic dispersion of 1.0 and 0.4 mm 
(1 S.D.), respectively. Linear regression showed a high correlation between 𝑉𝑛
𝐷𝐼𝑅 and a 
manually contoured volume of a different neck region (r2=0.849; p<0.001), indicating that 𝑉𝑛
𝐷𝐼𝑅 
is a good indicator of treatment volume changes. EWMA charts were able to detect small shifts 












Figure 1: EWMA charts for a single patient. The five fraction reference period is shown by red filled circles. Black 
filled circles indicate the EWMA statistic for each fraction and the red lines indicate upper and lower process 
limits. (Left) EWMA chart for the average position deviation of selected BA structures relative to C1-C3, showing 
that patient pose became significantly different from the reference period at fraction 17 (Right) EWMA chart for 
the volume change of a pre-defined neck region, showing that the volume became significantly different from the 
reference period at fraction 15. 
 
 
Conclusion DIR and SPC provided an effective tool to quantify changes in patient pose and 













B.2: Quantifying anatomical changes using deformable image registration during head-
and-neck radiotherapy to facilitate safe PTV margin reduction  
N Lowther1,2, D Hamilton1, H Kim1, J Evans1, S Marsh2, R Louwe1 
1Wellington Blood and Cancer Centre, Wellington, NZ; 2University of Canterbury, Department of Physics and 
Astronomy, Christchurch, NZ 
 
Contact: Nick Lowther, WBCC, nick.lowther@ccdhb.org.nz   
Introduction: Reduced treatment toxicity while maintaining equivalent local-regional control rates 
have been reported when reducing PTV margins from 5 to 3 mm for Head and Neck radiation 
oncology [1,2]. However, many aspects of the departmental treatment accuracy should be carefully 
considered before adopting this PTV margin reduction. This study investigates the application of 
deformable image registration (DIR) and Statistical Process Control (SPC) to quantify deformation, 
i.e., changes in patient pose and anatomy during treatment as a first step in developing a safety 
net for PTV margin reduction. 
Method: This retrospective study included 12 patients who received computed tomography for 
treatment planning (pCT) and daily CBCTs to verify their treatment position. DIR of the pCT-to-
CBCTs was performed to assess changes in the relative position of nine bony anatomy (BA) 
structures, the volume of a pre-defined neck region 𝑉𝑛
𝐷𝐼𝑅, and the relative position and volume of 
parotid glands during the course of treatment. The DIR results were validated against a manual 
method of registration (MMR) of the BA structures, independent assessment of a neck volume and 
clinician re-contour of the parotid glands, respectively. Exponentially Weighted Moving Average 
(EWMA) SPC charts were used to investigate trends in patient positioning accuracy, volume 
change of the treatment region and shrinkage and shift of the parotids. 
Results: EWMA charts were able to detect trends less than 1 mm in patient positioning 
reproducibility for individual patients. DIR and MMR results showed an equivalent change in patient 
pose as a function of time for all BA regions. However for most patients, the systematic difference 
between the DIR and MMR results for the maxilla and mandible was larger than the uncertainty 
intervals although they were small compared to the absolute offset of each trend (Figure 1). Weight 
and parotid gland change trends departed control limits after 5-15 fractions for 50% and 70% of 
cases, respectively. Future work will correlate these trends to help understand underlying 










Figure 1: EWMA charts of BA deviation for a single patient. Orange and blue filled circles indicate the EWMA 
statistic for each fraction and the orange and blue dashed lines indicate upper and lower process limits for DIR 
and MMR, respectively. (Left) EWMA chart for C5-C7 deviation relative to C1-C3. (Right) EWMA chart for 









Conclusion: DIR and SPC were able to monitor changes in patient pose and anatomy during 
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Introduction Reduced treatment toxicity while maintaining equivalent local-regional control 
rates have been reported after reducing planning target volume (PTV) margins from 5 to 3 mm 
for Head and Neck radiation oncology [1,2]. This retrospective study investigates the feasibility 
of a 3 mm PTV margin plan in combination with a 5 mm backup plan to account for clinically 
relevant anatomical changes. Specifically, the robustness of treatment plans using a 3 or 5 
mm PTV margin for anatomical changes will be investigated as well as strategies for timely 
intervention. 
 
Method Volumetrically modulated arc therapy (VMAT) plans for 12 patients using 3 or 5 mm 
PTV margins were created. Deformable image registration (DIR) of the planning CT-to-cone 
beam CTs was performed to reconstruct the daily delivered dose to target and organ-at-risk 
(OAR) structures. The cumulative DVH was calculated for clinical target volumes (CTVs), 
PTVs and OARs as input data to develop different strategies for treatment adaptation. 
 
Results Preliminary results for the 3 patients (7 CTVs and 7 PTVs total) demonstrating the 
largest anatomical changes during treatment showed an average salivary gland sparing of 2.6 
Gy (Dmean) for 3 mm PTV margin plans. Overall, the increase in reconstructed OAR delivered 
dose from the start to end of treatment was small. The maximum OAR increase was 2.2 and 
2.8 Gy for 3 mm and 5 mm plans for the parotid glands, respectively. For a 3 mm PTV margin, 
the cumulative D98 was less than 95% for 1 CTV (Figure 1) and 6 PTVs. For a 5 mm expansion, 
this was observed for 6 PTVs but not for the CTVs.  
 
Conclusion PTV margin reduction resulted in increased OAR sparing. Timely detection of 
inadequate target coverage due to anatomical changes is feasible and enables timely 





















B.4: Quantifying the dose accumulation uncertainty after deformable image registration 
to facilitate safe PTV margin reduction in head-and-neck radiotherapy 
N Lowther1,2, S Marsh2, R Louwe1 
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Introduction: Deformable image registration (DIR) facilitated dose reconstruction is often applied 
to assess accumulated dose to target volumes and organs at risk (OAR) in the presence of 
anatomical changes. However, uncertainties in the accumulated dose are seldom quantified. This 
retrospective study used an in silico model based on clinically observed deformations to investigate 
the uncertainty of reconstructed dose. This verification of the delivered dose may facilitate planning 
target volume (PTV) margin reduction. 
Methods: A cone beam CT (CBCT) that was acquired during the first week of treatment and 
accurately matched the patient’s anatomy of the planning CT (pCT) was selected for 12 patients. 
These CBCTs were used to generate reference displacement fields, 𝐷𝐹𝐵−𝑠𝑝𝑙𝑖𝑛𝑒 as well as a 
reference dCBCTref using B-spline DIR, for 3 treatment fractions. This served as ground truth to 
assess the accuracy of Varian’s SmartAdapt which is based on the demons algorithm. A 𝐷𝐹𝑑𝑒𝑚𝑜𝑛𝑠 
was generated by registering the pCT to the dCBCTref, and both the inverse 𝐷𝐹𝐵−𝑠𝑝𝑙𝑖𝑛𝑒 and 
𝐷𝐹𝑑𝑒𝑚𝑜𝑛𝑠 were applied to reconstruct and accumulate the delivered dose in the pCT scan. The 
total uncertainty of the demon’s reconstructed dose (𝑈𝑑𝑒𝑚𝑜𝑛𝑠) was assessed by including both the 
voxel-specific dose difference between the two accumulated dose distributions (𝜕), and the dose 
error due to the inverse consistency (IC) of 𝐷𝐹𝐵−𝑠𝑝𝑙𝑖𝑛𝑒which was quantified by subsequent 













Results: Analysis of the IC and 𝜕 distributions showed that 𝑈𝑑𝑒𝑚𝑜𝑛𝑠 can be accurately modeled 
provided voxels with a net IC displacement larger than a dose calculation voxel were excluded. 
The total combined uncertainty at the end of treatment was 0.53 Gy at the 95% level of confidence. 
Conclusion: The uncertainty in accumulated dose using DIR can be accurately quantified and 
incorporated in dose-volume histograms. This method can be used to objectively assess the 









B.5: Statistical process control to monitor anatomical changes during head-
and-neck radiotherapy 
 
Nicholas Lowther1,2, David Hamilton1, Han Kim1, Jamie M. Evans1 Steven Marsh2 and Rob Louwe1 
Wellington Blood and Cancer Centre, Wellington, New Zealand1 
Department of Medical Physics, University of Canterbury, Christchurch, New Zealand2 
 
Purpose: Reduced toxicity while maintaining loco-regional control rates have been reported after 
reducing planning target volume (PTV) margins for head-and-neck radiotherapy (HNRT). In this 
context, quantifying anatomical changes to monitor the patient during treatment is preferred. This 
retrospective feasibility study investigated the application of deformable image registration (DIR) and 
Exponentially Weighted Moving Average (EWMA) Statistical Process Control (SPC) charts for this 
purpose. 
 
Materials and methods: DIR was performed between the computed tomography for treatment 
planning (pCT) images of 12 patients and their daily on-treatment cone beam computed tomography 
(CBCT) images to quantify changes in patient pose and anatomy during treatment. EWMA charts were 
used to investigate trends in patient positioning reproducibility and soft tissue changes of various 
structures. The 90% confidence limits for both the EWMA trends and the SPC process limits were 
obtained using a comprehensive uncertainty analysis. These confidence limits were used to confirm 
whether a trend breached either an SPC limit or an a priori set clinical limit of 2 mm at a previous 





Trends in patient positioning reproducibility relative to the first week of treatment that were outside 
SPC process limits before the end of treatment week 4 occurred in 54% of cases. Only 24% of these 
cases could be confirmed at a 90% confidence level before the end of treatment. Using an a priori 









were confirmed. Soft tissue trends outside SPC process limits occurring before the end of treatment 
week 4 could be confirmed in 90% of cases.  
 
Conclusion: EWMA trends based on DIR data combined with structure specific action thresholds 
enabled detection of systematic changes in patient pose and anatomy during the first four weeks of 












B.6: Dose accumulation assessing the validity of reduced PTV 
margins in head-and-neck radiotherapy 
Nicholas Lowther1,2, Steven Marsh2 and Rob Louwe1 
Wellington Blood and Cancer Centre, Wellington, New Zealand1 
Department of Medical Physics, University of Canterbury, Christchurch, New Zealand2 
Purpose: Emerging literature has reported reduced treatment toxicity while maintaining equivalent 
local-regional control rates after reducing planning target volume (PTV) margins from 5 to 3 mm for 
head-and-neck radiotherapy (HNRT) [1–3]. As we considered whether it was possible to implement 
reduced 3 mm PTV margins in our department, it was recognized that many aspects of HNRT including 
robustness of the planning solution for anatomical changes may influence treatment outcomes and 
should be considered when PTV margins are reduced. This retrospective study investigates the 
robustness of treatment plans using 3 or 5 mm PTV margins for anatomical changes. The results of this 
study can be used to develop strategies for treatment adaption based on objective criteria. 
Methods: Volumetrically modulated arc therapy (VMAT) plans for 12 patients using 3 or 5 mm PTV 
margins (Prescribed dose 54 Gy and simultaneous integrated boost volumes to 60 and 66 Gy in 30 
fractions) were optimized using the local planning protocol. The planning CT (pCT) was first registered 
to each daily cone beam CT using deformable image registration (DIR). Subsequently, the inverse 
registration was used to reconstruct and accumulate the delivered dose to target and organ-at-risk (OAR) 
structures in the pCT scan. For the initial analysis, the coverage of the PTVs, clinical target volumes 
(CTVs) and salivary glands were assessed using the D98%, D99% and Dmean respectively. The uncertainty 
of the reconstructed dose was assessed using an in silico model based on clinically observed 
deformations to determine the 95% level of confidence.  
 
Results: Preliminary results (4 patients) showed that for 4 out of 5 high-dose PTVs, D98% during 
treatment was at least 2% lower than planned in both margin plans. The high-dose CTVs’ D99% generally 
changed less than 1% relative to the planned dose. However, for two 3 mm plans the high-dose CTV 
D99% was systematically 2% lower (Fig.1). For all high-dose CTVs, the D99% of the reconstructed dose 
at the end of treatment was always 96% of the prescribed dose or higher in both 3 and 5 mm margin 
plans. For the elective low-dose CTVs, the reconstructed D99% was at least 99% of the prescribed dose 
for all fractions in both plans. On average, the Dmean for the ipsilateral parotid glands was 4 Gy lower 
(range; 1 to 10 Gy) in 3 mm margin plans compared to the 5 mm plans. For submandibular glands, the 
average dose reduction was 2 Gy. Thedifference between reconstructed and planned Dmean of the parotid 
glands was not significantly different for the 3 mm (range; -1.2 to 1.1 Gy) and the 5 mm (range; -1.4 to 









Conclusion: Changes in delivered dose due to anatomical changes can be accurately reconstructed 
using DIR. Initial results indicate that 3 mm PTV margins are robust for anatomical changes occurring 
during HNRT with CTV D99% ≥ 96% of the prescribed dose. PTV margin reduction resulted in increased 









B.7: Dose accumulation assessing the validity of reduced PTV margins in head-and-
neck radiotherapy  
 
N Lowther 
Wellington Blood and Cancer Centre, Wellington, NZ 
nick.lowther@ccdhb.org.nz 
S Marsh 
University of Canterbury, Department of Physics and Astronomy, Christchurch, New Zealand 
steven.marsh@canterbury.ac.nz 
R Louwe 
Wellington Blood and Cancer Centre, Wellington, NZ 
rob.louwe@ccdhb.org.nz 
 
Introduction Emerging literature has reported reduced treatment toxicity while maintaining 
equivalent local-regional control rates after reducing planning target volume (PTV) margins 
from 5 to 3 mm in head-and-neck radiotherapy (HNRT) [1–3]. This retrospective study 
utilised dose accumulation to investigate the robustness of 5 and 3 mm PTV margin 
treatment plans. 
 
Method Volumetrically modulated arc therapy (VMAT) plans for 12 patients using 5 or 3 mm 
PTV margins were optimised using the local planning protocol. The planning CT (pCT) was 
first registered to each daily cone beam CT using deformable image registration (DIR). 
Subsequently, the inverse registration was used to reconstruct and accumulate the delivered 
dose to the patient in the pCT scan. Accumulated dose-volume histograms (DVHs) were 
constructed and coverage of the PTVs, clinical target volumes (CTVs) and parotid glands 


























Results Anatomical changes occurring during treatment generally impacted the high-dose 
CTVs’ D99% by less than 1% relative to the planned dose. However, for two 3 mm plans and 
one 5 mm plan the high-dose CTVs’ D99% were systematically 2% lower due to systematic 
local position errors or a reduction in the external contour. For 10 out of 11 high-dose CTVs, 
Fig 1: Dose-volume histogram (DVH) of the accumulated dose for patient 1’s high-dose CTV and PTV at the end of treatment 
compared to the original planning DVH. The accumulated D98% and D99% (red bullet points) of the high-dose PTV and CTV were 










the D99% of the accumulated dose at the end of treatment was at least 95% of the prescribed 
dose for both margin plans. The difference between accumulated and planned Dmean of the 
parotid glands was not significantly different for the 3 mm (range; -0.7 to 2.1 Gy) and the 5 
mm (range; -0.9 to 2.1 Gy) plans (p=0.58). 
  
Conclusion Patients at risk of CTV coverage D99% < 95% of the prescribed dose can be 
identified during treatment using dose accumulation. Loss of coverage for high-dose CTVs 












B.8: DIR based dose accumulation to validate reduced PTV and PRV 
margins in head-and-neck radiotherapy 
Nicholas Lowther1,2, Steven Marsh2 and Rob Louwe1 
Wellington Blood and Cancer Centre, Wellington, New Zealand1 
School of Physical and Chemical Sciences, University of Canterbury, New Zealand2 
Purpose or Objective: Emerging literature has reported reduced treatment toxicity in head-and-neck 
radiotherapy (HNRT) with 3 instead of 5 mm planning target volume (PTV) margins [1–4]. However, 
the loco-regional (LR) control rate was not preserved in one study [4]. The current study investigates 
the occurrence, location and trends where clinical target volume (CTV) coverage and critical organ at 
risk (OAR) sparing may be at risk in the context of reduced PTV and planning risk volume (PRV) 
margins. It specifically focusses on locations where the high-dose target coverage is commonly tight 
during treatment planning. 
Material and Methods: VMAT plans for 12 patients were optimised using either 3 or 5 mm PTV and 
PRV margins (prescribed dose, 𝐷𝑝𝑟𝑒𝑠𝑐 66 Gy in 30 fractions). The planning CT (pCT) was first 
registered to each daily CBCT using demons deformable image registration (DIR). Subsequently, the 
inverse registration was used to reconstruct and accumulate the delivered dose (𝐷𝑎𝑐𝑐) over all fractions. 
The 95% level of confidence of 𝐷𝑎𝑐𝑐 was determined using the structure- and voxel-specific uncertainty 
as described previously. The CTV and critical OAR doses were assessed using the dose-volume 
histogram (DVH) metrics 𝐷99%
𝑎𝑐𝑐  and 𝐷0.1𝑐𝑐




𝑎𝑐𝑐  were determined for local target volumes defined at the point of 
minimum distance to the brainstem (BS), spinal cord (SC) and skin.  
Results: For each critical OAR and for both margin expansions, 𝐷0.1𝑐𝑐
𝑎𝑐𝑐  was below the specific OAR 
tolerance dose. For the CTVs, 𝐷99%
𝑎𝑐𝑐  was less than 95% 𝐷𝑝𝑟𝑒𝑠𝑐 at the 95% level of confidence in two 
and one cases for 3 and 5 mm PTV/PRV margin plans, respectively, with the under dosage occurring 
near the skin. Fig. 1 shows that target volumes closer to the skin generally exhibited a lower 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 and 
a larger drop in local coverage during treatment compared to less superficial CTVs, independent of the 
applied PTV/PRV margin. Analysis of the local target coverages near the BS showed that for one 
patient, an increased BS PRV dose could be avoided using 3 mm margins. For cases with more proximal 
CTVs, a higher 𝐷𝑚𝑖𝑛
𝑝𝑙𝑎𝑛
 to the local PTV was achievable with 3 mm plans. Nevertheless, the drop in 
coverage during treatment for the local CTV was always less than 2%, with 𝐷𝑚𝑖𝑛
𝑎𝑐𝑐  > 95% 𝐷𝑝𝑟𝑒𝑠𝑐 (Fig 
2). Similar results were obtained for CTV coverage near the SC.  
Conclusion: For CTVs proximal to BS and SC, 3 mm margin plans with improved PTV coverage and 
PRV sparing preserved CTV coverage during treatment. Consistent with results of Chen et al. [2] who 
reported that ~50% of marginal LR recurrences were observed in superficial areas, our study only 
showed a drop in CTV coverage below 95% 𝐷𝑝𝑟𝑒𝑠𝑐 in skin regions. Careful monitoring of the delivered 





















































B.9: Quantifying the dose accumulation uncertainty after DIR in head-and-
neck radiotherapy 
Nicholas Lowther1,2, Steven Marsh2 and Rob Louwe1 
Wellington Blood and Cancer Centre, Wellington, New Zealand1 
School of Physical and Chemical Sciences, University of Canterbury, New Zealand2 
Purpose or Objective: Deformable image registration (DIR) facilitated dose reconstruction and 
accumulation can be applied to assess delivered dose in the presence of anatomical changes and verify 
the validity of a treatment plan during treatment. However, displacement field errors (DFEs) in the 
forward registration or inverse consistency (IC) errors in the backward registration introduce 
uncertainties in the reconstructed dose. This study uses an in silico model based on clinically observed 
deformations as ground truth to investigate the dose accumulation uncertainty (DAU) in head-and-neck 
radiotherapy (HNRT). 
Material and Methods: A planning CT (pCT), cone beam CT (CBCT) from week one of treatment 
and three later CBCTs were used to generate three corresponding in silico reference CBCTs serving as 
ground truth (GT) for 12 HNRT patients. To assess the DAU, the pCT was first matched to each GT 
CBCT using the same reference DIR algorithm (B-spline) to generate a deformed pCT (dCT). The 
treatment plan was then recalculated on the dCT and the resulting dose distribution mapped back to the 
pCT space using the backward deformation vector field (DVF) to produce a fraction-specific GT 
reconstructed dose (RD). The process was repeated using the DIR algorithm under investigation 
(demons) to generate a demons RD which was compared to the GT RD to calculate the voxel-specific 
dose error 𝑡𝑜𝑡. Inverse consistent c and inconsistent i voxels were identified by successive application 
of the forward and backward demons DVF, and comparing the net shift to the dose calculation grid size. 
The fraction-specific RD uncertainties for each structure S and both voxel distinctions (i.e., 𝑢𝑐
𝑆 and 𝑢𝑖
𝑆) 
were estimated using the 95% percentile range of 𝑡𝑜𝑡. The feasibility of incorporating the DAU as a 
confidence interval in dose-volume histograms (DVHs) of the delivered dose was demonstrated for 
various structures. For each structure, the voxel-specific uncertainties in the accumulated dose (AD) 
over all fractions 𝑢𝐴𝑆 were first calculated by summing 𝑢𝑐
𝑆 or 𝑢𝑖
𝑆 in quadrature. Subsequently, the 95% 
level of confidence for each dose level bin in a DVH of the AD was calculated by averaging the 𝑢𝐴𝑆 of 
all voxels with an AD equal to or larger than that dose level. 
Results: Overall, the IC rate of voxels was 98.5% (Fig 1) with 𝑢𝑐
𝑆 per fraction equal to [-2.3%; +2.1%], 
[-10.2%; +15.2%] and [-9.5%; +12.5%] relative to their planned dose for target structures, critical 
OARs and non-critical OARs, respectively. Inverse inconsistent voxels generally showed a higher level 
of uncertainty. At the end of treatment, 𝑢𝐴𝑆 was [-0.4%; +0.4%] for target structures. The impact of 
DAU is demonstrated in the DVH of Fig. 2.  
Conclusion: This method can be used in a prospective way to estimate the accuracy of DIR based dose 
reconstruction and provides a method to objectively assess the adequacy of treatment in the context of 
anatomical changes or variations in patient positioning. The DAU based on DIR can be accurately 
quantified and incorporated in DVHs. 
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